var title_f22_30_23008="Stapled circular colorectal anastomosis - End-to-end";
var content_f22_30_23008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Stapled circular colorectal anastomosis - End-to-end",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figure A depicts the pursestring in place in the proximal colon in preparation for insertion&nbsp;of the anvil.",
"    <br>",
"     Figure B depicts the anvil secured in the proximal colon with the pursestring suture.",
"     <br>",
"      Figure C depicts the attachment of the stapler, which was inserted transanally, to the anvil in preparation for a circular end-to-end anastomosis.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23008=[""].join("\n");
var outline_f22_30_23008=null;
var title_f22_30_23009="ARF fistulotomy seton";
var content_f22_30_23009=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Superficial anal fistula tract with seton",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This illustration shows a probe inserted from the secondary external opening into the primary internal opening of the fistula tract. A seton was inserted in the tract and secured to itself. The lateral view shows the relationship of the seton to the internal and external sphincter muscles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23009=[""].join("\n");
var outline_f22_30_23009=null;
var title_f22_30_23010="Patient information: My child is overweight (The Basics)";
var content_f22_30_23010=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/25/16786\">",
"         Patient information: Sleep apnea (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/52/31554\">",
"         Patient information: Weight loss treatments (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/28/38337\">",
"         Patient information: High blood pressure in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/37/9811\">",
"         Patient information: Weight loss surgery (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33876\">",
"         Patient information: Weight loss treatments (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: My child is overweight (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/my-child-is-overweight-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12426510\">",
"      <span class=\"h1\">",
"       How do I know if my child is overweight?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your child&rsquo;s doctor or nurse will tell you. He or she will measure your child&rsquo;s height and weight and use those measurements to calculate a number called the &ldquo;body mass index&rdquo; or &ldquo;BMI.&rdquo;",
"     </p>",
"     <p>",
"      The doctor or nurse will use your child&rsquo;s BMI to tell if your child&rsquo;s weight is healthy for his or her height. To do this, the doctor or nurse will compare your child&rsquo;s BMI to the BMIs of other children of the same age and sex. If your child&rsquo;s BMI is high compared to other children, he or she is overweight. When a child&rsquo;s BMI is much too high, doctors sometimes use the terms &ldquo;obese&rdquo; or &ldquo;obesity.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12426525\">",
"      <span class=\"h1\">",
"       Why is it important for my child to have a healthy weight?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to have a healthy weight, because children who are very overweight can have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Liver problems",
"       </li>",
"       <li>",
"        Asthma &ndash; This is a lung condition that can make it hard to breathe.",
"       </li>",
"       <li>",
"        High blood pressure",
"       </li>",
"       <li>",
"        Knee or back pain",
"       </li>",
"       <li>",
"        Sleep apnea &ndash; This is a condition that makes people stop breathing for short periods during sleep.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It&rsquo;s also important that your child have a healthy weight so that he or she will have a healthy weight as an adult. Being overweight as an adult can lead to medical problems such as high blood pressure, diabetes (high blood sugar), heart attacks, and some types of cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12426540\">",
"      <span class=\"h1\">",
"       What causes children to be overweight?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Children can be overweight for different reasons. Some children simply gain weight more easily than other children. These children can become overweight by eating too much, eating unhealthy foods, or not getting enough exercise. When children gain weight very easily, they have to work extra hard to get to and stay at a healthy weight. &nbsp;",
"     </p>",
"     <p>",
"      Although uncommon, some medicines and medical conditions can also make children gain weight more easily.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12426555\">",
"      <span class=\"h1\">",
"       Will my child need tests if he or she is overweight?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. The doctor or nurse will talk with you and your child, and do an exam. He or she might do blood tests to check for:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A condition that could be causing your child to gain weight easily",
"       </li>",
"       <li>",
"        Health problems that can happen when children are overweight",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12426570\">",
"      <span class=\"h1\">",
"       How can I help my child get to a healthy weight?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help your child get to a healthy weight, you need to help him or her eat healthy foods and be more active. Making these lifestyle changes can be hard, especially at first.",
"     </p>",
"     <p>",
"      To help you and your child start making lifestyle changes, think of the numbers 5-2-1-0. Each of these numbers stands for a goal you can try to reach every day to help your child be healthier.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        5 &ndash; Have your child eat 5 servings of fruits or vegetables each day. Frozen fruits and vegetables count towards the goal, but fruit juice does not. A serving is usually 1 whole fruit (such as an apple or banana) or &frac12; cup of vegetables. If your child does not like vegetables or fruit, start slowly. Eat these foods yourself to set a good example, and have your child keep trying them.",
"       </li>",
"       <li>",
"        2 &ndash; Limit your child&rsquo;s &ldquo;screen time&rdquo; to 2 hours or less each day. Screen time includes watching TV, playing video games, or using the computer for things other than homework.",
"       </li>",
"       <li>",
"        1 &ndash; Have your child do physical activity for 1 hour or more each day. This can include doing a sport, dancing, or playing outside.",
"       </li>",
"       <li>",
"        0 &ndash; Your child should have 0 sugary drinks each day. Sugary drinks include soda, sports drinks, and all juices.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You and your child might not be able to meet all of these goals at first, but that&rsquo;s OK. Choose 1 or 2 goals to try first. Later on, you can try to meet all of these goals.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12426585\">",
"      <span class=\"h1\">",
"       Is there anything else I can do to help my child?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Avoid bringing unhealthy food into your home. If you have unhealthy food in the home, your child is likely to eat it even if you tell him or her not to.",
"       </li>",
"       <li>",
"        Involve the whole family. Have everyone in the family eat healthier and be more active, even those who have a normal weight. Try to do physical activities as a family. This can be as simple as going to a playground or taking a walk.",
"       </li>",
"       <li>",
"        Tell your child that the goal is for him or her to be healthy and strong. Let him or her know that the way to be healthy and strong is to eat healthy food and be active.",
"       </li>",
"       <li>",
"        Get help if being overweight is causing your child to be sad, worried, or have a hard time in school. Ask the doctor or nurse for ways to get help for your child.",
"       </li>",
"       <li>",
"        Work with your child&rsquo;s doctor or nurse. See him or her for regular check-ups, so that he or she can follow your child&rsquo;s BMI over time. Let the doctor or nurse know if you are having trouble meeting the 5-2-1-0 goals. He or she can help you get started or give you some tips. He or she might also recommend that you talk with a dietitian (food expert). A dietitian can help you choose healthy foods and plan meals.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12426600\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=see_link\">",
"       Patient information: Weight loss treatments (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/25/16786?source=see_link\">",
"       Patient information: Sleep apnea (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"       Patient information: Weight loss treatments (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=see_link\">",
"       Patient information: Weight loss surgery (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/28/38337?source=see_link\">",
"       Patient information: High blood pressure in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?22/30/23010?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16749 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23010=[""].join("\n");
var outline_f22_30_23010=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12426510\">",
"      How do I know if my child is overweight?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12426525\">",
"      Why is it important for my child to have a healthy weight?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12426540\">",
"      What causes children to be overweight?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12426555\">",
"      Will my child need tests if he or she is overweight?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12426570\">",
"      How can I help my child get to a healthy weight?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12426585\">",
"      Is there anything else I can do to help my child?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12426600\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/28/38337?source=related_link\">",
"      Patient information: High blood pressure in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/25/16786?source=related_link\">",
"      Patient information: Sleep apnea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=related_link\">",
"      Patient information: Weight loss surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_30_23011="Mosquito vectors of infectious diseases";
var content_f22_30_23011=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mosquito vectors of infectious diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23011/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23011/contributors\">",
"     Cheryl Whitehorn, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23011/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23011/contributors\">",
"     Johanna Daily, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23011/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23011/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/30/23011/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mosquitoes are insect vectors responsible for the transmission of parasitic and viral infections to millions of people worldwide, with substantial morbidity and mortality. Infections transmitted by mosquitoes include malaria, yellow fever, chikungunya and other arboviruses. An understanding of mosquito classification, distinguishing features, and the insect life cycle is important for disease surveillance as well as for designing and implementing effective measures for disease control and prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=see_link\">",
"     \"Arthropod-borne encephalitides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to the epidemiology, clinical manifestations, diagnosis and management of the infections transmitted by mosquitoes are discussed separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mosquitoes belong to the class Insecta, order Diptera and family Culicidae. The two subfamilies are Anophelinae (which includes the genus Anopheles, the mosquito vector for malaria) and Culicinae (which includes the genera Aedes [Stegomyia], Culex, Mansonia and Haemagogus, the mosquito vectors for arboviruses and some filariases) (",
"    <a class=\"graphic graphic_table graphicRef56132 \" href=\"UTD.htm?25/24/25996\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23011/abstract/1\">",
"     1",
"    </a>",
"    ]. Each subfamily has hundreds of species within it, although only a few dozen bite humans and therefore are capable of serving as disease vectors.",
"   </p>",
"   <p>",
"    Planning disease surveillance and control measures requires identification of the mosquito genus or genera in a particular geographic region based upon the distinguishing features of each life cycle stage. The following discussion highlights the characteristic features of the mosquito subfamilies Anophelinae and Culicinae, to facilitate identification of Anopheline malaria vectors from other types of mosquitoes. Techniques for distinguishing the Culicinae genera are beyond the scope of this discussion and require more detailed entomological expertise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LIFE CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mosquito progresses through four distinct stages: egg, larva, pupa, and adult [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23011/abstract/2\">",
"     2",
"    </a>",
"    ]. The full life cycle usually takes about 14 days, but the duration varies with temperature and species. Outside of tropical climates, most mosquito species overwinter as eggs, although some overwinter as larvae or adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Eggs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female mosquitoes lay up to 200 eggs per reproductive cycle, and with sufficient nutrition can lay eggs as frequently as every three days. The eggs hatch into larvae in about 48 hours.",
"   </p>",
"   <p>",
"    Mosquito eggs are cigar shaped and about 1 mm long. Anopheline eggs can be distinguished from culicine eggs by the presence of \"floats\" (little air filled sacs on the side of the egg). Anopheles and Aedes (Stegomyia) mosquitoes lay their eggs individually. Culex mosquitoes lay their eggs in groups (\"egg rafts\"), which are collections of upright eggs typically 3 to 4 mm long and 2 to 3 mm wide (",
"    <a class=\"graphic graphic_figure graphicRef53881 \" href=\"UTD.htm?0/33/536\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Anopheles mosquitoes lay eggs in clean water (such as rain puddles, water tanks, and irrigation ditches). In contrast, Culicine mosquitoes have a broader range of breeding sites. Culex mosquitoes can tolerate high levels of organic pollution; Culex quinquefasciatus in particular is associated with areas of human habitation and can lay eggs in dirty water (such as pit latrines, cess pits, and blocked drains). The eggs of Aedes (Stegomyia) mosquitoes can withstand desiccation for many months so that breeding sites can remain dormant until there is rainfall or flooding; Aedes (Stegomyia) aegypti in particular can lay their eggs in domestic water pots, tires, and garbage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Larva",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eggs hatch into larvae that live in the water and come to the surface to breathe. Culicine larvae maintain a position vertical to the water surface and breathe via a siphon, which extends to the water surface; the Culex siphon is longer than the Aedes (Stegomyia) siphon. In contrast, Anopheles larvae lie in a horizontal position parallel to the water surface and do not have a siphon (",
"    <a class=\"graphic graphic_figure graphicRef53881 \" href=\"UTD.htm?0/33/536\">",
"     figure 1",
"    </a>",
"    ). The larvae develop through four stages (also known as \"instars\"), which lasts 7 to 10 days (at tropical temperatures) before reaching the pupa stage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pupa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pupae float on the water surface. In the pupa stage the head and thorax are fused to form a comma-shaped cephalothorax; during this stage there are no distinguishing characteristics between the genera (",
"    <a class=\"graphic graphic_figure graphicRef53881 \" href=\"UTD.htm?0/33/536\">",
"     figure 1",
"    </a>",
"    ). Pupae breathe, but do not feed, so larvicide cannot be ingested during this stage, although a surface oil can induce suffocation. Metamorphosis from pupa into an adult mosquito takes about two days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Adult",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newly emerged adult mosquito must rest briefly on the surface of still water until its parts have dried and hardened before it can fly. Males are able to mate 24 hours after emergence. Females are able to mate immediately. &nbsp;Females blood feed at three days old and lay eggs about two days after a blood meal. Both the male and female feed on flower nectar for food, but only female mosquitoes bite humans or animals to obtain protein needed for producing eggs. Mosquitoes usually feed in the mornings and evenings, avoiding the heat of the day.",
"   </p>",
"   <p>",
"    The head appendages of the adult mosquito consist of one proboscis (the elongated feeding apparatus), a pair of antennae, and a pair of maxillary palps; these features require a microscope for visualization (",
"    <a class=\"graphic graphic_figure graphicRef82494 \" href=\"UTD.htm?42/30/43495\">",
"     figure 2",
"    </a>",
"    ). Female mosquitoes use their proboscis to cut through the skin and take blood feeds. Male mosquitoes do not have a proboscis suitable for extracting blood. The antennae of males are bushier than female mosquitoes and are visible with the naked eye. The unique palp characteristics are the most reliable for differentiation between Anopheline and Culicine mosquitoes (",
"    <a class=\"graphic graphic_figure graphicRef82494 \" href=\"UTD.htm?42/30/43495\">",
"     figure 2",
"    </a>",
"    ). Anopheline female palps are about the same length as the proboscis, while Anopheline male palps are club-shaped at the ends. Culicine female palps are shorter than the proboscis, and Culicine male palps are long with a tapered point.",
"   </p>",
"   <p>",
"    Living adult mosquitoes can also be recognized by their stance, without a microscope. Anopheline mosquitoes are oriented with head, thorax and abdomen in a straight line at an acute angle to the surface, while Culicine mosquitoes rest with the head and body angled and the abdomen directed back to the surface (",
"    <a class=\"graphic graphic_figure graphicRef71887 \" href=\"UTD.htm?6/4/6209\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DISEASE CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts at mosquito control measures have targeted both adult and larval stages of the life cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23011/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The adult mosquito has been targeted by using insecticides in the form of indoor insecticide spraying or insecticide treated bed nets. In addition, insect repellent applied directly to exposed skin or clothing has been attempted. The larvae may be targeted by applying insecticides to the water, applying a layer of oil or polystyrene beads to breeding site water surfaces to induce suffocation of larvae or pupae, and releasing larvivorous fish and copepods to consume larvae. Genetic control measures to prevent eggs from hatching, larvae from surviving, or adults from transmitting human disease have also been attempted.",
"   </p>",
"   <p>",
"    In general, measures to control the adult stage are more effective since breeding sites can be very sporadic in distribution. Targeting adult mosquitoes reduces insect longevity and hence disease transmission, while larvae from missed breeding sites mature into adults with normal survival and capacity for disease transmission. In addition, larval control for an entire region is difficult to achieve, since mosquitoes can fly in from uncontrolled breeding sites up to a few kilometers away. However, in regions where gaining access to individual homes is difficult, larval control may be more appropriate.",
"   </p>",
"   <p>",
"    The epidemiology of malaria is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16473?source=see_link\">",
"     \"Epidemiology, prevention, and control of malaria in endemic areas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two mosquito subfamilies are Anophelinae (which includes the genus Anopheles, the mosquito vector for malaria) and Culicinae (which includes the genera Aedes [Stegomyia], Culex, Mansonia, and Haemagogus, the mosquito vectors for filariasis and arboviruses). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mosquito progresses through four distinct stages: egg, larva, pupa, and adult (",
"      <a class=\"graphic graphic_table graphicRef56132 \" href=\"UTD.htm?25/24/25996\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Life cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anopheles mosquitoes lay eggs in clean water (such as rain puddles, water tanks, and irrigation ditches), while Culicine mosquitoes can tolerate organically polluted water and will lay eggs in clean and dirty water (such as pit latrines, cess pits, and blocked drains). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Eggs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Culicine larvae maintain a position vertical to the water surface and breathe via a siphon, which extends to the water surface. The Culex siphon is longer than the Aedes (Stegomyia) siphon. In contrast, Anopheles larvae lie in a horizontal position parallel to the water surface and do not have a siphon (",
"      <a class=\"graphic graphic_figure graphicRef53881 \" href=\"UTD.htm?0/33/536\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Larva'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most reliable characteristic for differentiation between adult Anopheline and Culicine mosquitoes is the head (",
"      <a class=\"graphic graphic_figure graphicRef82494 \" href=\"UTD.htm?42/30/43495\">",
"       figure 2",
"      </a>",
"      ). The palps are sensory organs found alongside the proboscis. In Anopheline females, the palps are about the same length as the proboscis, while Anopheline male palps are club-shaped at the ends. In Culicine females, the palps are one-fourth to one-third the length of the proboscis, while Culicine male palps are longer than the proboscis and taper to a point. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Adult'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Attempts at mosquito control measures have targeted both adult and larval stages of the life cycle. The adult mosquito has been targeted by using insecticides in the form of indoor insecticide spraying or insecticide treated bed nets. In addition, insect repellent may be applied directly to exposed skin or clothing. The larvae may be targeted by applying insecticides to the water, applying a layer of oil or polystyrene beads to breeding site water surfaces to induce suffocation of larvae or pupae, and releasing larvivorous fish and copepods to consume larvae. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Disease control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     White GB. Mosquitoes. In: Manson's Tropical Diseases, 21st ed, Cook GC, Zumla A (Eds), WB Saunders, London 2002. p.1741.",
"    </li>",
"    <li>",
"     Clements AN. The Biology of Mosquitoes, Chapman and Hall, 1992. Vol Volume 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23011/abstract/3\">",
"      Pates H, Curtis C. Mosquito behavior and vector control. Annu Rev Entomol 2005; 50:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23011/abstract/4\">",
"      Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev 2004; :CD000363.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5695 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23011=[""].join("\n");
var outline_f22_30_23011=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LIFE CYCLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Eggs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Larva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pupa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DISEASE CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5695\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5695|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/33/536\" title=\"figure 1\">",
"      Mosquito early life stages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/30/43495\" title=\"figure 2\">",
"      Adult mosquitoes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/4/6209\" title=\"figure 3\">",
"      Adult mosquito bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5695|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/24/25996\" title=\"table 1\">",
"      Important mosquito vectors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=related_link\">",
"      Arthropod-borne encephalitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16473?source=related_link\">",
"      Epidemiology, prevention, and control of malaria in endemic areas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_30_23012="Dorzolamide: Drug information";
var content_f22_30_23012=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dorzolamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/25/26004?source=see_link\">",
"    see \"Dorzolamide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19443?source=see_link\">",
"    see \"Dorzolamide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trusopt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sandoz-Dorzolamide;",
"     </li>",
"     <li>",
"      Trusopt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F162789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Carbonic Anhydrase Inhibitor;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F162755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of intraocular pressure: Ophthalmic: Instill 1 drop in the affected eye(s) 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F162772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19443?source=see_link\">",
"      see \"Dorzolamide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F162756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15804886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clcr &lt; 30 mL/minute: Use is not recommended (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15804887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F162732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 2% (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trusopt&reg;: 2% (10 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10534784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops; preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trusopt&reg;: 2% (0.2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F162717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F162735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If more than one topical ophthalmic drug is being used, administer the drugs at least 10 minutes apart. Remove contact lens prior to administration and wait 15 minutes before reinserting. Instruct patients to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. Ocular solutions can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may occur from using contaminated solutions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F162733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F162787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Bitter taste following administration (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Burning, stinging or discomfort immediately following administration (33%); superficial punctate keratitis (10% to 15%); signs and symptoms of ocular allergic reaction (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 5%: Ocular: Blurred vision, conjunctivitis, dryness, lid reactions, photophobia, redness, tearing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction (systemic), angioedema, bronchospasm, choriodal detachment (following filtration procedures), dyspnea, epistaxis, myopia (transient), ocular pain, paresthesia, pharyngitis, Stevens-Johnson syndrome, throat irritation, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F162738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dorzolamide or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F162721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions, has caused bacterial keratitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Local ocular adverse effects (conjunctivitis and lid reactions) were reported with chronic administration; many resolved upon discontinuation of drug therapy. Choroidal detachment has been reported after filtration procedures. Patients with low endothelial cell counts may have increased risk for corneal edema; use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is not specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Systemic absorption and adverse effects (similar to sulfonamides) including, blood dyscrasias, Stevens-Johnson syndrome, toxic epidermal necrolysis, and fulminant hepatic necrosis may occur with ophthalmic use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; not evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; not recommended with severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral carbonic anhydrase inhibitors: Concurrent use with oral carbonic anhydrase inhibitors is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Some products contain benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F162783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F162726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F162728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13386400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies following systemic administration. IOP is usually lower during pregnancy. If topical medications for the treatment of glaucoma in pregnant women cannot be discontinued because small increases in IOP cannot be tolerated, the minimum effective dose should be used in combination with punctual occlusion to decrease exposure to the fetus (Johnson, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F162758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F162740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Dorzolamide HCl Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (10 mL): $66.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Trusopt Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (10 mL): $92.04",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F162730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic exams and IOP periodically",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F162741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Biodrop (AR, PY);",
"     </li>",
"     <li>",
"      Bolano (TW);",
"     </li>",
"     <li>",
"      Dorzolam (CO);",
"     </li>",
"     <li>",
"      Dorzox (IN);",
"     </li>",
"     <li>",
"      Sefson (PE);",
"     </li>",
"     <li>",
"      Trusopt (AR, AT, AU, BB, BE, BG, BM, BO, BR, BS, BZ, CH, CN, CO, CR, CZ, DE, DK, DO, EC, EE, FI, FR, GB, GR, GT, GY, HK, HN, IE, IL, IT, JM, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, RU, SE, SG, SK, SR, SV, TH, TR, TT, TW, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F162720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversible inhibition of the enzyme carbonic anhydrase resulting in reduction of hydrogen ion secretion at renal tubule and an increased renal excretion of sodium, potassium, bicarbonate, and water to decrease production of aqueous humor; also inhibits carbonic anhydrase in central nervous system to retard abnormal and excessive discharge from CNS neurons",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F162737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Reaches systemic circulation where it accumulates in RBCs during chronic dosing as a result of binding to CA-II",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: In RBCs during chronic administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: To N-desethyl metabolite (less potent than parent drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal RBC: 147 days; washes out of RBCs nonlinearly, resulting in a rapid decline of drug concentration initially, followed by a slower elimination phase with a half-life of about 4 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug and metabolite, N-desethyl)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Biollaz J, Munafo A, Buclin T, et al, &ldquo;Whole Blood Pharmacokinetics and Metabolic Affects of the Topical Carbonic Anhydrase Inhibitor Dorzolamide,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1995, 47(5):455-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/30/23012/abstract-text/7720769/pubmed\" id=\"7720769\" target=\"_blank\">",
"        7720769",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson SM, Martinez M, and Freedman S, \"Management of Glaucoma in Pregnancy and Lactation,\"",
"      <i>",
"       Surv Ophthalmol",
"      </i>",
"      , 2001, 45(5):449-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/30/23012/abstract-text/11274697/pubmed\" id=\"11274697\" target=\"_blank\">",
"        11274697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilkerson M, Cyrlin M, Lippa EA, et al, &ldquo;Four-Week Safety and Efficacy Study of Dorzolamide, a Novel, Active, Topical Carbonic Anhydrase Inhibitor,&rdquo;",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 1993, 111(10):1343-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/30/23012/abstract-text/8216014/pubmed\" id=\"8216014\" target=\"_blank\">",
"        8216014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9386 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-218.189.88.190-50AA3700D9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23012=[""].join("\n");
var outline_f22_30_23012=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162751\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162752\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162789\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162755\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162772\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162756\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804886\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804887\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162732\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10534784\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162717\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162735\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162733\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162787\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162738\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162721\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162783\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162726\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162728\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13386400\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162758\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162740\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162730\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162741\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162720\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162737\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9386\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9386|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/25/26004?source=related_link\">",
"      Dorzolamide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19443?source=related_link\">",
"      Dorzolamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_30_23013="Aclidinium: Patient drug information";
var content_f22_30_23013=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Aclidinium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13764?source=see_link\">",
"     see \"Aclidinium: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15682238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tudorza&trade; Pressair&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15251723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to open the airways in lung diseases where spasm may cause breathing problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15251722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3993254",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to aclidinium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701034",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to milk, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having a breathing attack.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15251727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not to be used to treat intense flare-ups of shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15251728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15251729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Peak flow measurement low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor right away if your normal dose does not work as well or if you need to use your inhaler more often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15251725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your puffer (inhaler) use checked with your doctor at each visit. Read and follow facts on how to use the puffer. Make sure you use the puffer the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3993263",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Prepare puffer (inhaler) by pressing the green button.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3993264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Let go of the green button and make sure the control window is green.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3993265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the control window is red, try pressing the green button again.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep puffer (inhaler) at a level, upright position.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694848",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breathe out fully. Never breathe out into the puffer (inhaler).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695515",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place mouthpiece in your mouth. Close your lips around the mouthpiece.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696125",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and breathe in.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3993450",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may hear a &ldquo;click,&rdquo; but keep breathing in.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hold your breath as long as you can without harm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3993451",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breathe out slowly through nose. Never breathe out into the puffer (inhaler).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3993452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you used the puffer (inhaler) the right way the control window will be red.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695186",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using more than 1 type of puffer (inhaler), ask your doctor which puffer to use first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use a spacer with the puffer (inhaler).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse out mouth after each use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15251726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15251730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3993541",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store puffer (inhaler) in sealed pouch. Use right after opening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3993262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away inhaler after 45 days of opening the pouch, when it says 0, or locks you from using it.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15251731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86871 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23013=[""].join("\n");
var outline_f22_30_23013=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682238\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15251723\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15251722\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15251727\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15251728\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15251729\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15251725\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15251726\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15251730\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15251731\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13764?source=related_link\">",
"      Aclidinium: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_30_23014="Autoimmune chronic hepatitis after treatment - medium power";
var content_f22_30_23014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autoimmune chronic hepatitis one year after treatment with prednisone and azathioprine (medium power, hematoxylin and eosin)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 294px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEmAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDWWO4vGVbq2MN0rkFOc/8AfNSXbvpxF21wEmB+TyiCeOxqYwXNzZTmJ5bryUVZptxLYPQk9axjbTBUBURxqON3JNdTetz7mPvKzZ6vpXiCDWPD6rqlulzLGBn5R83vXLas8OlQzyWipHcycmPgYX0ArB0Oe8XV3hm3RWzgmJMd/QdzReyXLapcfbX4DFNjLyuKlJI5qeGjCbUdn0M3TZvtdy1zLH5crkqWBIz64qrqs9iuq2bNG6TRsDGOoPOefyrp9Fito7+K5mtftcCZDxq+3nHas3U/sCaihlUxmVv3UbYJAz0zVKTbujr5lflZ6tY63Nd+EMXTW5laAlxEu0Z9RntXnlta7mIit1YgE5OMr+NaWh609g0YLKtuuQQyjjsAc1m+LrK1m08XFrfmED5mUZz+VKC6HHQpKhKUUtx0Mk1tbXERIDSDG0Hkio/DthP9sW3DtIrNvO8fdFZ813O1kLizHmStjDYzle55712Pwtsbqa/nlu2Ri8BHJ7ntQ9Fc2rVPZU5TZzkdvqYdrbUrvcV3AYbI25yKz30gvqokgVmkcEMY8ncMeldD4stbqz1HYluZYmb5mU8gVJZeKz4Qhgls9H+1rKD590742f3UHer96b06i9rKNNSpq7MHU9B1WUxLZLcRKjhsLH1FXzqclpdra3FjubGH38fhXT6p46ltriG8lVYhgfukXJOe31qhfy6f4mX+07GFIbqY7pZefnIGBx26dqm7a95GarVW17SOnqZypA8G5XZGY/6tv8adJIFhRGdBLjgHGSKx9YkSwv4lublQVAOUUsPpntUeo6VBc3kE91c+V5eGVi2F9s/nVKO3MbrXW5cMtxBJjG7d1JP3TWy86myVblUeU/x55rPmsz9mV/NEhPOQe9QeHryOS+T+0YmeGMjK8gGoavqOVmrosBHYObfy4nYEliKfa3Bt5UdJSXTGXAxmrfjK/wBPaZZNDtefL/eRgEjOcZwOfesmxZ57fd8gCsVGV27h647U7PluRGXOrtWv3Op8TXWqJpOmy6fdott5pa7jcZ8xNvYjoc1zECpdMWbdHH3ZuRWnp2oyToLCfcYVyDgZ4NYaeG9auNZ8qJ1Wyk4Xe20Y/GhPSz0sZU4+xTTdiTUbUsrJH5bHG05A2sp65z1rR8PSSaMLdrHylWNdphH3duOlQa34Vv8ARLmOG6uY2hkGVcZIqtpM9nfySwae5eSLhzICPbI9aTba8jVOFSmne6Zc1+7u44JdTQxT3DYCB3ICL/gKb4fjvvE9rFJeRJb4HzsOQTnt61HMJBMsS7AxHzHt+HpW1Prq2OmRw2y+XdQxlYxgFXPXJp3urJakzUopKC/4BbuvBOo2cDS2yLdJjhQ2CB64rnFsNZbUoYYbOVIiNjq4I/HFa2keMtWtIWn1CLdOsTFMDBKjngD1xVu2+IA1WxhvII5980W5Vxt2/X34o95XbRzKWKi7SSZFb+F7qNoIr3UoVmDF/JLAu49AB0qDxVfSjTZNOaOUxbQjJEu5sfSuX07Umm1OXWCkv2gHain5hHjrgetXprl7u4M8hye55BJ7c9qbTT1N40pt3qO5W0mDZCkYYs+/JLjBr1zTr631Lw7czaXK8lzEGiZGypVgOhU9D/8AWryaeXyIQYg7PuwT1r0iDUWtvD0c1/AGmdchhwc46n3qZ66swx8HNRt3PNNQ0a7vZVcw3KmMnkJkHn1PQ16b4fjs5PD1szw26zRLtlSdAQxHfP0ryrWV1jUYJY7V5l5yu08ep9812/gexjm8FahDqlyfOhJ5wSUJXrjrRLVK7LxsX7NNvqtid/GUKKf7Jt4MKdu9EVcfTvWVqHjltSRIoXia4ik/eLLzle+B0Jrm7C2AlNtGCZs4ByCD9agvNOK6oXkVUnXjEbfK3emlFMtYSkntqZ90J7nxLeW8tqBp0rFonPBHoR39c+ldb8M18L+GNVvJEu2W9dcGSRcKo64XJrOld5rWNQcMDu2xdl75rA1rSG1GxeGJjHuYEOV+9g8g0XT02ubVKSqQ5GzX8TRW91rsjadr0V09zMXPnHywc9AjYwfxqXTNOMmrw2l0xgjLbZDjPHfGKx9M+Ht9ra6clvvZLUYWccBj1I/OtPUdPvdGuPsdyHBJxxwffHrROXN1CHKv3UZa/iXPGFlaQ6rJNoQnliVFDLI2PbC561iW2inWLtZ5L8WdtbRmWWSZtqoo5OT68dqfHHqK34htSrSbgCsowrIe9emWen2ltD9juDZySSqPO6MxB7Fe4Io57WZjUqOhDlTuzEufFto+jImlSRssUC4KscBTwpGR0OO9ceLjEM08kqxAYJZjnJP0rpfGejW1lp99q2jrCbpfLg8mNdqbQegA4xXI3LR31hbtLAYmf5ZY+5HYgev0o5VuthYZx5W4o3LTWLSbwmkMUW6czMGyuCefvZ9PasLUFuZI2jtXy33gvUgetRWRW2mitbGJp0b+HaTn19x9a0td8NXWmiz1CWWRJJ/3hXPoMYP4dqFZM2VoO19WZMLp50cUyrHcsvcg7+eo/wDr1YvLdIVR54PskRbAkLFkx7jsfpVXRktZdSS+MZV7cqG9JAD3A4BrQ1JZ797+S8u2vI7iUOgUBRAo6BV+nBPeiyvqOUpXSRialYQBTdvapKY1DJJG5wwJ4OKt6vrMV74KNtGVXUQyAw3L5VYx0KZ7mrywRW+mtNaXO4hdgjZQQB6Y7VzGk+GLvUdQllvwJpZTyu7OB6j1rSDjbmk9iZ+8T2SbrGFCshlC4dY87WPpitbTNTl1Z7jSTbyRxZzJiIcLnkZxx07Uy+tn0Z4RBZSywRAGdlOSMkAbRjnHU+ldXqktrC8h0u2KR4CbuSXBHLN3BJJqHde93M6lRSfKlchNwNIuGtUHkLcoJQjndI4PPy4wAR1rMvJVgtYY54rea7jAMjbiMZO5c9jn07VqMkt9p1nHdaYWtYM5cku20DncxGVX9a5yKeHy1DK8oZiMA4UjoAp9h3pIimr77nVaXfzaUJvshXFwnltv6H3x6cmo4LiKGKIspmYtzGw4HufXpSPp91O7KtvNuUlAojPH4Vk63HdaTKk09rcI4BGGUq2D3wRz6VCXQ61ySlo9Wa2i3V4/i+1u55Vk0+OYOUKkHAGAMelaN9NDqupXt3MuDLKzeny9v0Arz3bqk99DcW8rrHGS8i5xgf5FdKt9BdwkJIFuIiPNVT19/wCdUwlSip8y32Ln9oWtm6wRyYLnKo3J9zVO4giu7hJZollKPuRiM7c//qq7Z6baS51K8jLGIYgVzjj19xW74It7TUb6ezvTCzSPmAxL5bIuOQezUr2V0TUqKmnK17GRCfNUsn8PGSOp71Dn7Q0iTbWg28D3rY8XWa+GtU+xy3CLbuoaOVh2J71z0kFxZ6jJMJA8IH3QSQen4f8A66pLQdOoqkVKOzL9wrWWnGOzIVimBhR8mR2/GrfhyO90HS0m1CcNI465I/WsCS+lmmYwg7mP3WOf0q1qmoXupo0N6tqlnEiCNQp3577uxFNO/utjnB6K25ueIGsNftLVZQ5ubZg0bxyFSCPcdvasbS7+S7v7iC5ikhEXQ84Y5/yaaukWV7ZQW9xPKtvuXLxNsJcHK1u+PLS00vS4tTsA0jEhTGrc5xyT6CmvetFGKcaclDuVJrCG8gmLhQD0DHrWpaaQNE0uH7QyxyTKWSLocD0rnLG/a40+GZ4XUMQcN1x6Vv69rX9o2cSrGTKihAxHQdwKjW9mVUU7pLbqUrTXEi1eCHUdOS5tScjevT3q78T7XTGfTf7KkWKaZWkVEXdgAclvT71ZgeNXTzHBRVGd3QVV1C2mutQsxBe+WsZ9M5HXiqi1dPYmVFe0U10Lmg6WXs0hac+SuFLPwWYntn3rQfRWiLhZUd/4Vfgn/wCvXOeL9Curh4dlwI40JwDlgc9ePWrQmaIQwo8rhVCqXOTwOtDV0nfVlJSbunoVbayn/tN7h4nhnOY9pz0+n4Vt6Vou+Z2nm2IPvdv1rX0u2w9nPrCvHDdMY4G25ywGcn06VieICLTxEdNndir42lPQjIOPSk7yJVbnlyJ6nS6VFozxCBYFNwkocMZjlse46j2rnPFtveJr7HBWPIIHT5e1Zs1nOl7BPBKUEbD7nIfHeuy8Z2JaGxvAxeEqIyVPTjIpbMxUVSqq7vzdxPDmrWl1E+na4vnxvxAW559B/jVa48GafHIstrdi0Ly8quCWHvXKy6HLPqUV4krxmJcKucDHrya77T9DhvtIGq38X2hrZ98a7ivzDGTgdaWi2ZnXSoPnhK1+h514ie/0TxX/AGdFAs1qBuM/c55BHPHarunk6jZXAkiBkjHBHGKsawlxd3VxqMwDs+Wxj9APyp3gm5ysl61oVhRWBiZSNzDoKcruzSO3n5aV3uZGj6rDd3VxbvDJG8R27m749P0qLUbPUWu7RdPd4izfMpU/N6c/nXe+MdIs47Gy1ywt47e5nIE0SAckjP8A+sVwV5qt7b3n2+JLq8NqykwRcbueRjucVUdZXiiKNb2sOeOg+60+Xw/qcOm29o8glj85ZDJgjcTng/SrcMc87MixiVR3BACn1Jqx4l1F9TuRczWyJL5SskMgxsyM4I7Go9Gs4r6GaG5uY7Tz8RRKWwGkPRaJXZcZtU+aZaW2ktY4p7hYHUMD8r5PB7eta3jbVk1IJDbylBEOm4cHHTHauMtrS6snWKd5CIpTHIScsOe1dHr3hGLRYjqdrM81vqMokdZGzsYrzg+lTpfczmoKpByeutjkNY1C8j0iSOAyMJfkDJklcjrkVa8MSTxWLWEt7Iszod2GORkdPfGe9bGheXoNyGVDLFKSZOMjB9zVe7jjvPEdz/ZNrJHC4BMhAwTjn6c9qvm93lRs5XdmtO5BpIjsrbyWjkkYSbvNJ+bJ6jitRbiylu1JUOsY3yKoy2fX3qxomhC81Fmn1SG2t44SjWzIMyN1DK3Yg44rN1jRY9KnuZlnW6mljYIqjaPXH1paN6sxdSMpOK3NfW7JBBBPptvczm8kWFXt1ASMMPvyEkbVA/WsG5tP7PgaN7pCsQJbb7dxVnwxrerW1qrzoqgnY0PQsg9qPF2vW13M9x5Fu1qIliih8shlb+Is+eRQlrykw9rCdnqg0fX9TuvDFxa6HqIsbhXwk00Wdg6seO+KpXuuy67qDmZw7woBiQgF8cZ+pIzisKCWf7XZm2t1h0xkyyKMcnPP8q3THGHaSyWNY35YSpyW9jRKyVjWNKMZudtS7oSyRfaLzaAqJkGQZwe1ZF1N9vHmK0b3QPWM/MG/yK7+70+8PhBLLRri3tyHD3kzRbhtPWNQe59a810yyi03xDEsU+J5XyhY7kByW6dcZFKKurozpVVOUn2LiahrMt1eW2qAJZQsuwEBQcDOSR9ajsrWO/vIVmDxs75wkuVUf0rUutTke8klcI0kgDqDGpVzjpnpjvUXg3UrWLXoRq5BmunZEUfdUAZJOOg7Und6pFOTjFuxP4nhvNMuktdNha004MDPdLIDJLjB2gjnk9T6CsrUby+1WffPPK5ThFLEhR6Ve1q11V/ENw6p5+nFiVEbBht7YrnNXiuorfdAWhCZLA5HHY5/pTa2SFQSsm9WRanfrpohFzNguxGzZhvx/Oobn7Ybgm2B2gEu6n5VIOcN6YFaNiw1ONALWOabgBuVKkd+e9bHhnwxqelXV5NrRsBp1y5EcLyHzJCR34wRg01ZepVWqoLU5Gxsdfk1IuHt47WSMo0rYZIQekhbOC3NdjpzzWMccWp6rFdIIdqiOJVMsmTzvGMelYPjKzC6db6RYObS3iyziM/I7Z4/IVTs7F3to4EkDPgKgQBssOn0JoqTUl/wCVT51ds6vULiS6sCukyRw3YQkpMDwwHAPc1Jb6wNK0WJNYsT/aczAyQxH5Vj42n/AOtXE6jpGpSWyLqEkdlK7hlK+YenUHA4NdpoWhiQ28Ul0l3cPjMrdwO3PNKSUVvf+u5lJQS1ehgXnj7VrXxAkekpNFZopJU8wuMZywPftjNVIPGum6lqb21/p0kNwCxaS3yV8w9G2H0P51t3VtaXOsywpbH7Mh+YmPGSPX2NVLq20vSgZfKkglZzgFQd5z3I7UNp9BxUNLI9G034hS2bgXtrvd2zlj90n0NV/E2uS+IEVpLUFIuFYc1xGq39vbpJ9u3AzSERBh2Hr+PNW7C6mFsssWIyOSjHAHvUWtrY1WEpxl7SMbMk+2XGkwXjwwKWKFG3qDge3vWZp9rFs82OHZJJHvYepz6eldBarDcWrzXU2yV3JGF3Kw9x65pIltQvmyPMDt2qFTIAPai9kbqSTegpvJLqWNb3ywyIFSNeFXj09azbu4urDULVtOhZ5RIApTqOf/181o3dutxp8S6ZNCJd26YTcMPf/wDVXaeDLbT7a2afMc14Ccu54A7EA0XSVzCrWVODaXyK3jzT5NW0exvNSgVJI2CKDnkYz/OuVkPl2zBSCxGACO9euxmHVbEwXMkLgnuQcVzY8E6RotxNJp/nTpPIZXEkm4Rt3xnoPanGS5bN6o4cNjI017OSOPvdGl0tLW5kQAToHBA6Z9azrd47szRLCwcttAK/e9xXo3iKaW7shBp4SOREAV3QOAAfQ9f/AK9Yml+Ftah1i31GzNvMjsguEuCUijQfeZEHJY+mQOaqKTWrsdMcZyw5qm5jReDdQi1C3vbq4ItYlDeUG6cdMdKikwrTpLdtLEzb/n4213Hji5Pz22nRgTFCxP8AKvMY7e7lgm/tmM+QkbF0QZZ8dAMdzVRbktSsPUdSPtJl9Zzt2QBZI2535HP0qkzXEWovNZXJKSDHlEdOOvJxWzJ8Pb3UvDtv/Z00qQjEqIT+8A9x+NbXhHwFqscTzeIJbeNF4hWLJIUDGXJ/iPXijSKbTHPGUIrWRyt7ZyajF5MoZc/NuRQcfhVmMQWelbfJne7hICtnkgccitPVLO6S4mTTtrSgHYrvtDH+7n3rMnuvJRH1WNraUgEo45B79KV21bobKalsT+E9Ka+8WbppXMUxyyyHj6V2vjS30/QVhuFiiZ3+VUI4zXKvc2rQGW2SRLliMFTwoHcCmX0dzrbL9rcSiIZx70nrK72OadOU6ine0V0Nmy8Wudr3wWZAB5YjUbV/CsTX9YttV1syqywyFNioR1H9KjeBoY0YRfIBjABxxRpXhy01nXbYzD7PcHOyRwcdPTvS0Rap0qV6iVrGVe2R8sSZdDH8wCt19q25/ExvfDlpaTDyDkfMTjkcDNS+IdKl0rUDazOsoUAhl7iqn9kx3loJ5nVAj5w4yKas7XLcqdSKm9exkXlvqdxdwpBJgBuW3Y69zXputXEel+CLe3tZCzsNjkHlu5P51wsMsdy/lwSGaQMR8vGfwpkKzs7rNKzkMcK38FJrv0JrUvbSi29FrYk8ycxrCYzKpGQW6j8a7WxvtG0Lw/ZXEQFzcuSTFnLF8859hXJ318ojh2gc/IVx0xVXLTXGIo2H9zvuqbXJrUVWSUtF+ZX8ZeI73UtQhOn26mFX+a3IyoYnlm/Cug8Fw2s/iOFLgCLbmVeylx2rmbDTdTvNVvDbWbSWgXO4A5BHc/rxVxrEFo54JJFmiyd4fGT6Vc1okU4QcHTg7fob3jPQDF4in1NrhRBclcqUGY2A5/OqGhR6fLcyfaZoykLrLDLIBt3A559DUOqvfzRwre3hdACQh9+M/Wuem0YW1g1tFI5jkYsx3ZJPb8KL3Wr1FSpP2Xs5SL93fXV54lv5HhRbaVmZWI4I7EHvW3c6hPdaZa2c6rJbxtubB5rn9Mh8mBo3dWRiGZpMDHvx0q/HaTy3AWJiu7phuKUmr6GjhFJJ9DMtrw3+sXFpBaTLGp2qdpJPPXA9etbK2lzp90VmjeCOXCiR1IGP8as6ORouriR42l3dSrAN9RWzceKpbqGe0ltPPt3B2IcZX3PvSk7vRGVSdRNKCujjfEeoQ2is42+VHhAF5Z2Pp61mWeq297aCZVk8k8q5OPx/+tWlqtm0rxeVbRy2zffV+g9/apLLTLU3MUFwkAtZOPLi421XupG6klEoafeT3NrJsiCAH5JG5zz69xUccmo3Ms/2uxie3RtymPBx/kV0+paNaaOUlsAxiAxibPyk9/ce9Z+kINNtrq9sbqRLq9cCfcwYDt8o7UaatEKrzK8TGMxntv8AR4AkucBOSG9DjrT7HzJ5T9sVVmIyflIGc8cVWu9QudNvYYJoE8yZz5M8A2jHo3r1rrdG8EahomlXGr6yJL+VyCkMTneAx5J/Tijl01CpXhTS5nuX9Fu9Ns9Omm1S5SXccRxwS7iCOu70IrjbjVrM3aC4kS1Z2KRTsBxn+HpkDHvVO9S0sDLJBbC3geVnKoOrE8k/41F/Z1trVxDHD+9KhWGThgp5wQKElfyCFJRvJ7v8DRlSKWcm6kVlVcfIeGwcZqkLQLMlzHOpiPCx7cYB7/Wu213QbLTdHRzIkU7R/KCwOWPQHn61y+mSw3kMitbTRT/c8oqTk+g9fwqFtdDhVjNXiZZ1a9025mFzKzWrMI44h83mZOMYq+HQ2SxBF8uAFYrZkwgU8kVavLSztrOSAru1F+Msc+T6498cZ96yYJfsVrFbzTQTM8hSMyHDEnoBV7rQFaTvYw9Yu7gCSyhhENpJEybo1PAPU8dxWpZasJ9HtbcPJMlovl5c/M59z+lXfE9rb6Pp8TvkzSgFjnkZ9B6VlWRhljSQMpiIBC/dx/Shy92w48s/eNbQtPfxXBcx39uIXtlEm5SVJXtx3xXM3yzeH7qeeKwnWJJTG7vKOmchl9M+prq7K7ks/NmtmQyFVAG4EEdQM+mcVS8SXN94gkiuL7Yl0ibZvK/1YIHA/CqhPWz2Zl7ynpsZ1tqK3cQmeV1TBkO9iSv496d/wlE0VtcNawTXFtBDhZISVdpWOAu3qBjk1euYlu7UQR2+6UrtI8ojcvfJ6e9RSaXb2SrYXLRQyN84Vlbv3B9TSjy6tq46mul7GHpur6pco8d15sLh/kZgcjueDzx6+9aiF9Sj/e6haSXRXc4kAAUZ7d8+tSXcsdsmZA8ixER714b6ZPQVVtNIin0y41u080SR71aCRdykHqVPUGjR3b0KdkdJfQW2t7JWhhQFwqRjOFOOahvpIk029VHb7TZgzMLf53kTPK7T9c1v+JvDc9vpZu9FuorzAJjcDDKf9oVzXhzT5LK//tG4mYX2wu5DfKOen19aItW5mUpqpD3Gay6hpkSraKs4vpYlmUZChVIzgjHWhr1En8hXw5TeoK8ED0qK/aHVdXTVIWUq8ZSQbckMBjIPpVm2C7ozIwZUGNuMFqTSWxUNFdl3UdOWx8ndPG6zqJUliOR7g+9c/f2UzrvsJnE5GySUth5OmCT9c1vKoZAzQt5YPGew/wAKcvkOqh5NpU8bu/tU3tqEW0tXc528g1NrMQ2V9NBeDb+8EhXPrz71f0O2utHvv7Wm1GaadlCTJJL+7c45OD3zWwscKrIDGJU/iJGapXdlBerFaNhVdgApbqPX61Sk7W6Dk1PRo7O21yGbT47sRgvgtuznPvWNF4n1GeYCCZPLzxtGBW5F4XdtGawt41SONCi7fTHf1+tcbFow0lishYHJ3FmzkVCSscdBUZNpajPF+ralcWbNBM8M6neWXvjsKueHfGC6jbPFqFkA4G1W24Lcdefeq+pFHjAVg3HbnFWovD8V1pcV7Y3KO5GSqnGSPQ1bd48tjeUKSSUtDYg8fzadp0dtBYrPJHlQWfZsT8RzWFqHjDUtS1WS2BkjhCZ3AnB4z9MdvwrFhhuJL4gjzUVcEu3PtUc1y1tqcMJgkZZP48cA0KK7BHC0YS5orU2FeRcStLyvPzGtbXbyz1XSIbi5tUdk6tjIz04x60+38LX92kRlj8qOcA5Pceoro7/w7a6X4fS0khDSngNjn6VKaTTMauIpc8Und+RwySo2jySQq/mBSUKnHFR6FdzyW6SspMjBgRnqB3FWf+Ed1rT/ALTdXoEli8mYPLT7iejc1FCrSmVQWBZSp2nGKt2tY3jKM1eLuaFjLeOGeCF5QgJOMkAe+Ky5J57mYTF3jkjcjYTj8q3Ph9et4XiuAYJLqGUcnIyCP6Vypmvp9WnkkX5HdmVR2HbjFKyu7CpuXtJJx0XU2ptTvYw0vmmeUKSN3O4jtzUWg68+sanYaTqcaWpvXkjLgfL8q5H4kfyqhdaikNzBaTROJJvusFPWna7ousxR2729ybISEMZdmWwDn5Se56Zpxj0Ypxjay0fQ3LfTv7F16zbTtRtYvKuQ8/nKHaWEAgqozwfeurvtHsfFcpubKdba9BxKi8hvQ/WvO4rCD7WJ5XY3D5IOM5JGOTW3p73NhKWtL0fJ1GfzxSm+t9TnqYeTanGVpI2PEHg86XpcdxFN5k0ZzKxXsewrmt8kEG5ItpI4YHOM8c1sazqF1q2lNaeftlDA8k/MR2z+tcfo2mazaCdb8TeQxyAxyM+o/Wkk3G7exeGU1G1V3dz1vwhM2m+D31C8f7wJG7uBwK8dbW5rC8d7y1Lwu7AbRgZJ/Xg5rX1XXtS1TTYdJ0+YJDCduOBuI68nv6VnaNe3WuPBp9taNPfK4EsxA+UDqfr7etOMLJtk0KLpSnUn1f4dDbfQL6axt9WaCe5t920wwEBwufvEHt9Oau6jpcFjGlzBNLjaQRIOYyehPqK2ZvEcOlgWcdzEB9zygNxBHUZ9fUVR1rxHa31tsWB/MPy/c24+tTd9iYTrSltp+hxWheH7LUNZuYbmeSYX6skwHynGD0Pr6VueJ9Hl0M6RFo8M11ZRxCKZpGzLGR0J9feq9hL5MrT27hJI2BIVcFfxqrc+IrjxDbkafd+ZAXKzK0ZQsPX1xWilKTu9jecJ+0UovQsX0+pRRmaCyMrbQuMDoepp1vaXbCIMRHuwW+b7tUrC3uvtq7ryVUnKr5bHjb3NdhfeFpYdCuZp/Ms40U7XR1ZgvZsf0qNNh1asaTSb3IrKPRtZ0WafTr2R7ZWaH7QyNGPNXg9RyM1ycNoqSSfZ2IkY5ILkBm9j2rQ1CRjYxwpLMegKFsK3vgcZrImv7watBpy2xdWICHaT+vrQk9UgpQlBNydzoNIv7zVEFvrOIJEUklkyMDjnFZ/iSyl0u1SWEecGY/uWH3R69P1rQihezubm6e4t7kQjyHe3kDKsg6o3+0O4rM1HWBNeRfbjDGViKo5U8A8/mcdaIrXYUXd3pvQp28PnRK0YkLcFYw+Qp9a6HUPHGu3emXmmvElqMeSLnHJ/pzisTQJNY1S1uJxpp2QyFUaNt4lX/Z9cU5dF1DUdWjkRZ1VBykq4Cj2zRy2dn0HUVOo052djjopdQj1gabdQNcBnBAYdVPfcP5H0r0Cb+xdG0pHs7UXGtTDErM52IfYDrWgNGjhSYrLIZFQsCTkMR71jIu1BOWR4XwrMADt546d6qc+Z3SsJtVdL7GRqVt/anNxO4IPK7iMfStvS9dg0zRbiyS1Zr0jbHMG4APf1rK1GUyNOF/d7l2rkYzVXTXMAkWeQ/d3BtuQDnp9Kh6rU0lBTjZrQhtbZo5ZZC0kksh+YMKmhtxPdJdPbgvak+W23IBPGQPWpoZHuDiSMJOeqjoMd8/StVdetYGisbeCUQlf4owcnuSe9F3dtCm2kkkc9ewSTyMGl8x8nqc5Hvmqd5YM1nJbsuXdtysgDD6Yrc1EQTwzLbzrGzjBO0grnvTfCsVppllc/ablCxO8mTuvt69KL9Qc7R2MzTbSPT4IYJ7hY2forsFLf7q555qtdeHNT+0fbLOYmIsWK7sHGORjv9ap3txb+IZ/tAiF08cn3yDuQdgB2HSt+XWraXSI7STU3stUjlBjby/M3rjoAeMn3q9nb7yZOaSZz+s6rqlklvbwRuYS4YmIngj1xVrTPG81/ewxz6a8+TtAkyNwxjcG7D2rcN158ohg0+a7nI3LEABvb0J564NZjpbC5liljltWJ+ZEYEKT29fbIo91R1iF1N8rMXXtXj09PMljMs8zEoD90DPOcelWdKTzIbfWMywtFHLEsSn5C7jGD7jOapavF5OpGWN4108KCA4U7TjnOeevpXYW2ntP4YnWxVrn7ZIt1sVchdvYdueap8qirbiqS012NbUNStdIR5kv/ALNbiXygDlgfwH404WX9pBo4dgkdNxAPyMp5yPr6Vj2UVrd6hKviO036UDuxH1U9jW5d6rbWesQrotm7WBXiVyW2/X0A9Ki11puaSbi7JfMoXEaaTLbae0TK5HyBRwc+4qzbaewuLeOZykch27zVDxDJNd63aXFtdqDAAZIgeck5Jx7+9aE93I8jR3R3NtLIwokrJM0Tk1qdnp3gvzZd1xqHlxEYHqV/Osjxh4PudOV5rK6EpKnarjgj1rBvS8tuqNK8m0CRV3EEMpDL+oFaen+PdRt/BWo/brRZbmLAiEi8sp9jUxUnqjilDEwmpRlfy2KFrqzaTYeXcSqjTqscmQcF/b2qpBYsNYivhnejBtpAwce/p7VBY+JLXxBBD/a2kgI5PywDaQ46fgRWzd6Zqdtd28iJt09/mzxt9wfcccVe2nU637r99WbO5sPFFslqryTpHKgIeMqcGuM1rXY9f1p4VijiSNCQGP3h06/XpmpyllJBiaXDNwWwOTWeLCB45ZPPwxBAwME4rNWWxz0sPThJyW5RkSFYw1qQrcAgtkmunfT4tU0mztrtTBbxOs6iJ9gO3kA+qk9RXMaRo015JuKMIUb5nAPNd5qk8htEhiiRUiGN3qAMcnpTUncrEPVRRzippmrTSGyvbaW43suInGdy43DHtWVBY31prLrfyZsJBmOLZjn16VzNlplrNrpuEvBHLE5CLaL5KJznoOW9ya6vUPFTX00GmAkz24JDYxjuRzWso8rtDVWLSmrI7bSvGU+naeltcQiYxjbGzdcVja94p1DUJ1a22xFF78k1zuoz3JsZfs4VpiuBnqM9xVHSJTa28MeoXaeac5LtkD/ZBPJrNQVrkQwlKEnPl1PSPBfiC2Vf7P1pgrXRMaMWyjE84x2rg/GHhjVbHXG3ao8kInaWDy02gRkgheOpGMfjV2do5OedyEYK9PrWhBrVzGFMhE20fLu5xTjJx26kxoOnUdSHXdHOatqX9n2cXmiTLvtYIcY7/wAhWrbXF15B8mUDzEx8y88D1p+o+Mpr6/s7CPSLO+medY5lK7SiHuD61teL9Gj0V7SSIkxSr8yk52N3pyVorTcr2y5lCorN/MvfDKytblJ5NYkgur6Nh5QfAOMdcd6w/G+tXuqX7wMgjjhyqxqeNw965iHw/bXMryzs1yu8Opdj8pHTp3ratdUjCmONEuCWIZsZGalpJ3WpEcPas6z17LsZelSTYRb1fKLHaCP5mtmXwjPolpLdLdi4t5ApPBygPf369azr2+t9Qs5UskiE2dqSI5IHPIOPyrZ0DVbz+wptKu4Wu4ypTfuIYZ7Z7im20v0NarqaSj8yqybIg8UjS56spzg1DNq13a6Ffz3lzK8NsvmM6r8yDIHTv1rN0XSp9FmkaMXLQsTlScrnt0re0m5e0klW9jDrdDBB5H0I70OyfdDmrq61Ziy6rpdnbRveTtO03zKoQgjjrmvRPhNHZyaTf3EMSi4ZyDJ1JGP8a4vxZZ6fcNZB4kJVSZD1w3UUvwohvrDxPqc098zWbJuCJ0xu+UY7d6mSTjoYYuPtcO7aGbDowttRRr55d0bu7YPDktk/0re06ztvLkuLzdFbSMTGXB+dR6GqWr63cwX15DLCkr+YQiOueOxq74n8WNrOkW2mwWaQpGiOzEcqy9dvbFOcnJ6mjVV8qS0e7vsaNxaWLRItlMpmJ5RxtB9ATWNZQWsmpz6X5MVncQHzH+XYoz6461gW2qGXU4bC5xC8n7xG5w5H8IPqa7nUNTQxhDKkpBEccMm3zdo6NxzQtNGTOE6bUU7mNe+GJ7jX4bgSxhlxgZ2g45B56VoeOdduLTRDbwGS6ZgFdImyAO/aszU9Q1e7Robi7LwFi20JjAPXaeoqW3t0NunmPIGwNuCSQKfNqm9bC9m3Z1OhV0GxbVrq3t98sG9fNZWBZkGOmPWtDW9FGhzQyvO85bLRvyrKfWseXUb3TtUs59PfehB85j1IB6c9OPTnNSJ4n/4SRyxUmGGTp0bOBgflQ4v4uhb9o5pp+71J7Fre5I8+M+VI7OyoAqs56s2MZb3qDV9OjuN9parLPE+HRI8l0Ppxzirv2NGu4YLWZBLPJtAYHqfpRpFzd6DdyXc0TWkoYqBPtBYevXgUld6oHJR+HfsW/A9tLoMO6aN7dP8AlmjnBB9cHvWZ4s8U38erxLpyIU3gvIFLMT9c8DFZnia/vdf1l7iS4+zkr+6RT8ijGD06nnOaj2RfZm2OzSRr8zZ4c0WS13FCjzS9pUWo658QazdXy27u4tHXLGIYzgHkn+lWtESG2u0eSLARt2xflyR0Oe9VNMsruWATCLycsepJzntWnpruDHZ/aAnmEoNwwFbPrSb6GrUUmojdZv21BVhkiT/WZVjwwHp+PrXP6gkQkEUZKsV+43Of/r1b8SaLq9ldRL9qtoYXYGQTMFJwc8eox9K05fD8ltYRatdeTLFEvmo0OWbAz1NDSVncmNSEErPQy9V0K602ytphLAbUkCb5sNk84FVJIHkfbbyswPIBOAcdia5nXPGUUFxF9qkWaNT8se/Kr7/nWhoPiaK+lSIXkG9xgRhSxP40uboUpPaT1GXWq3Vvcpb6kjebhhuRRgIOoJH6VbhurS5ij8sOIuVIXqD7e9auuXgg0WIW1g13PPzNt6Rj+7jvms+1t4RA3lwyWjBSyqCNvTpitJWaTtYISdncrS2zWGm3K6YkUfmLwyIQwOO4/wAKw7XSbiG/iuNbjjJQApIZsBvTIHPFejaZ4MuLKyjeTUIJlZid6s2Vz2Ppiue1fStNt9Tmmjgj+2S4W4bzCQwA4yPwojNJNX3IVRTa5NSWyuryw1WyvNOuY7ZbV90uU3syAZ2DPAz0zWNfeKn+1ST3un+cZ5GLcYCkngA4q7HfQxTSWjgM08LKu1eEbHH6VXhtyrAyMWBHIJxnt6Uk0viRXIuZyLFhomn+JNFNwjXdvJFKyHLgHIGcgdxg1QtPFtxY6qtjbWby6ZGoVF6OqAdQfr+db2lXLWlnew2nlbIomkZ2U/Lgevrmuc0+Jbt0eF4JJYh+88qQsAevpT5tHpoSoXk+c9HtdIi163u7e2kVJrdQ3lNIFZ17bW6HHoaiENpaW4jMrGYKBhSCvHHJ7n6VRj0+7VkCZkOSWKelSLY7JkSfMSOwG/8AhHPU+lZ36GyjaT97QSxsIrLWP7UikRrxiSVfJU9v5CtbUdR0ppIWvovsjTNtLRkbSfpjinf8K7uNKFzqyajDcrKCyxlyD1zxVbT9IOrwyyX0SFUXKwscHcOhBq7pu7d0Y+0pTTnF7G3pmm6ZMqyz3LpGCAAGG4g9CPasDV7jTbfXG01VleJjhJOPz/8Ar1Xmt4luo5J2MflkjaDgL9falJimw8UsUkZyd6HIyOuaS03NI02pXcmKYrSw/fxvgrknPQVrprsd7cQ2t25VMAjAwoz3zWHgCJYmh80EnOMZGe/PWiXTi0QBG1e2Ow/pSsaygpfEd1d+HrK4t5Fsp4llK7lkfOAfX865m28IarJqCzajPCpjbA+zyFldQOvOD36e1Q2F5dWsBikbzIgflyeRXRaZqsV7GqLK6TKc4z6/yoUmlY45Qq09ndFqW+XR9IaKKLc6dM8HOetcreand6hMWIPOfkVsDPuK3PFzL9mgR5YzKW3BFPQf1rlNVuZLWKM20YlZmxuQcinFX0ReHhG3PbVhYWltayu7w7JpAd2Dn649OalvYLVPMv7NUeZVAUsPmbt+OK7GDw5BcaNFcuWeaaIMzt0BI5FcNaaNdDVLgSSu65IEZ/h9OacXfVsqFWFS/K9jqPBemTanpn9o38RiIBYKRjoeOPwqp4j0TRViWT7KIyjEkxcbyeTke/eux8IzSzaVLb4JMUZOADg4GMe1ebNHqs1vIdX2JdYLMsXKI3ZR6gcURb1adjnpSlUrSUnsOvrgw2LDTwBKrZ+dsEj0p1l/aOqojQxp9oVQzoi5IHeszRdJ1OS0ubq4VpIo24cYJHr07e1begXZtZ2c5SN/lZhgFeeCKbdtDslom46sytQ0Rpr5ZoWkh2nexTPPsavan4iaBrew1C5z5ilt/lFwuP8AJrotdsr4aSlybqC4lySZIFwMHlSR6jpXHxWUlxPE0jsWH8XdefU0cyestbGdNqquYn0KKWfTElt5vNtbob435Xjkcg9D7V3XhOx0PSdOc3E1sJCMsr8sPoPesLU7tLqxtLfTHB3JhnUDBPbBHWuX0uaKzgljuJZLmbHDkEAnOD1680muZNmc4SrQ5W7Fq6sbWLX5dSijEULSbxAi7VJxjr/OtW21tfNQG28uMZ+4cUlk63N/bRzPE9uWAKjgZ9M1L4qkjF+0ekQh4Y2C5HQn2pOTm9TSyuoNDLiPVtWv1a0V0h2gFF4H5d6qX+oFNVgsLyFlnYbBkcKT0JqwZdSbSrqzs7ya1eYAGaDmSLnJwT+VdNqf2bWdLtZPLje8tvkVwMSEd92PejmWlzKUpU5pW0OC1Jbhru2ihw8T/LI4b5lOcYI/lXd+FdO07S47wTaik89uo85IiG8skZ2uezd8Vzs8CySBC4i8o7ivQk9qh+23QuZDcvAkE+PMWNApdgMAuR9449aTaasVWhOquWLsuo7U54ri9mnYBY5D2bLKB3xUc6IbbduaJwhETNjBz/erLhtk1jUZ7jQ4JFvt6RSLM2I2XOCR6EDtT9Is7uCS7GoTOmXZTFNkkEMR/nFW4W941TXwjrTT5p1hN5LG90hLKU7A9KsReFHv9TW4gjummOBtijJ5/wB49M1u6dqlvpun3MX2XfdAcMACX9uRxWLo2t67JpaHU57iK9dnLxZGEXPAGKE205GbnUbairHU6v4fh03SNs+qww6q6lli4cKBycjIJ4rOa/0qOABdOaViv+saQgY9hnpXKzxabrZnlUmTUIAVMhJLgdyp/OtDT4BGiQW6PK23AB5Y/wCFJqySJhSdv3krv7jV0+70PxKZobeJ7G4jO2N0bcr8fxA9Pwrl9Y0bVPDdqzTW6XHmS/L5R4b1ztHFdrouh2OhWdxLdIsLyne8kXO3H8IHr9Ko6x4n3Rxwx2EElgX3bZgd7HHBO3GPwoUrOy1RNOUue1PVf1scdrslyrpeWmpGwDwqUj/iik9M9/rXV61qq+IPDVnaSuZLgBJJZ1AwrAc49Qc1hwatomsXMludOktcA5iZhJGxHYHqD7Vs3D2S6TNdLakxw/J5UfykEDjgdvpVNvRW1Rc0rpyWpV0bRVumjtBIIDDGSJS27OO3vmoIbG5tnure9ubWOFX2qiR5YEe/fNZ0UsWqwwy/Y3geP5gVkdXB9jnOPanx3lxLrJtHsSUddzXDPxn69c9qi25q1K+r0O2udUhfw150Y5WAg44wR6cdc153paXlqzT3N2lykpGIzn5O+ea14Ult9JmiabzA8y5GTwuTj88YrKsoXuNcFvKYYLORwgmjO4ID6j1oWiaIpQULsm1C6s/EEG4SS3ADBRIjjKEcYx6YzW9pmq3Gk6Hc2YiMNjMNsaStuDHaQRk9M1g2Fv4btUmh0mTUFulmYMtwgCSAfxL3x6VqCA3ReQuJMIVxxheOcU5rXl6BJQqQ1Wh82+LtKuk1OYxoWi3HaqnOBmt7wTa31jBHO0RySNgYYIz15xmvQ7DQrGK/nu0kN6jth8OreWx5PTr1rols4DYooQZiPO4dvXj8Kz5Ep3MYYSMKjqp6si067a62CZWDCMF1YfzxS39g01syySvGjchkPzD2x6VZ8KWUeq6kUeJY7aLJdJ5Noc9O+PyrOv7mG21d7e2eUWrOdhLbs+1Vaz0OjmTfKdT4VvLiWwkheSVjaDd1H7wZ9+hri1+2zT373m0PLMyjDD5TnkmtvwXfyy6gz25kw0ZjkiYAMwzyMHjpzVXVSt5rF1d2sTodxHlB9pGOPpnjmktLpmcVy1HYr2mjLqErJK8TGK3kkaTptQDufSsnTr5ZmNz9sV7VlxEqqcqehOe9aFtrrWWsXNncWwNrdxbZGYja3bYfbrVSLR7zTbmHyYwmmxjzP3YLAJnkD0z6mrs7WZV3zO+xoeBVk02+u4tWu1mW9Qww+dnoST8w6gEUz/hDW0rULqC3eVY3x2y23sAcdPesmL7XNqktxK/7tpMqT8uB6D8K3/E2u3LTwSWMsnzJlY26RgDBBPU84pOTu9dyXCSknHqbmiay2k2iCOVhK5y5fvU2oavLJbN9qtmnilJBKLtIHY1mNIZVeLMZAGG5yRViGf7RfJPfy3U0MVottHErfJGFP3wvXPrSjbdm1SCvzJFlLqQ2yxpKY0j5VDJyBVSU3379YrkwxyKVEgYFhn61LpHh+71PxCJGu7I2IVireZh8Y4G0jrVOO5vLfX5rWW3h+wqGTzgvJI759T6Vaj2fmClFtxRa0afRo9Mg8OXE87zAuBPMuR83O0t+Nb8fhK3sbQot0mxvvKWyenXP0rnZrdFdpZbZC7DAlIBIFaiXkr2Js/M3R7dqv0OD296mUrsl05L4GbGkWulLb+VA6XTKfmAflfXpzUr6HBcOfst4Y1H3UlGT9MiuEsNJXRw0lo7h2bdv3cita31G1gv7O61rzJXRtscqzFGAPbHQ/iKOXXQidKcfei7k2t+Zo3y3kDbVOflGQy9iKw7RZ11STUIrsmGUfJE3ylR9K6/xX4ie/mjgnsIZbHy28u5DBGjfPAI7jH4Vzkgt1eCaJt8IXLRx9W+pOaa0RpRlOUbzWpPrGi319by6jbykXIiWP5j8oUHPT8etGm200lvGryoZAuGwcZP0roJ9d0SfRvLkupLKYL5bGRS64x0BHNeb6l4futOYavY3dxNZu25pIEZwwP05H404pyVmKnUbupaHa2ut3WmBIYp3eJjgxnkVpanZx3bxzvI0ZfBbacA1kS2a2lpDdXTsCV3srArgdRn2psep/wBpW4eC4Bt0+XCnjPv71FuqBxTfNE7vSLd7OHzrS4ACqeAe2P51xWo3Pm3M6QyFwzHkHn6YrK33SXhZbg+SQMjdwD3FT23h7UZtQl1SymaS3RPmgAJI46/Sny26kQpKnJym9zT8Ny3olubJXVRcIViOPuuRwSO/NY+o6NqmkPZW1/d7pym+QDjd83LY7inpqkh1AwWUqx6nGAy+ev7vcDnBxzjANdb4lu7nxBLHISojij2gJyMnrzVO8FZ9RSlKNVW2e5gWWpyW5ktfMO1gSoNZ939te6sGW9jWOHeZ4wMGYEcflVy4iit7e5vrr92kKgbtpLMegCgdaqy28CzxTyHE+3KBjjcMeh7jNEdNUa+62WrOeyjtI7K3RonXhFRfl+grasfDmmf2bdy3+RJjcZUICocdPesDwh9i/tR7+adZ4wDyCOT9R/SpNZ1yyWVNOjE9vp4wVGCw74LfrSs72RnUUm+WOnmZ8ui6UkVhqcBmlmgfcsTyHaG9So64rT8Gw6ZJqWpQ6nePI3mNfMmG2bWOAufqMccVlane21nZecYfMiOFVYz19/yq+gnvY7YwqBEqA5IwQvUA1Tk+WzKnTbWkrEUep39peyJa2vmWRdirg/MBnjPP+cVNH/akur21zp1x5ZjZi9tIcLcZGPmPoOtaGm2cKSXD33zEp+7Td39yKZDCs0GVYEITtycMPxqea2qQOzTiWPiFPaWcNre3H7lzGI3EfzZbsf51xlhOsqTajfzKumRlf3mCA2fu8AZyfSr+qPeSXEMMtt51rIMuXIIPP9OK7PSDolzpf2JIVUoAzwFOdw6HkfTpTTUErq5DTpU0lf5GXayS2lywtCibOMjvTJStxcPcagnmux5J4/LHen6rp15aM7JHJMpJKmPvz/Eew5rU0XUNQ03Q5IH0xbgTHPZzHn+8OuKzS0uE5pLmhq/uOfFzEsDyNERIJNiA5Ix2qxbzaAI4ptV/tD7Wsv8AqIZNkch9GPce1OtLG6WByIjNNklhxj24HSqeo2cjQKbK236grZUFNzKe521S+LQqajONm/xMfX4oDe7NOs5dOjlm81vs0hLgD+E5BGDmvTllgh0zzbGOMxtFvdkwC/HQ45riHe6iSR72BY74oMqUxj1xml8MeKZbOQ2M1n5xj3mQP8gYE56Y4/rTalNX7GVWnzRXLr8yvpmsR+IJ5o55sSLlYoHcDGO4HfpRNGk0am4CArlduSDn8KztTtI7m/mvLGxhhuyAY2aVscdyoxXR2+s6BaeHJpkSV9SVdhwQ6bu5BOe9OSTfumzk6aVomh4O8IWt8k89+7QnGUHAzn1rktTtBoWqXzpI8qQOQEdhjH079cU+DULu905Vju5xJICVePpx6r7e9Xms7nU7GKYKx1FYwswVc+YR/Fj3qdr3ZK54zcpvR/gaPw+v7K9SaG6hgUyLuV2HzY7riuWktpo9ZnR5EaBWZYiqk4G71pYPtdtK8N3E8WGwu5drA9zmmzrcTQfZUk8gMd3mLndj0xStZtFxjaTnF7nRanLEngSJVdY55UVY1IzvYNya5XSpb6W8gguDDIryjY6MMjkYBwPrWvq9u9v8ObDWFgYiB5IGRh8z88Nz+OcVyfhvUDdiaQJFFNbOrF0OVYE8c/0qlGSg3bQig4u9n1Z1XirToLfxDdC5ZHlADLKrH5cjp9RVrwlmOx1KJLmNtoyGf7oXByTxwPWsq/kdTMobzsnfz3/OmeZHNbxRsgiyCNwPX688iovpqX7O8OVmbZ6RaaWZJIpmgEvzsw5yO2Paun8J2xfU5Jnmil08RDKE5ZyevtjGeKx9C0TUbyGSMOt+EOTIG+6uOQQe36VsaNdR+HorqaMpJKVxHEpDZYn09BTk7t63ZNWV4NR3OYuLaODWbqcCR8FlWE9F59e9WWZbjUXt9MuI8EhnV1IMDdx7/hVe+vbuzcKIg0rOTMJR1z6A9K6TQ9M006XFdG3i+0XTMrO0hAUenHeqk76scpciRj3GnrJdCKO9lhuY8Hz4nwyv1GOKjuIbtI2Qu87rySQCHPc4HTNUobhjrNxpj2s2Iix88dDz1NX9LjiTVYVuJHktWcrIzdAe3NTK60ZS25jJ1fQpLzTluJYLmOMHcoReAT/SrGm3N8thdwx27MZU8v5TkCNfUeuf5V7OYt1rbwny2gIDKIzyigd/aub1KfT57xbOJoWeJipktuSfUe+Pakql1ZnFHFc7tynjw+2CIrPffMHBTywSQMc5z0HTir9xo13rhtltbjypYzhTnqT6/wBKvajZ6hpms3VqbxpLfjynPV1b1HY9qo2dzeWeqETp5Ni+EaVXHmDJ4cYPUda0Une6aOxyvG6O21LTrW11WKbTYjIl4MSBpMCP3A75rTS/soLaQXFtJ8gwAD0rnLq+t543a0m89IxtXBDYYdgRW1o9zb6naxQasywzn7sq4BPsR3/Gpa7hJWir6iadeaBqsnlQziO7QFn54z6j+XFYfiaW+sXtpbaHz7Y/NJIGz3xj2rXbwWNK+0XVk63CIpLbTlkU8nA/wrOs9Qiu4neNJ4FjITax+VuOvcGqVk+ZaocGnrF3G2KXGr3EV0nnGDGDH1xjr7Yqzp32y4uJob63WK2gP7uUcEnPA9DxzW94G8R29h4i/su+ttsDAMsoQABv7ufeqvjm8tV8ZyQ2nlpAw810bIznrt7ZzSu3pboR7WXtfZ8vncNLtLJ3nE9w6leVUdzTrrQLK6uo2ulkaOFwVB6c8/jyOlc5q1lNfzwtaztbLG2WOT09a1oLy6stssN1zx8rjcG9ODS21T1NZRb2Zb8R+FpLrTJRZb50cH5QQSD7etYOg2l3ZaTFa3Vs0YhJ2sVIJHXJrrvCcmn6Q81pDc+Svlm7ktpCW+Z25cE9uOlXfEfia0ubUR2lqxAGDIF6+pptu3KtjnhVq8yja5yotbWdXjkEbIw5DD+ldJ4B8yxku4bNgP3YVP7o554rh7zT57rUbe5W5kiSM8xLnDV03hXxHaaXK8UskUUpcI0jkYXPTJ7UmtLLU1xKcqbW5L4x1NVFzHexRSQRf6zA65649qx9Figv4DaaTA8ST/NkHndjGck+1T6us0GsypdQpNFI+7zSRjB6Y9RioLu8trGSPfMsQf5V8tT69eO3NUr25UEIpQViwz6VolvcLrH2gmEHzGbrn0x9a3PAfiTQncXVpqLxwlhA63CbMFjgDr3yPzritesptStbiJZ8yy4G9uQaj8PeGZDb/wBml4Q0jh2EvRgGBIz3PHFU1Bx13v8AgTVpKcGpPoeg+LPBVzHfXFxYbp2lYlQEAKg9hjqK5fTdD1PTNQb7ddfZ7ZnwomcoGPUD5u4APArV+IF3eatdi3S4ktwIhGgQ/cPfp3rj9W0M6rZ28WqXczx2MpuAWLOVTHzKnOQTjr1pU9dJMxoqsqS5mj2LRbbSbqyWSG4eQ+X5js0X3vpnt6Vyvj7S9H1H7E65FzGxkhVTtLAD5lz3B4zTPDMmsataWE3hm2gbRZY8PLNJ5TwKOg2Hk1X1FTDeXMGrXNtc6mu4QeQDiCJscc8Fjjk1MU4u9zCnFe10lfyMHRWntNOlSK1itF3E7V53E9yTkmriRJPbiTVbZGeNsb4tvK/TGB+FVopIDM+mPMz3kaebjp8hOOD3NQ6zfNpEcTRW5mZyE2k5AGDkn3ptNyt1Z6SSex02rWujTabst52VQi7DGAXGO3TFYNlqN3DPOpt2tolb5GXkOvatW1Szjt0YcCQZwcdwODVmO/sreynsGsXleWNnF1uACHOFjA6++ai99DK/Iras5WHxDr8GrJ5aQS2kkgMu9ASAODjuOOe9dpfWq3VtO5AsfPjwkmCOcdcHvXKaRpz2RkczmNlO8mfoP/110+p6/wDb7C2s/LWPDbnO7jgcAVUpaqwVItNci9RsOl2H9hwNaTXcs9sRFPLPHhZDj7ynp1qQwjTGtbtF82YHqTkZ96zL2e9sNOuoYXEkE/zGEdGYDPHpmoPCOptfSwrqcRgh8zG13O0nHUE9PT8KTTa5iVCSTu7r9Do/EF21xBHCjRky4Zs9gOmD1rlv7GfULrdFeSQTQAybvMALjptOetdb4phRY4praPZICFKE7gR65FczFNJcOBdBdqg/Njr+NJO2w6FuT3dA024uPO8u0yJyvG1ug/CtzVtcvdIt7a0iuIm1JmElxKqjcF6hCfWk8DwtNqT+W0Z8tM5wBnniue1yeG2117G9Um6dmO0rknqaEm27dBSUKlXkktiYeJYde1G8jvbe6V4m+aTbwR0yB/KrPiSGfTrSOR/KnhmCFJkXJIPI3enFZMUsMl4LNZZBMybgCeFHbJrRmvZLCxjt7nUDBHKQI9zAbueBTS12KlHltyCapBd22mC5kgjhW5ARGJHzL3/Ssy30aziso4dOYXAPMqs+489jmtfVPCV5JpV3fLJdi8cASETlhGo9FB+XI61gW8v2C1SFkkluCPnYjAPuKb2tFipS51vqjVttCu9R0yWCwjaGLY2GHGD3wazNNv7jw7p8BtXdorcZLSE/MCeQPQelTWWoie23wvPHH5giljLYyven6nbWbKZIRtQruEZywYjsRU3fwsu12+bVHU3c0F34Tvru2Rp42hMsKk72JHr71wejX0eoaY88kEtuytgKX4bHUitnw34nj0K9eweNZ/NHMC8bGxxg9Ox4rH8XatONX8/Q7S2jimkxiSIfdwM4B6c56U0tLNfMyowlTk4paHaalb3E3w9g+dfJR0mPsDn0+tcYkMAX95eIC5+VY484+tdl8P8AxBFFbXWm6g8TQXPKJIPkUngqT+tcV4kmj0fUFTRbdbuzknaIsrZ8sg4aM+49+1TCLloKlKUKkqcvVCtfaVqFtHYXcF9cX0kwgSa0GViz0Zsds4rM0q8tUubq1MNyr2h2jziNpOSD8vrkdK09Njj02483TpJLZ1bIcE5PsfapXsZJZWuBgtM5ZpXkzubvTco2aRtGLjJtvQYijyWQrPbrLlXK4BII9KrRJDpVqnl3YlRcvJJMNuznuBxjpxTtSN41q5szHJOjYXrgjvtz1NadvpLXPg+5vNbiNtvYQfZ3BRpmxnKk84B9qaTtrtcJzjF+ZQUQySxzsguzJ+9iuIX4bsQVzVYX2pRSRS2rfLLnzQFB2tnGME8cd6lFvBb2tr9lkMDJlVjXncO/Pr61HpU0s/iHybuzY2cY3falO0M3pn1oSeo3ZLUzdOvdRlup/tcTCItmNuFLc9+ef0qW+0i5vDZI5mh2S/IoXIJ9zng1r61LZ+afsSq398xr0P1qt4JSSy1uBk/4mEczESSOSvkDHzEDncxH5UX15loKUrRvYs+Kbifw3sjvptktxDtUuT8q98Y7n+QrGttUma0jVFMjhwflQ/8AfS/hXUeM9FGtP592N626hYoictEvofXrzXH3DX1tN5MYVII/nEvTB6f5FJWsu5FJqUNd2bWu2mqT2drdTl0KDLlkwwT6dcVjQoIpWkC+bC5xgHk11GseItS1rQ5YoYVQiMIzN1YAdB6fSuQsGBhHnSeVJkkxhwAQO+Oxo3iOlzJWkjuLHw42m6TFeWxDiTl0I+dfQ+4rC1TTmnljmdnJi+YBf4j1rf8ADOoXWjeUdWkOohDh03YOM8Y+lXte1DRrwifToLmB2zuiwME+3oaFdNs0U5qXLJXXcwNJ8eTxaI8w06V7uCQRqDkq4PqMdqv2LtOB58TQmYLJsAI2Z5IxWE2sanJJbCC0a3LzFXUnPyetXIbi48RzXulRPOHjG5nX5TgHoPatZQXRW/EFFRuyW/1GKO9FoG3TAgBgn5c1rJfxSRKNRh3bekpXII9KrT6NHBFGx89bhANxcZ/HNYWn294+sTSzy+bZtuVUWTcD6YXtip5FbfYpOMkelWc/g2KzEuoXD2wQcsZMLzVlrbQVbzbBJJVUAiSVwUxjjGK8+udFkvvLSO2mCg5ZVUsGq1e3MWgeGLS1v2mSFJNiO6k8HJCnH86lQvotzmlQtK6m/vL+uXMbW7zW8KPcIpCADn125+tVbO8uJLRXvLdAWHIxgipbe5dJFzteIjGPX6VJO9vHGxc+Ug6KVJP0ovpY6ElHQWG2u2tvtEEQCqCAp5z+FV/A2kW+pS6k2vW0VrAzCM7zw+euc/09afpssVqJZUupcHkYfIHtWb4l1PUJvJexWOVwfmVumPbpVRu3yomalJNLQ09bn0278UfZtKeQ21narbxQ9EUDncP5c+lMWxtZJ1W6+Yg5QsBwfbNMhhbaZLcRF3ADFfvD2qCw06WCSVbi5nklY5Xf/Dihu+oQioRUEy7c2ptgpydpG4dgax9YnvLyyP8AZ7KJ1wDu/hrs7O80jU9Hks3nRb6EnDf59a56COKzkZE2JvyeB1pxfK7taihNyuuxX0qC8lhhe8kxMqfvGBCgepyTxWzKyW1u0SMWm+XccZKqe/vn1FY2m3K3Gozx3iRy2BYBo5ITglWyMg5yOAatavrF7ZsY9KtxctcTl555GLvntyeFUDgAcCjlu7BNybSS0LWkahqVkGt0neS2KtklQCM+9VtTsxptzb/abiKT7SvmKc5JB9609N1mOPeb23WRwvCKMBj2zWSyza/cma+jKTqcIG6Ko+n0qdHuKKkp3tZfmWNG0yH+2IvK+YYOCyfMgPb6HArrZ7HTN0F3PYp9ot8gSkHjnv7Umh2yaZpz3VyimbJ3tI+3aB0/D2rl7rULnVTLDPM2xDvC9A3vUavUxlerOy2Rlaysz6oTZW8b2Zm3Y3cAewzU15ESk6I/lM4+Rwc7DVO0sjYagBcCaW2Mgc47DPIHvXRTWUE9zI9jGhhCgxlGJJPcFTVNnS5cujGadoz6xpbPcTQqYuMMxAOOc5zxXNXVrqLO9xYzJJGvy+W3OFx2HHOec5rodRMz2DxpEEmA6D5c+w4xU3hnRZ7iOE3kTRKw+Yodu456f4mhSaVyeblvKT0NTwToF3rmmebezRwRxY+ULnLDr+ArlrySwvLr7MxdZoZ5ItgIG/DYzjt04NdZr+vyaI0Flp6bIoh0Qbt2R3rl7v7HJPbXd0zi7kckSqgAQ9wRRHTUype0lJzl8L2RX1fX73TzElnayyDfsGxs+WDWrY3cc0khvIXd2GW3HIbj0p0Vi0i+YgRmLcSH5eat6cljrtsXsY57e5ikNvKssZC7h1+oPtQ7W0RrKcIqzJ9CvYLfWbUJGkUU5ChQcZOeD/St/wAQafp99qUl9eItpJCvltcNjL+wPWsSTRYNMtv7Z1N2nksxujtoEIfOfQ88elYOt3Y1SVrvULiSONF3RxOMbV9cdzSt1Ry8iq1OeDtbqaeqroU1iU0hFa7UgeduIUfie9YF/o41B4ZMeW8JyoZsg/T8u1V9AhufEL3Nhb2LhJv9WBkE4PUnp7100umwaHphsoNVjmvw+HgjTKpk84NVZx0vqbc0abUE7tm1qXioQeFnlgSO11CL/j6WNAWdQOcfUV5Vc6lcT2D3enXj2yRth3lBCgDqN3P/ANetGbVlubqa28oFYH2sSMeYO/PepbERXay20cDxWqkfuHcNGwPPK/0qorkWwqVGNJPl6l6x1LGhrKbaC484bzMsALFcchc+vWovD2uSXWnXKWunrC0jmNZXAB9+vNQXuoSQtexPK8qIQyZj4jUfwoBwABjtWPYa0mrz4iuZCyDcMjpjvUuDSbSNIxUlqaxEQmUXVtCZwvE7AM+B6EVoyWcUoWOaP7LMw3pvPDA9CTjiq9t4eudX1G0meQQjAwp+VnA6lR3HqazddGof27hpwLaI+VLCwG4bT0Hc0kk+ouZOXLF6jNZ0vU7a9s0hmNsAP3quhAYZzn0birnhi3Gs6hJZ3jixZpw5dSCZSoxtOevHQ1tXGttq3hxRdKvnxgI7SLlhtHX8QP1rgdHewuL+4ubKKRZhwy5IA6HIJ6etO75fQSUqkWpaM7XX9Cn0xnmt5TPpm7Bm28xZ7OP61z+qXVlaaQbiGQXao4R1gc5J/wAPet6DxRLc6fJbGGFyyNEzBztcYxkj1/rXMhUgcDT2aMsNsiqmAcep71KsviQ6aqWtM9W8Kala32nWU2mW9qkRjB8l02shA6N3zn864r4ma66+I1tmMoXaqwgjcqE9cE1n+BNSkvvEccdsk0BL+W+7J3DGcn6V6nqWkQ6rpcsUjwJqEqGNLmWIOUboDjuRSSUJWkjgqcuGqqe54PHPfnxIlrYwo6RANKxXlM9Tn1rU8Y2sd7Dp0SXps/Jt2hZS4VZXJzu9zzRqovtKtXtSz3FzbN5LZHzuQepA7elZN8qXWnxy3tvJtwGeM7vlY/w++eK1UrSTXoei0ppS+ZoaNZPFBb28UrXM/wBzBGGYHPGDVnU4F0Xw3PLpqMbsMWmaNuNh4Cr9OprYm8a6RZ6Tb20xMckyeWoJ80wnH3VOMg+vPHSuNg1nUJrua31FIprGUEFN2Mr0+vTtUpNay/4cz5p1NlsM03xDfwWUc+ZNrnzNnXdzjOe4rWuL3TGivJJrYQyuytGVyVQ8Ej0FXfFGkQWWkafbaYUjS3URmIxNlA3OSx681j2thayzhXkKyDAbnhvz4qbrcuLU1zWsOtorhYp3sLc3TAeYiM+0H3Gf88U+30PVk+zy3kSWIdeYnYHcPqDW1YXVl4etrqNo3un3Yj3kDjHr6VyuvXuo6uglhuCZUOGjwEEa9gO1VHXT8SOablpsd59nYRCWW2Zbd+kjIQGP+961UliR5GaJTsB+pzVzxJ4suJ/CS2lkYbC6mKJ5d0N+3jnaR0J9+lYHiKcR6btjSSbLBT5RwQfpjiqjTbSv1Nac5O/MrGqLWR0aZoD5CHaZAp4/EVV1PWU8ONFfpFJvJ8sjIBOR1Jrf8EaxczSvpOpW/k2ccIMIYfM4I+ZW9/es/wAXWsOgGBrwLLbXS5hyM5XPRh680oR95Jq/6i9reThLQvx+KW1fSI5YodiyKDh+uMYB/SsqLWNS024aGOOGG2bo3lgkn6+9Su/2W0kaWMsqIDGiDOB6VDBrt48KsII2j2gjMfIGe4IqU99NBqmvhijt9H8T2VppQ+3LmZX3MVHauRk8TwarqNzbxktGHLBHwwGTwDWEmuI00x15I7SGQ4DbdoU54wR1Hua3V8CyaTbyakk8bLMu/B4+Unt6+tU4qK9SFTpU53ejZ0nh/VdPh3tfSx2/GA0uMZ9jUPjTU9JtNJklsgdQllIf923b8q5G9s4dRjUSAsi4Aww+XtmrFnZPFGIEAVI12qcjJFJJLVg6C5+a4mnw2raSZIhPbSTISyuN21s8H6VT8MWNzazyPfziWEjkMxfJ7sPQe1NltL57xHjvpIYwP3kXI5B/wrrtAujBpupwrLLNJdBQIJNpWEL1K8Z5qr2i0nuXNyitFcsaFf6XplyJynmqMnGea0rzX9H8Wo0dsptruLpI427j6CuN0+xlnvZIfsrsxPyuf4var3iDSL7QbMbdLWCaU5jLEHp1HB61PLG9luYVKUHUUm/e6amfq1t/wjwVFtA7yNy6knAHTH59Kv6PYWgvh9suGhS4ILBuQDilivfOtraC+dVupsIi9TvweB+VYt5D5OohppZY5l4WPs3H+TVNt6P/AIc2SbVupvarbW1pqDQ2cxnVedyp19qy7C2kfU3MAkMkh+YOcj6AdqzoINQjvgxcPA5BLEYx69+vTFddO99p/h4voEUc+qSSKjmTBUR5G7npStrZPcJSdOK6sSDwnJDdTXUQD3bgYi87aGPYbuQtTana6joelHaLW212U8FMzrCvpk9Wx36VS1bXbxLoWLiW3BUHeg4AHvWBY2FxBqM04u5JPOY4D8kZx3z27fWhbXZlGnUm7zenYm8Rx61eJayNP5hTqucAtxyR+ddB4YsLa5u9ly67MYAdtoz/AL1dDo+j2RsGF5tbepJYYYnIx/WuIs7BbS2NvE8jRROeGOGIzU35lqVGaqJwhpY0vEsdhp+rMlnO1zboM4ByA3pnvWBYaje3Uc7WEn9nywv/AK2WISKy85GOPSrPhrw9rDTagI2+028rFolfhV/Hv+FXtT0vW7TRDO9tE14GIeONtyhfXOBzVrlTsrMacUlCUrs0rPxwl1btPDYM2wYOUwTkdR/hV/R/GmlXdssiw3NpInDI6FgSB7fyrlLH93axkskTquQqDo3et9tFAthPDcW8smAzQxgjr6E8E1D5b2sZToUlZS0K15qyX1/c3XkKMr/GNrBQOtM8JatpN8ZZ2s/NIccuudvfoenHNU7uVHR3KCMoD0BJ47Vf8AwWVxbXLogSUEsISQoOepx3NLTlehrUjGNPyHak0xvpGfZDbscqicBBUlrrc8NvHamZQoG5WBy+M8H1q7qtnYSQiUzwWsobaIZpsl/XjtWJaeFLyK+OqXMsb25XKFH4A55x9OKeltTNSpyikyS5uHmcvI8ksj8Es5Jz61JZ2S3N2vnXltFGi/dcA1QutVd71LS0giigK4MrLlmPPJPaqMvzaukstnNGmwIzxqXRSM5Oe1Fu5rZ2stDp5rqHSo2ttKnEfmk+ZKnG4egI6fhWFciJoJ4o5Y4JWUMm9SQ+CM5xyOM4PrSzqHSK0nuo0E3MSlwJHx7Vpad4Vk1S+W5WeKMhQCCSc4GOg/lQny6sh8lNNt/M5zV7t7CxZoVjck7gjL8zY9cVoeH9bSztGvrq3WO4mGDvAChMYxz69c1veIvBekx2CHVtXQSEghIsqw+nUmqGoaf4Yl0v7Cl3qN18oCs0bYB9OcULlaWhHtoVFaKbT8mZUUkU0ongkZFdh90hlYex71nW2t21j4nili0z7ZIkpimYptUOBlQ3Yjv+FSiO1tpobK2vFRQv7uJiQeT/ABZ6H613vhzQPM8PyJcW/mNOSVMTBiq9uR3obUPiW5dapGEbvY47QPFZ0nxjqOo6lA+oatdqEikdtiQKeQir2X3FVNQnFxqk5n2tds5lkC/7XbHWrWv+EbfQ9bzPrFqDcYx5z7Gjz0Ddf0qNfC2oeRLe6QLW9uopAksazAuEJ5cE/wAvarlaWpFOVGH7yOly74M1bRL6+uNMubqGO4mClVZcKUU/MMnjJ/pUXiew0TT7uSDQE8y3yd7jBXJHIB7j3pt/4c/seJLlLa3/AH3yiVRyvsR2rBuZbptQETRhIsAcE8N9KhpP4S6cVKftFLTsWPDmhEEpp6qr9QJH5I7Dmu20jwOZopJNYn+yFG4hhILH0JPbPpXEW+qz6VrS6iwUWdo6l3j6sMjjB9cmvZZruASiRSvmcYGTnB7fgKiale76nPi61SNlDZlPTNMsdPE9tZWkakt8sh5kI9z1pAE+0bpH+UNuwB0xVqJ1uoC8cQE7N8oQ9R0yaiW3adGtrq4X92xaNW57HgEVBwczbbkznfG2nxa7FMdOIGqIA8dxIoVcDgo2OSD69RXk/iDSPFGmh4NU8mJZDuia3ckMvs3t3717W3kRuq3E2Edvk2KdvsM1i+PJXeeXSJLGcxG2S6t7vHy7gxDKPQ46+tawm46I6KFVwlGHRnjxso7S03zkQxjld78Biep9aL77Fcz2yStCLmJNz+TkhwMHOe1M8QRfaofs5haSTJdYypB4/wD11LBeSyaPaW1zbxxtaIxQJEBIM9QW6n6VSVld7nquUm/I7nT7e28Y6bDKt5NYtCjW80fJVmJG1ivfBxXPDwx4isvtUUscd+qPhHVyfqQSPxxV/wCG17HqP24XUFyiAIq7OpPPb8Ks+NtalsTNpVkwifYJJDn5ueie1K7u4M5E3Go4wOC1+0ubjVorJZEMCdZFcMd2OelbVzb2J0iAxXUsmoPJtlhK7VCgcEHvXPacEgM0sx3SF8kN2PbFWNY1W1jk3hHG9uUzjavqKuV5NRjqkdKVt2dle6ZBe3VtLdXGBA28KRkODV+6u7RI5ZVjWXaw4zhgOmaW1kt7mJjFhRG5DE8H8Kz7HR7axvHYXj3HmYHHYZ7+ppvtLoaXvsbmnamrRKYVXdkkAjJGPepNe1z+14oE1O1WQwcKVGNp9cVdk0e0cn7HPIjDgHIIz+FYN5ZvaMlvcSRvLIrMp3fe5qF3RmlTlJN7jJ7hlKoGkfcMAt2H1Fdf/bOlReGLa2htYDcygISWGXfvzXG+CrOTX572wWYGaIbZIy2SDyDjHaq19Bf6devaWn2YxRnDTT/PtcHGAo9MVbpe9aXQmfLUajfY0rjSw+6C6gjkI6q4B2/j3q1JrWrSxW2m+YrafF8xycnI/mKfBFd6pG/lwb2QbnZRx9fpT9R0s6fbxSSnAkxwOKzTNG4yaUtzCv8ASkvrqGJZns98gZpV5wD3Ar0LVPDNqlpEuks0oCZebeCrcdcdc+4rkJZUJ84/MUGSR1+la3gy8utc0+/ks45FtoR827ov409Wr9EZV+ZWknaxhQyI0pAIdlJU8ZIIo/teWy1BmtbR7i5SMtHHjCuccAtWz4d03TjqsjahcfZbcks5UZ3H296qSPAdQkKmQQgnaXGcjPGSO+Ka0bNHJSbiWtR1uJ9SUQSRxTBVMihsYbHOKkmubrUJmW7vJZFkkDKkhBWMgYO09cHise60eNnN7HFL5Tvnfzt3Yx19cVdtNRsiY4REWVc+a75BPHG38fWjp7pHJFJNLYis9OtNE8USatfs87bNkaGQ4jY/xAeuOKi8TX1rHML2QRSJIwCKASxbHYUatpVxqAWSOdTbAHLMuVwe49/rWzpGkzGLzI0TdDjBkAYt26etNyWjbuGkXzt6k9vZxx6ck2qQOs0ikpEhxzjjIrmNJ8RXMt1cRXVv5UcbgJwcdO2e/FdvrespHpcLgK94CQluu1GkPHRicD9a5VNQh1661Mf2PPpzaeQkkrsp81jnIwAMHj3pRi+VuxnTqXfvot6csOq6vHayTLFIw3ou8AsPbPWku2t4NauLaPfFBEdqebyzHu2QcAVhxWSTXxe5hjDREGByNzClltXuNfSWK6kjjQfPHtyHNNJG/K+a99Do7S8llmaCQYiVc7geTzgD/wDVUOk2FwPEk893OZtLlwyDBWSJs8j0IrS0c6ZaqJZZg7r0Urx+FQ+INdaWzaGOOOOBWJaUD5jnsMdhUXb0SMdb8sV89joL/wAWeTKtvospmCDBeUDp6Yrl21CfVNckuZxcLMITbbVlKoAerAdM+5rI8KhLlSkDNGm5mLt1/CukisrdiNzzx9PmytF+RtII0KVNaIxLm/iXUpIVtZEj+VFdnyxOPvH16cn1pU8Qy2cMWnwzpJcMm8SSALJ14H5Zxiur/sXTmiDF7pgMgAMpx+fNcu1v4aTXQwZ5r23yDuXlMdcH2zTTT6DjOEtLPQt6fY/aIlntYJZxKP3wRS21/XJrL1LS7mDVrWRmkt1jHzROhUk5PTtzxyfSuputa025svInjEcIG3LMwUg+tN1OGwj8KZa8Q2Eafu5ZLjeUB4IyeaI3vdE+2kmlJbnO3Vlb6jeQ3MDhriIB2JOADnofX6iuh8IXl4UvbO6i/cDJUDHVicge3eub0m2t47dFtJd6LyJNxyM9Dz2rs9FtYEtytvdJJcE7nU/fP/6qmb6DrNKFmZt7pdvDtlmZvs56ZGTj04q5eatZvp0lpp7sN/yGIIVG3vnNY+uWOqLf65NM12lkyxGGUyL5e7ByEUcgjrz3rAsrh9Mif92t5KP3iQSMUEhA6EnOAeKfKu5MV7WKk3ew/WbGQXEF5HErzIv7sN0GOnXrUsl5qBtzb2dzLbgnLBDgEnqN3YVoeJtU+0WEUtlab5Y4c+WowS3dAe4Ht1ql4O1GwRbW+1+ydLchg8Dt91x0Yg9vamuaykauV4XlH5DLfEQk8+RbjywA7Kckt3NVxAj25hs2mVSdz+Y23IrW8S3Gk3F282iLL5ci/vH2hcnttHSsG31pLfVrrSxbyNcLGhMkgBUDPY/j1qdXdocJc0VKxtJ4fhmt/wC1JxboY1JQliSCo7noO/WsXTNZ1eS7vE/tNobRVzb+XKU+nC45qG0vnub+a3uIpBDFIQ2+Q7fQEil1G3jtGmltUJVR5yyJycjnA96esdAUU/i1MnWLSS9uWjv7TdBGPN8wsysTjr15rQ8FXq2E73FopX/lkTKSGTnPDZ4H1yK6XSfGt3qelLd6zDC8Mh8pmXAY474IwePpVj7b4X1ad4bG3hsScIhxty3qSDgHNU3NJxZk6jty1I6HUWXinT9UtXsr63YSEBZG4IHoeORXC6ho2sad50uoxTPp8b/urhOVKHofXNWU0W6svEcFjIpQ3C7mmjVgcj+E9s++cV0Oux/YPBUVgt1dXbxyFpXuG3yMc5BqLJaLqcsHGjUXstUzzU3lpbahFG4EiyMrEFcggNnmvcbqXTryE+VEyOBneF259a8A1XUrO3aNrjc0kpKowXJXtzXrugXsl/pttIoTgfvFZt5244JGc9e1KcXo2a42HNaS6F+MsbuNlRZJo1ydx2ZXPp3pt/LdtOEEkRAA7Hcoz27VKktusRmvW8iNFyZJHCLge5xzWNceItHsJnWXV0mk8oslpEwkdt3bjov1pKLeyOFay0Wpuz3NnYQve3eVjjYGXOCCR0A9TXmXiX4h6rdeIrZBBIliMNGkY+Uj/aPc4H4VzPjDxTqdzqtsrRu1o5Uqqn5VJPftn3NaF1p1/Foraj9lkaJTt3fw7s4GfQe9X7PktezudtHCwh71Tcu+Nrm0N7ZS2hSQX0bTM8A4jx/Cw7Hn9K4y+uoo7uO3FvIZXGcr0Hua2bWa5htopJfJbLcx8Hj3FQ3d/ZwfvbiNI4hgDZnkntj6UJK6VrnXBOEbXOyt7KPw14XhvQ/mS3A82NVHJkI+Xn0FeP6tJqkF9Lc6mfNe5YsXBz9ee30rrG1GC5QCNXkhVRkK2QAf9n6VHpLWR1GI3ivFaK3Jc+/p6e1EXyqzIjT5bzb1NLwjodybUX88Z8pSFj8xcgAj731rrr9tA1Sf7NfrbpdKNqykBiSKyvFfi3T3sbiDQr1jPIoSRkVtkWRj/JrzI27oqtNcs0sT5EignP1PXNJQW8tGYqnKu+Z3XY911XwwX8240nG+T5/LQABmx2H4VxNhHfP9oS+VVZWIC42keoIr0Hw74g06+Vf7bZYLlVAWQS+UHPp7E+1cZ40kh0PWPNiN45vXO9SwZVPqufrWkE5e6aUak4zdOfQ1tCuopIwJ2KSxNhdx5fHPfgnj9ara/eIBFc2VvFNfIpWKZl3MgPBx7VkajaG8sXhaV4zIRhhwRjtVXRrd9Vu0sNOv5DLYjDiYbfMwcHmnFK3MjeUFfmZv6BqOo6fEl8WVZ92JAABvHv3qzrtwZZDqIjKJICxQDIz7VheLZ7rRIIfPhMLSSCPc67lyemD0rqfE6SWOg6ZaW8tv53D3KSAjMYzkq3QHOKXK7qXcylKEZJrdlv4c6rb2uqfZ7jY32oDYrDnPpUHxWS/vtfitrZ47aGIAbOx9x6/SuWsLpZJ5Db5EkADCQjp9DWnqV02o+U0zs0uMAk81NuWVxfV/33tb9B+laNJdzvbvMEON27I4+la91qiaRp82l6YHCE4kk3ct2OfrXL6ILqw1iaT7QHXDcMeBn26CotRljt1e+8xmA+UvyQBnpT5LvuaSjzy97Y6Ce9hktlit4iDj7x5rFvpr1TBHbWqTEt87A/dH0qvBr+mTeHjBews6icSxyK7IcjgAjvj0+tT295BPbvOJ1TfnDs+0fTnvV8rjugj1L3/Hrb3b/vpFdt7xCUlN4GMqp4BPc1FZaVc6ppJmjRbLcSN+8ADsOT1PsKm8Ny21rez2kV5brdRqkkgn+ZVDHCgDHzMewHNaN5q+nDV7tdUu5bY6YYyz3UXkxhn6bTnj8s0nzPSxlKryu0SNtF8/RBpt8rzRYGXkz82Od3vWrBMNPhK24dpIUyNnReMBiTWbrmo3Fg8OoS3Md1ZkkJa2R8x5gxASRXOAAASSP1qTU/EwsytpoUMTQk75JLlVl3HHToBgVDTtqJOVTSMb/kZdrrNrfLK9/YODbuSjlAckjlgexp1nqkuqRkafbiO1BG5cA7vcmjwv4nsfEeqNZ32m25TBYTQx+USMkZ+X6elaPmWNtdyppLnyA2Rvxg/iKctLqxa0dmtfwJFuNHa3WKcfZ5d2Nxyf/rVj68kloIBBHPNDOcLLBGZAvpkDnvVHV44dSvlikf7OyHJ2DOfXOa37PU59J0txaNvcKUVSDnb3oStYppxV4mdb2GpWk1nAthcXTzsfMkAASIe+cc+1bGpeGJL3TpPtV1FbqwyVxkgD1/Kqmn6jqBj3s/LEghu/5/zqve6rPPqIs7uN8sBwvC5xnBH070tebTdEvnfUgtYjpekp9lAme3jLKSctIB2pw1e91HRnms0jtLpgWWPZjPPOCf5Vt22hXiQkoFQKCUQHcxz6VNFoVuPL+0yMG4PznGP8KOZLWxTqQ6s59JtQGnKJLx4rp0BdlbKqfSo9P8pdYisN9vJqU0ZYODgMAeck12niR9M0LSlhtrGLULq6wqKpyVHd2bsBXFLpkUl5DeohjuYeFkB+Vvw601qrsVKr7RNxVje1vwzfT2c8JtzJHwTJbuDtxz07iuN8N2rLaXljdWcojEpLC4i3KwzkEetdhoninVXSW11Kyhjg3ffGQxOSMDn0wc+9WoNMXxMlzHqWlS2ccMuba4huGVnHrkd+OR05pxfLFxkZKrOn/ERwhNsDdxaaD5sQxtwQCR2+g9quabbzvHHM8hil5IKEqQfbuK1fFFuYNQA0e6itJrd1aV9iuZgP4TnrnvWtqeltrWmG70WLZcbPnVRjDfT1pSadvM29tZJvZnP22taheQzwXTboger5Of8A69E3lW0C3MolKs6wiTZkKzHABPbk9aoad5rI8F+WknQlW429+BXU6Vq8OmbrJtslhdEAo3OCe4zUvR2HO8Y+4jK02y1RLyRC/murHyzgDAHtnmszxFHlZjqxVgBvYAbWTsCMc9667UXtYJWns4ZFkjQkZbFcZqmnT3+qJdjUEy6gSxyZJcdx6H+lOD1u3YUZOWtibw/o66rPbtZ3EaQCMMokk4bBxgD3PaneI4Z9P1eCKVEjnckthCytH2x6fjUmnwWNnIHv7KO8jiKPaoxwkMy5wwxz36dKivdTlfVlN2jTTSELuHIUHgAUPV6ahFz53fYv6dFZzRxpNGFkdwoYk4Gfaux1DwTpv2ZPKlukEi4Loowc/WvOrqO+i1NpGmT7GBkIjHKcDt0zkZzXZeJvGMfh/T8PeTXCIqJ5kMe5RuAycj0qHF3SiznxDqXTg7GG/gm8jv0stO1DT2sgdxW8kKSgk9QBkGk/4QaTRLh/s88ErykKYkbJYHsuazNYsr3+zm1dx9rsZWDrcgbsjP3WPaqGm39x5kMkEZgYk+4OPX2qm3a99DSEaj2nc3Ne8QarYrKYL54DCvKPjPHY5rm7PUL24lGoNJM07/6wO3B7cdhxXWeMtR0nxV4YjTUbCSPVYiu24hcBWA9T1x14rlLVYjOiEttBWMe/YfjQmuXTcuglZuUbGl4R8NLO8z3Ekpg37mLcH2HOcfWut1E29ncW+l2+m3UnmwtKt4vzRR7f4Cw6N/jXQ3XhJBb6SkExhELkygDIfI7881X1680rQrj+zWupVlnUM0W3Kn3OOhpOXM77s8+WJ9rJKH3Hm+vSpfi0trqNJrSMtmGfcw3Dv196ypoFVwbZYrZF+QsIsbh2GetdlqWiRX9rFLolyl05LBojwwJOeM/hXFXt7Gl3/Ztxps0eAN86OVYMOxHTGeKpNy07HfTlG3u7kF7bvMh+zOFkRskluorVbxHqB0B9LaZGs5AI5Aqgtt3Zx/ntTItT07+2LCDUUkijndVJA5xnHOO1df4h+FcU5kn0O9CLNhts3I65yGFTe1ub5E1q9KEkqi/pHn1q1rDq1vcyJI8CYWSPZxjua642vhjXtRNvdpb2lu/MbnMRb6ds/WuSuNG1vTr2a11a3k3o2E2JuDDPYgdCKw9T1GdLW4WSJomV9iBgQwP0PTinGLcvdZU+Worpm7qvhSPQtWnltJZJ4P4HAyEHvjt05rNE0VvdmVVwjA+ZhhyT6e9aXhLxRe6fpphuFS8jdfMVZgdyj03Dt7VneIIYtUkFzctDZ25O8NEny9frTblKVpMcOaOkunUqaVbsNUuLmIMRIpwNpwoJ7461W8QQ372i7N5CHJ2cZFdx4ZuLWG2IjuEaMZCup4bjg+2D1FbLiO5QkeS8bDbvjxgnueKOd812TKoloWPBtpHd273mvQRtLG4CYGQh559Kn8Z39pFdwF8wzyNhVzkn0P8AnvVbR/sN14dsIvEW1ZZ7hSkUT7GfaeOnOKp+LlhuPGDeZa5EAXjzO3bP/wBertrr5/0gjrVuVhrdpHfRW/mSNc8NtkTK59Ce1dHolncRXj3elW6RvJhywXdkd+1UdFGlN4jt5b2y3qnLB8Ekfh6V6tBaXELNLaLC8LtxIi8cjoR6dqzlJKyRGKxHs3y23PPPFF0sjgXsKSyFg+2VQSrDoacl3Pquh3ulzKCzgFHJyV/Guf1aGdvF17NJOyxJIyeXk4x2rc8JSRq92VK7vuY3H8ap+7a3Qtwj7NOxcs/CTCCIvPBHKY9zeWD8wHBzWXrunrYXSRoxdMDkdvrWlceKLnQ7ayt9Ot1uZpGbzJ5mAEKA/mWOeBXPDWr+6u3nuXD7myQDyefek092Kj7Vyd9hiadClxJLKRIkg5Wc8eop0KwNp1w1lJHdQuxZlRg4J6EDntTtYsLfVIoLm6tJr54G3xQRSiPcx45yQDjrjNc/eay9nq2qaXc6vc+HYbeP7ZatBjdM5UfI23g89hW9KDqLR6/18xzqcnQ200sXltHFNp8cagbgdwQqcdMjgmg2rWVqumR6XYXNqzjel0jMUAP3hjr9OPrVjw/eS6t4fYa/eym4jEcsstqdjSj+EMxHBI64q/p/iiG8Eo+xW6bfuiNSCQPryaiUpQdt7MFeS2OWv9Mj1BtRtbfVZnvJXWa3tpZSkSOvI2v/AA8HpXWavo0d54ctobzEsLxL9qUOXUv/ALLHlh+NUYWtLlxcW9glvcFTuZskjHbFZOpalry+Va7nkibhssMIO5UjoPT6VXNKdlfbuDpe9dfcaN6n/EtjjtlEUVtH5cMbqAqj0JqPSdPlv7Yp5DPN/ej6YqNdODaYySSsFIG4k4Bx0x78VV07XLzSbiRbaExxRkLk87h3+tZu3LobpStaO5qJ4fs7cus5a3kYEMANp+pxVfTtNs9NeOOF5GjQbcH5se9bviXxFY6xBYRwJvuifnKqRt46Gs82QaDbG5V3+Xbnk9vzqbu1mTCcpK89GS7NPacziYByQHG0/lnPBqPxUZk1GzttIhe5gkX53i55/pj3rM1jw/FpVosMN9C6XPCyJIDlgcEe56g1Hpcz2t/baerSFpFP77acD9auyWq1FFJ2lFiXUeqQ3rfOwt1AA9B1z/SpvDl1q76n5upWUklrGch2U8j0z9Oc1durSW3ngnjklC9XVxlWJ7/j/Sq02o3sEkMMKysWYBSPu9eMjuKhPoaPVHUXPiqY3BhtDFEeOCNxxj0PFc5rS6ku28il+0tLgbX+Yg46AfWt3T/C17ev9rudPa0nBIPlHzE29ip4xkdjyK0tHsyuvLajTbrZHF5n2wlfKBP8IGeDRdRehyKrSgrxON8QWmqWVql7DZFfNxvTdwpx1IFaWi7b+eyt55Avm4D7eqn0rsfE1xBaaTdRy3cTuVwFRw5HucdBivPbWzt4bkywO5kkHyseMDrwe9JO8TWlUdWN9jT8c2FzaL9n0+aSN1YFS+0Z/wAe1ZdzrGs2emWq2E8pcuFmVCcEcdAOnfmpY7aRrua5neV9/BZiW4+tO0yWR9YQa2f9FHypgYz6A+3SqTsu9ilG0bS1ILy8nF5boLYypINsjkcLz1z0HrXb+BVu1gujpjK8sZBKdA4rG8aTWTaUTZfZlnBCxogwx/Cq/wAPteTRRnUpPJllONwGe3cColrFWRjVvUouy+Ra+ISS3dwLmwt0gupPlcEjgjqe3Nctc6atxZW/2pyJ0+ZwGyMj/wCtXQeLtZW/YGxQqqMWM7jAcnqapx2E9/bGWNziNss6np7GmnZIujeFNKWhr6XavfWkpZJEAGxSw+8NuQQfSubkBid4WEZkVijbiAc+1a2h+Izbx/Zry3kURN+7MR+Zuf0rB1O0g1PWo7iF3tld8rG5BJPue1JLVpjg5xbutC2TGyRebHkR8ZftVHV9WnF5ZWkdqqEp5fmIAC4zjkd8V6JZeGbTStLkv9YZJpYl3mIn5F44yO9cCmuaTruoz3MlmUiUhD5YK4HrRF3TdromFaNST5FexUFpPJJIsszYQjCMxGff3qXy4cCOeUjy23bcEgn2x/Ko/Fx8PzSTQaU+oPfWcS3BjCB0lU44U56isyx1K6u7v5bZo7RohIk8gP7w4GP8Kv2UrcxpGspo3vC3iu+0XUri2bTWk0uUkyq3CgeoB7/zrP8AFV5awXIm0CB7mCY5MMuf3Td9uOxOKS8u4LS9hicG6Z13NIrDAyeBjvUdxcokcYEOXY4Owg4o2afKKNOPNzrcpXIT/R7Syd0v7pT5ETc4fuM9Pzr074X+GDHFHda/iW+gPyR/wofU9ian8JaBItiuo3ojiTaCrsAcg8ZPpx3rS1DxvpWnRCK0gmvigwZUACE+ue/1FZSldWijhxVedS9Klr6HUa3fQadZtdXTfu4wWCY5dscAV883niG31a5ub2UM1wXaR95wCAegP5V2b+I08bPqlp5jxtbQOEhXj5m+TH4ZriLXwLqGhWzxX1vI8btlg+MFSCOMGrjBRjaW/byFgaSotqe5reEtZii1W1uYLgRQFh5iPyGHfDdjVLxZqEupePLu7htg2nfdV/u7uOarR2KWsRgizGgYsIs8/ryaivLy1tIN891Gr9F2nd7Z4/WqT1aiju9nHn9pfUWeKJzGxeNY/wC+wAK98ZrO0fxr4ntZZU0rVW+xq+yLzVDDPbr0FdP4ctFn1MWsyJNY3Ay4xlVPqPSsG8s7Gz1a9061dGigmbZGsnIGevvUpqz0uEuWcuSSFtfH3iyzt5X1e/juvvHbKgJUeoYdOa2LXXNO8Sabbx+JkiuLtBndJCEMo7bXU81naTp0eoTTiK+so5goVY7k487vgHpkVj3M9vGypc5AdsKFGMHpgfTFLmvrbUj2FO9o6NHWXfhm1WGKSynmg8xchJB5gQemRyK5668N6xf6qbG1/f6UgxJtUoTjnIB9+4q3pmq3NjZjyGaYkkHzvmQDPepn8W6nLEwjW1iGOiIRkeoyaIycdiXGrsmZep6DPotmiyxPHaNxuHIz70eBGlt9YCW7+bFID5mTw3vj1rQlfUNTiid7qA4bayFwhXjrzxT0W/8ADajUkjt50LYYJgqRn1XoaG9LXKcny2luehapoS3jTS6ci2+o+R9nhnKCQxD/AGR0rm/FenNoskepQwTTzzosVxltoygwXwen0FekaVfWK3JUxny42G2RuOg6AepxXnnjbVzq+vSxC3P2YAghj8pJPI/GtIzls9jKhKcqlkiv4MsrWbxHF516mJ8hGOQMn1NekLqaeCIZIm1CK5LkkQ7s5Yj9K860iOJ7pbSKxC5Hy/NnH170uq+HprzYGZFEZ/vnJ9ql+8/e2NK1GNSVpPTsQ3t282ptLK67pyXxjr61ShvG0XWBHZxTlpzliSMAHtjv0q/NpF+PKjtoCWXuxyMZ5xTpdG1KDUUnaaT7OVwI8ZA4/wAacWtbnS3GyRmWR8qa6H2gzzTSZwBnAq5e6hp2kIZdUmYOo4hjBeTOQMbRz3o8N6XFpusTyiN5GuJfLEnmqqqhGS4zySDwB1qvdWN/Lax213cqk0TnMsErP5w/vNnHzVq1ByvJkOcn7sdDVudUe0vbWKK9ilt7l0ZoDJ/q48dVQgcnvk54rYN34c1CDLJHNJFlEZoxIVU9Rk1zdzYQF4i8CvLsKGQ9RketTxaBJounzOtpO/mDcrDkMcetZtppW0YnTXVj9T1CPTdOEMk889osrMhYAudx4U4GDgD0o0iOO/lgNkgzJgqV4znpUFra39/o9xdTaVvZVJWEHHmHHAGe9aEmrP4bfSvs9mFuJkVpotu7DY5QH0H4dKbjfRbj5lFcsdzpb3w59jiuCXUzIgf5c89yPeuUuFeQAw43KfmLVq3viy1Lqb9Wg8xgpfcSAfoOaynsbjVLO6XesEQkwrg8Sr6/SoSdrsmk5x0qbm5ZXOlz+Hp4NWgR4eRPuH3l4xgjofQ1zSWtukYSyaWS1wVjkkfcxXnGfer1xphg0pEdi0fR/wAqqs9lBbFbQu5VPlQDHNF7KxpCKjJtdRugeGZtPSZ4LgsWORkc1e2ymRIpi8TgjbnOPrnpWlpV/LeabDM6eVIBtdAP84470+eK1lS6uJXR7xIWjjKy4A5yAcUX5n7xMptbmBeWUWpPAsyMY7UlYFBCjGc8Y9TUkl09rIp+66/N8oyVIpriVbGGVynmAYkIPeksfM1PUmhP31AGSOtKTez6Gi2L1zerLbiWOYs0q8REYwff/Gs7Rr2ewLXereU0aNwSQoUdqlS2vH8SQ2KLG0D/ACgnjn6j+VJr2lzpeSaXfWV2LcYk+0ggISPTuKqK6fMlyivd7mtf66sMtu9vdzNOSWRASM8Z4GfrUOreKtR1rTzYsZIVkyCwOGPoBXK6vKkVzZw2siQXCEEOwLFV6AfieK7/AMPaDDNZx3WoqzvIeEB2r/iKlrlsyJqlBXktjlfCayzyR286lYgwTLDll6n8a73xFbaKjwCK6s96KAVVx0965zxALa1lEFpK6yAfMm7J/wAcVyemWQOrTwxytPPP84iYnj3FN2k3LYXI6jU72R6fqxt7zRrq1VooopoCokgkAKccMO/WuCeFLiGH7RNvmhUAnpvI7/jUFnaz2etz/bpQtqy7Y42XDA8dvzq1PpuNU863kcow2bSMBT/Kj4dEx04KGhXls7XzBcOUEgOcIc8+/pU32L7SkVwsZfyzwCO1UNeth4ceUXAaSV8NsQ5PPPJ7VreFdTvLS3Z7y2jkgbpGzAFc+nNDi0uZbGrn7t46lTVIk1HS3szFKoJ/1i9VYHv6113gKxTRfAuvah5zybtzMrEHB2BRx68VyFjqssjyqyi3jLt8r8D8apaQbiySa3S9Lec2W3EhWx7frSd+XluY1qTqxstBfDyvIs8odmLMSNxxz1rpPClh/aOt2gZAyq2+QYztAqvY6NcagwhjmUx8ea7HCjmuo1a9tvA2mLDB5Ul3L8okJwM+ufSpk3KWhNarZckfiZteMLA6hpE9nEJElkACyHgA+/5V5S1g2gqLO7DWrMcscA7gehGK3LDx1rlg0j6hPFd2qEZRlxgHsDWZ478Q2WtT2bW9vmIRkhG4Yk4J57+1OMXt0McPCrRfJJaFCeOIXDM8ZOwHyyhxn6/zpvhrXEstYaa3JmmiOZYGPylfoRVjSLeW71GKNoZpISMvIMBAvpk9T7VH4j0qy07Xrg2uRvUHaTymex96OlmdjcZP2Z20+vaLqcka/wBiWse45k2quSD6HFcrq1pb2hknsrfyrPkiMfMVHPb14rIjZI5oVcqqMex5HpTlOpSapPEIEktUBbKk/J6ZNOKMoUY0X7rLl14xd/CtqJJ5pNKIykKDYx5I+bPbjOOlQQubi0WaCbZbOMqpGT+IqxrHiLURY2tpFpNvcRhvLkDRAhR/dz2GCasXrxaRHax2Ea26mNZZFLBmTPOB7dPwpyS5VbzFC8em5p+AYEsNX+03GnOBdMEkkjjOMjkFvatn4geOpdK1SCxtNOhuIyoaaS4yAM9AOP1rgfDmt6xZeJri+utSe9tn4aIkkbM578Ajtiuv+ItmLyC31aNGe2MaI5HTYTlGH4nFS0lLXU5atJSrxlUW5Zk1jw74osUgu500idVOYHVcs3Yo/f8ACvLV0bS2URRs74fczyLjB9vb60zUrCO7u0uhKmYQB5TDBPb5fzqaG2t7eSeaOYzeZjfEy8g+9Ne6rRZ1UqKpXs9D0bwJHZ6lpd3poCw6hFKJGkQ7Q69iPbtgV5prWhLZeI9SlfEV0srbjzliTndj3BpItXu9J8QWbQw3IK8sSCNqntj0xXpV1aWHjSyjmRlS+VQBPEeQPRwetS+aHozCX7mpzvWL/A8oube7vJrWHS9zS7+Y1GWPv04raHwy1a7uhdX1wsLRPuC7CcDrjis7UbS98A6tLPaXDy3jZAkAyqqa1pvih4mt9OWTNuz7Ax823+bBPfmtfeSSjaxdSVSfvUrWJ7vw6624FnMruhIkjf5A568fr1rkLaxuZ/EHlC7ht2I2tHJICcYxgKOtd/8ADfVG8ai5XVyUvE+ZVQ/K49QOxrjdfne08T6pFYWMUQt32faZFLPJ6+w9KUPd5k+hMK0pS5HuX9Q0aNbSYw3c0kqrnDqAGwcVzGmrqkFzMjEzI2QVxkN+FOvPE9550cEscHluMj93jGfx9asaB4htbK523v2h2YkK6LuA9/XFJKVrG7dtWfSWtazpf9nzCG0hmdMPKFJDZx1FcNP4a1O91Ca4sbJjp8nzxSK33h2zzya6/wADWJfw7Kut+assO4MeAZUHTJ9e3rXl/iW/1CPUHg0SeWK1bO1gxAXn9KIRveKOPDe7Jxp7rudr4M0MaZe3jXyXEbyciRoiQpz3J7V2GkWWl3pk86XzZTksykIp46HFeZ3Fv4u1bR7QLqUm4HDl5Pmx6Yqk1lqGmtM8yTqPvPJg7frnoBScbq99S50ZVW7zsz0O60uGM7VubaWZWJxu4GD0PPWmLbzQAmR40GPYgj/69cAddtbe5QXLiNZCApRwQT/k1s6hqlvoltG88jsd/wC6C9WAPA4+uaXI9EX7KUdG7lzWPDj3LrJZXNsJGP3JCVBB9D0rMHgnUL28hmNxBCsJ2ndOMZzzxXYeFtTj1VRdWhSEA8IefLPXnOeKstFePql1c3vlGFcrH5YB3f7XT1FCk0ZuvUi+Rmba+E3jnjeUrNHngxkMCR703xxrE2kSQaTptn57Om65nc4SMdlUdWP8q07jVdGsLKZZb6KK7Y7kjD4L/gOleY2V9qV9q95PeN5nmMdhB+7/APWpx7sqlGdefNPZfI0Tqup+bEH2iNMYRXxn61UsfE1xqtzeSXNkitC2AxXA/CtWz0W4vXV32xqeS5PSoGNjZS/6bfIse4Aqqn5vxPSmnfSx1/u09NyG502HWYT5lmQ0Z3AhiB7kmpNMujpUzRXMPmWycgI5U5xxyK7CCKzubXfpcqvbL1JPygD3zz9K851L7W+uyyEqLTkIBwfYiktrMmE1VvEveKfHkUUcFpa6ITbyOBLlzuz7Ef5NS6fHp2oX6pb3EcGBukidvmUev05qXS7Ow85EuWWadz/qu9V/ES6Z4auvL06wC3V2cSsPnzz0zz+VNJSSVhrlg+SmdjPpDWsDSrJGsBAKSiQKrenHevO3tbu2v5YZrCURLgrJnKnNLdJJctF9puJMIchRLxV/TNVm0rVLJ7tXlt8429cD1pJ203HGE4Ju9zRs9DmEHmzrsRhkL1yPWoLmRbFGS1VlmkG0ELg4PWux1fxNpL2scenyobplPyqmAT681wN9p+rXGtLfASbFAG1QW/Dj1pRV9zOlVlU1mrC+G11P/hJYke1KRQSBwcn5gD/h+Vep+Jrq1Hh+4nljIbG0FuQ5PQV5THPrWl61DcQ2Uxt4+DKVOBxzk9vTFXbnxTL4hkgjZlWBZNqw5yC3TPv1pyjqpE1aLqzjK+iOdS4tbq6VniV3jyFkK8pXoVlqFwtiILe4hm8teJljw6j6VhazoM2jQGc2ywhifuDjJFYeh3N1HuN6cBmxvQcqvrxQ7NcyNmlVWmpeu7GM6jJdNM0kzgnexPpjp61naRfi1uUlaWBruJ8LtOePSuzigSxfzbW4juNqb1kAyD6ZHpWL4gbwxZSJcxaVc+YjBg6qFBY+g9KpWluSqvRLQ0dRjj1SK3vJIozNGd6AAn8/asTULvUTPuhdI7YAEbSOW7nHX0xW+niKyW0jkgUCTbuI6YPYVyVjtv757iG63xmQkovc+lKLaV+w4L+ZHZaXaWet2vm30xOpHHmSrGAWIH3sdMYrl9etXjuHhjnTdG/LH+Jf8atJI9pPvUmKTjG05z+HasvV4V1mKaF5midjlnQc/nSjq9SoQcW7PQlaea2jV4LP7SQ37w7SQo/p9a1bhrSXEtqjsyjcyEDj8aueEbjT9I0uPF1J9oVtsgcklx2Pv3rmNQtZJNRup7K52xlm2bSR1PH0FCtsSpOUnobPhnU7hde8mOJjZSpiRc8/lU3xBis9Zv7ewka6e5gVnDmP5CvGQT7etT+CbOS0hN/dhTkHB3EH69OSar6//aNvpOq3U94GTVJQkJUH5EBOQO3oOOtODSk2Yzs6qcTCfyZLbyZGLRs4J8tM9BjqT7UxrnT7a708fZbq4jeURNEgBIHUv9BVWxjECLCZWllJyNpPHtjvU15puqabcqNQiaKGYFllzjaQfukduMULRtHVJJ6Xs2aXi3xgouLW00HT2t7Nf4jyT07DjJqG3SW5nCmOW4LcsFOXJ9fUis2e8t7aRRcyM4YfNjp7YNTRTPZ7dTina3AQopjY8g/TrSs7KysTGEYK0SO6tYZdQe1uIJIrhFx5bZ47811s0mk2fha3EmoLp93bElYouBcZAGHz1/GsjSxNfeILAW8ytHcDa3mfK4J6EHvVX4ieFJUu1S9kOzOVdCPTBB96cWrpNmNS05KDdnuYWm6pNPeTw3kHlQhiVk5w/PH19eK6/V7C0u7yRtUd4/IslmcoOPMA+6PbAFN8GrbwSXEUsaNvC+VKVD7DyD1454zUfj3U5Z9ZW3tZbb7PFGEn+XBlyOfaktZX2HOTdTkj95y2k6+LmfEKxYQcqOuPXFXpvtZunmEsuJAsfkM52EdQMdAe4ql4c8N6df6hewaReSQai8J27wTHnsC3bOKjsLvyLSDT5JfMut5JYkk5B6fh0q5K13D+kXeMnZrVD9Glja2k8xsyBwRvXDDHX6+9T38uoW1/BLayIqRMGWQxhsN2yO4+ta3h20Oo69jUYoo9NgiLbolw0knZf/r1P4x0C80nTEurWL7TA8ZdrdWJKehAHapveXqQ6sFLkZgatruq3jR3mtzWks7L5IZYtnmDORnBwTz1xVax1bUNL1ppbBR9lZB5hzgN35PrVbT4Jdcto4WtJkkDHG3OB6nn2re1ODTLHSmgS9RrmJc/e3B/UY/xoemltR8sIrktobjy6N4psgpnNtqfMiLIMru9PcGuFltpprtFaMictsUBcr9APShZ43IKb/JLDbIp4B9iKs+EdSvrXxWGmtvNjjJIB5J78fhUpaCUPZJ21LU+n6l4NtrfUFWO2uJ2PkInDj3I7dayNP1CK51TytZMsYkb97KVztJ/iOO3P61p6zrVx4nvW1K4QxIeIYyMhFHasy9v7aGCZZFMUsi7CCOPYg1Wt+VrUUFLl5pbm94l8GaNHpn2uDVYZJVOEUS7g1cf9migljllV4g2f3wyF47A+tXI1ilEiBRtKjDIQDn3zVC133Bk0i71F44c+YEcbk3j0PbiiKutXsOPNDRu569rPju7u4biytI0ilVcbgmCRn8s0/wDpz6ta7bwpvtyZMSEANnsx/WuXw01xfC3gbfkLG2Pvj3rqPAmonw5omsahqVo811AhZYUH3lx1NXOOloLsZ1EqdN+z3L1z4ttYLeY2UqQXEczW7m4jYDepxtX1zzj25rlPHGt6jJbeSdFS8lYbyZDIFjHZgg4bOT8vtmrOiPput+IZ9f1ydTbRw77MtKPLj7kLGD9ealWe0164OpJqN4lgspa1ikXYpwMHA7rnOK0SVOV0tvz7GUIrZ79zChtLW5jgaeEtcRkEBlx19R2Nb+vW9rcz2ouSRiMZXHT8qwI7EtrH21LzzI85eJc8e30q3qd7dx6lbSR2rPE4x5hJx6YH/16zad9Gd7N7wprltoniW3imjD2l0BGyjsCcKx9Oa6fxhq9rd/bodHAWC12xyTg/ekPJUe+K53w5pUNzdRXt4scUUJ+WSQAf/rxUXjLXrTSrKDTfDNuk0Zmaee4Gcu5/r/hURim9NzkqQUqykv+Ac/JpkM2ow3UjMxiHy5GM8571YvZGt7ZntbcTTFyPLUnp3OKlhmu72CSX93tXhjxkfWqVvrUlvcO84tI1b5I0Tdn/geep+lNXer6Hbd7IvLcM81vcOpGoQJsidmbKL6Yzjv3qC0u7TUDNb3EIuJ423FiP4u1aFtdQ3qsi22JGONyZIFdb4Q8Gl2lu7iPLAZBAxk9s1LnpdmVSpCiry0OCtIm0aO4tbZ3S3mkaZlLcbj1x6dKadQlEwLyMVj6A4I/GrPiRP8AioprgKSsUhB+XIOOwPpUM8lotvtWEM7g7o3bGPbHeqlrq3c1g1a/KaUOrS30amwVWbaQWVchfXHpUFm8kjhprcl++45GaydP8Sw6ffSWem6UywKm5pXJcnjJ46Vp+FfFU0yT3V5Ywuv3IldduCPp17UOEkr20I1V+WIx/COvXd+13wLLt0A6f41BaTypey2VxGyiHgO3Q16/4R8VWviSGfTbi2FlMYt+VPynHXH0rzn4kaZLHq0KQDygUDAoxwc98/rSjLmfLJHPRxM5VHTqKzOdur+2tNUtvNTyyGAWTB43GvTb6axttMh+0zlJOQRjDFvcf1rnfDmg22oQRSaiiS+Sd6bm28jv/WsTxXq1wl1PczLJIEIVBndxnA5osnZR3LmlVny32J4NSu57+4ewef7MCPOjLFuhwGAPepo9K0/VNatJ7czQ3Iw0pRflyv8AF0/QV1fw4liuNCS8Xy0mZymJAMccdaxPEOrNpPiuRtPC3MsLhnhjfC+4JxS5mm7aEe05pOEVqj0XxTZz3Hg2RbuW3JVVAfpn3JNeVX3h3UbrTYIbGXd82/ER3A8YzkdRVHxZ8Q9Z8QauulfZ5NP0wqGZSdxLY7t6UvhvVRpetWNxA+dmd6j39qSvT333JwtCrCk7732OmtJYbHwoL/T54b3zd8KSxncgboTn1HPFcBpUeomOb+1JPMZ2zEQc8e4rrNW+INxZaslvodpaHTRx5EluAjOTycDpknOa6fRZPDviW4e4ntxZXsIBlRBmNj2wPf0pt8sfJ/eOFSdL36kdzzOa0ngj/efcYH8Parfh9oLG2URwrkHcXB5J6AV6B4vt9BWxUNO4PXzShKn/AGeOc1xlrcaPM/2e3gngcfKxBBBPqBU9DohXVaN7M0/CnhNtW1O51GSaRoSeFA5Zjjr7CpvHXhv+wkX7EywmccMTu2t610ejarpfhi0VruWWIRrl938bY/wNV/F+p2XinSUu9M3XMaHCgZHPuRQpScrvY4fa1Pbbe4ec2iXkNowun+0XIBIkHUemT3o0S8W4v44JoDJOG2yIBkGrMlzJasAYEimXhh0NYK3c+sxXdvOrWJY48yIbXPPXPrx+tWlzXcj0bu2h6vqunWmoW1vHfl7fYVkCRl1KkHIHH0rmviTp017DBZw3KqiHeql+Rn2J60lz4zeDTX+120l3qUCL5Xlk5mwQOR9OprjvE9zBqWt28t+H899rLFGSAvH3DxjtVU4y0b2OOnTkp2fQml0SW1uobtmuUliCjDR46DjB7V0Ovaw+uQW0IgkjnhPzk87mI/nWUb26n2LLlYsYJC4K1J9tWe5XTpr3e+0MVVNuT1xu9ajV6nU0rpvdFjwf4Nk8ST3NtfzLEoXncfmJz2qxqujto92LCVobhYVCoFbG0ep965ya3J1KK7jnm+0W7YicOQf/ANVS/aoJw+64TzFbMjM+SG75PpRKV+pKjPnbvoXi11HcW5RolmhcPGIh1xzXp8Wsad4jtI0MkVtfcb45wAGI9D0NeNXuoTxYurPK2ZTmUdAR3Dd+atWGpJfxQzNcFd7FGfbghgOuPr2pODtdmdWkqtns11O/8Y3VrpcPk6aY7m+IZ1ijUBUYDrx16HivMdRsdQ1awguLpzbNK+WU5GOoz6++K047qf8AtWze3mQFbnYcrguWGAcHryelR3VvfQiEawqiTaed2Bxx07Gqi+WKtuKlT5Hyt3E00Q6HEw3KYyN0jKcnp1zV/TdJ0m90e48R27+QkB2nzkx8x7qR1rA1TytQsvLWQwsp7fxD0pdW1OG50+20h3EUEfIjU7d7/wB70zRHVFzjJv3dC1BqF3FdCSxvnhj2kbeCG+prf8Fa9JeMbLXriMXCkqkgfbsjHTNctp2mpqMlrY2DssrPtHPGe5PtVjx1pa6HrccFuC26BWPPBI4PHpReLTRnVUHJQ6s67xRqelWFpc2OnzmaedFTz0xlQSCfcntXn00MJ+1RravHG6lmaY7e3OBVSySG8163gljlVz8h8snDY9u3Wn+K9IutL1cXKy/ad0auDzhRjo3v7VUY9L+Y6aVPS9yxpmj/AGOwZra5BVwHeOXg/lWpocuoaVqTz2scEqy2zxJvAOw4zkehA4rGMr3kcdxcJ94DJxjyz6cdqgutUa0dLTzm8woUU5xjPXHv9ajVtmk43jYkhl8yEJHMQAvQcEVY0SOafWL23kCywyRK0ZYKSrDt09CawbKOSAFJJzIS2QMEEccg1f0W5ubLWY5gixorYBZsA54/KltdIcldEGs3MI1l7ZIVCoQo3DgsP5VLpNratfGDUnFu7YMZfgE9gT2/Guv8U+E4ZzDqemyDznH7xADtJ+vauHukaMywXkUiSdXVuc+mKpNNaGdOoprfU9Z8NWv9p+H4JbsNHenIYr0JrVa1bTtFubGS6PnTfMsmASq++cg8dq5/4fXV1bIbDUt7xSZZcEBkPfp6+lXvHMovo7byJWjCjaW24B7/AIelPXna8zOSblyvYVdXOn28UUjWl44UIJDaIGIHqAMD8Kwbzxhp89zcwXcMivGOZAu1OoG1QPqBWZPcNaRxu+8lyVGwHgccn86itwzXtw8sQXGMOFxu9j6+tXy7yZtGnFbE+n2tvGLlrCTZIRwHfdzWra3V9DojQxEyztIFUdWA9cVQgVIJt7yACVuNwAGa19N0+PT9UGoPeGNiTvVjlQPr6USlzO7HJpLUotrV1f6lNZzoUgtxjex+/wBM/wD1qbdJPFNG1oNyEkMGOT2/TrXb6ta6TBAdQu90sezd+62hSfYdq4+x1+O7nd9JjQlX2jzRxn3pXT1itB0580dEP1B3trZHFuSXGMAFRn3PpVeWGG4WPzowJCofaP4a6yx8T6pl01WKyuY5QVZNgwprnb67Q6p5A05xDt3GZDtUH0+tSldWS1HCc7+8ibQdcj8O6tBPNaG5t5Mo0f8AUV6jqnjO2tNIjY28kMVwv7tlXIH1IrxrUdVtrTYPKeVC2BtIJA9STXpFpfadrngs/wBgXcSuuEdLzOImBGSMe2eKnkWja0OTGU4SkpSRxF5LMgKqiSEyFgGOcZ/nXPw/bLnVGutVt40ZHBQKNucZ712T2cUDyZ1CG6KZzJGBlh25rnhPcXN1M1zHGFHEYB7Vona9jtg1LobGlW9nJek3u6K3cZzHjdn2qSWyigk8wbvJzlQ3PFcpb6tPfm5S2jcyQHaquMZ5496nm1DURFCt1E6sx2kDOBjvUuDW4crcrpm9ZGb+0GlRlERUgjdyM0mp6tcXeqxZhaYHALHnHPQe1Zen3gkd7dpA78/QntzVnwxLNDNK2rRujSHyo1jwSrE8cegpxV7inHl94ua34seGSLSY4m82YjMikAfQCs60XVFvGgjXFs4ADHnOeowajk/0S7uJLtxI6seSvAHvXZ+BtRifSdQvLzyltkYrGrDO4AdfzOPwpOyWiIlJUo3SL8Gu2ujeHGsp7My3QDbZAAOT34rzV/s9ik9205Etw4BZ2xye2O9PfUrm61KTKMRkgc8L+HpWpZaHa6pbwXlxKr27EsrI+ee/+FFuTR7DhCFO8urLd5pVrN4eWR5h9vlG5W3ADbg8Y9sVx3g+Jby/a3k1GHcmVV3z19M+9dn4sMcNpalUbyol4AbIVT2B/nXMWFlayNJJAiRFhu49aSsou4Jya0ZPfaSLSea3umZZrdtpaL5lJ612vgX+yZtPub+1vFEwKi63MBsI4BweoPqK4iB5rPz5LsBY3BB53ZHrWba2Vrd2sckO+KAvuKEY3HPcetNK61HUg5x5Uzv/AB9qUVlbRx3LqxkYFdvPy4/SsXwtpsk2v211bq8VkgLyPgHe2OF56DuT7Vi3slu0qRToJnz8okPSu8sZdNl8J3EKajHBMylG8pgkkef4lJ9uKS91LzM5Xp0+ValDxfJY6vaWc1jdfarf5kKrkFWB5H1qLwRrtv4V1CRJ4XewmjZGjBGS3aspIYrS2hs7Dc1vH/y0Y5Z2PJJPr0ps1pJqEqZhLGM5+tJ2+HoNUlKnySKviOe61XVDdWJjgRpCWikI+7ngf/qroW8J3cPh+TWblkihUBgGOCwJwMVneHLK51XXfKuISlrGdxO3lgK7b4m6nCmiabpoUxqZN7o3H3Rgfzok3dIzqVZRlGnT/pHmyTI9xDPtPmodocN/OtDUNJaVVu7S3DyJyM9R7iorS0RriK3t0++4wB3JNd9a2brK1vCy/INrJwc8e1Lms9DWrU5F5nH6DJCqbNSiZJ+mJCAAfbFS32jW/F3bIY7rbzwPnHTP1rEm07ztWnv724ZdrFTACODz0Fafh5po9RW2dmexlZd8ecnPb/8AVTk+V6MGn8ZjWkv22R7eO2mSSPJX5Sxbn0HSodK8PxDVbsaliDS5Yj5m/I57YNem3dhDYO6tcR23yllZ5AjdOorz/VdD1NrK4TUdUgvYCo2C2IbaM53H39RWkJLWzsZKr7TTubniW+0WXQodK8Ow+ZGBg7uEA7getc9ZW8cYjjeFokxhDGmQCetUy8OkwwoScAcY5B9TXTzR30GgXetiyxYRxfKWxzkgcfnWdnt3NFakrXMXVLm4063ml0+QNPkYlAwc/wCz+nNZMLard3sLyyNuYB5PMIJb1zn2qxbXB1GxaQ7gjEhoyMg4PY9cV12n6bptp8N9R1O7Iad+YfVGU42j26H8aq/L7ttQqTVNJvrocmyyNdMHuYEiL8AYPXjPtxU2t+FBpN3bR6hN5wli86OR8gkZPykd/aqE97biyW5lRI4XwjAA5Y/T1pswhuJ47+a+uRbwQqYs5bI/ujPTrSjf0HK6aaZ0XgW3g0vxBE1pIk5eNgYnyDjGDt9+aq+PtKittbh23DEPAJDvYkoST8vH0rMg1YK1vqVmdjW77wzr0weQR+lWtavYvEd5JqTFIWkXBKA4JHt2pWd9TNwftFNbWIPDMMlxq1ukagFSXV2bqQPzqx4mEf8Aa1wGkU7kUqyE4BxyM/Wsa/8A+PaV7SV/MgQk7c5c47elY+mauz2rrd/u2c7CWyafK2uZbF6c25u2eo2VtqEK6uksqYPl+VjJbsWHesnUY7e6vTc3Ea7t5YfPj36d6uSxDzoVlt0aUfLG6gjcT0yKta54durO0W51KzVQqlh5TgZyeNwPIGTjiiLS62CTSeplyWF+oFwY3+xyKMMR3NJeW2+IB3fHTDHIqXUte1K/01NNBt4UjTO5ON4HQZrCtLjzAFjMgkz8yZyCfWhXkrjTadmbuk+ItV0MRQ2shltXbJik+ZVwf0rc17XtH1+EWL2Qs75Y96XSHIVvQjris67Wz07Tv4PNdflb+Ik9c1zkHiS60u/b7PbxiQjaxaMHI+tOKT1S1OepGN+Y9quZtL8P3tjb3jvLcXLKSkcmCgLfe6d/SuZ12PVU1/VrONl+wFm2bz09CPesfXYhfax/aO9zIuCWY9xWz4zu5r3Tor+0+YTQK5QH+JflP1GRmtI6NJa3/M25HFpsy7kSaVp8av8A6Tvk3MAxYJ+PWl1e5lS0tzGfL38kHt68/j1rI0m6vF093uctKqkqBx+BrX0S/XULONb2GN5Nx8tiP5Vo2ovmkr2Zqk7aGqWiiNsJzmTqoxnNFu9xdJeT3llJBArGOPeeZPUj0FVtFvGvNVaO4tgEhbh26A5rrvHUyGwVbJop5gN2yMjBOOBn0rF3T5WtSG7SSMmzdZ7cQ3UjmELjaG+4DSxaS1gjx2luFYjcdq7g3vXP273lzaKtyht3OQOMce3fFa3huS88Nxm6Fw0rlujHIIx3oknG6b1LatrEZZST3OsLbJEAucbyTn3zmuh8ZWa2rSS2L7mfbEytwvHJP1rK0trTxH4gXV/MZbiyBfykyIyPXHrzVbxBLe3Oo20UMqJbx5LBj1ySSffjiqsubTTTUz1lJeQ1Y4oYkedA4PG3Ht2q1prWdtZ/ZopfJgun3My/r0qhJIGiKSHcDxn0qCOexim+xW0qvJAoklGCdu7pk+uKzS0bNZbpPqb2heH7fSo7h2vluFkfIyeSvsKry2N5Hq8zYRrHb8i9wf51jXkzzuiABNrAghs4J9fSpIdU1CPVGtLp/NXG7exwF47eoppym2xODjq2dp4DsrW41K5F3BlUAf1+tZ/jGzm0vxBqCpKJNLlRDbxbeQx6/l/WrcVjrclrBHYxRiwvo/8ASZix3lMjCpj19TVDxVfCPUoVm3CKGNYkL5PQcUkra9zni3KtdPQxLG2s4J2lO5Hc54I7nnNacbGyvt0M6/MOCp5xWfeW05SGeFiozk/LV63HnoCzqQnVu/5UPXVnVpYrX0gW3na7dWgIy+7kfXNULXxKlppyoAz6dkkxqOW55H1rfvNMB09JZlHlyhgyHqR9Peq6aRaQ2Ie1QSRqOVOMDP8AWmmrWFeL3Ol8Ov4VlsDqUN386qCYrgEFc9gOjVgy6hZyLPbaDm1tVZmCAA5Zjz9BntXPyNbSamLISCORFztHAxVi10aG0kZ4Ljd5nzHDZA/zmk04rUiNNKV27nc+D9Lkv9E8jUGN0JSw3Z+n6c1yeoWgt72W2tsYicgA+lQR6nrMF3Hp9q0sNsyl8occHOearajb3dzNbLYTBZ3bGxWwzN6e4pcrbs+ooRcG5N6G94WhtLjW4bTU2XyJMgbjxvxwM1tfELSLXStIgGn2ypLu+6vTHqK4rx54c1HTIrO6DurKQTtB+9x6e9dP4a0608UX1rJrFzdx34iZEUf6pcAffp8nKlNvQyqy95VYv3Uc0YYnZXdIvtWB82MkCqNxp32qGSN36t2Xt1roNZ0y8069lhRN0qsQHXofoa6HwV4Plv7ZrrUBtRcnC/xf4VN+XW5tKvCEeZvQ5/wzo091bvbW4YlFBJzk/Wk1JZtOk2vu3Kee2Pwr03UNU0jwrosUtikRups7FByfevKdZv5dQvnvZ2BMhyef0ApKVzKhWlWk5WtE6vwH4psLHUY479WUTYUTEZCE9zVv40aM13JaXZbcAhQlD2PQ+1cPaW0tzH5UMDSOeeBnA9favR5JpIPCqnVATbsijc+csQOgpL3ZcxlXgoVo1I79jy/S9RhtrsSI0sb2/wA29Vz7ZHrXeR+ILXU7cJZl/OlXg/dwTwcD1Ned6+FkLtpkYhYvnBHJqCKHUVNkizARHBnKH5g3bBHetOWMno7HRUp86u0bGtaTqNjIrTxshc5MrrwRWZoE91pV1LN9qEspbMYbJ2+4r0vU7yNPAMw1W4DSmNY4EZtzuc/ery6wEP2iSTzJneU/wjIGO+D/ACoTvF3FRm6ifMtjakvPtUrTXbF5mGSZTnP/ANaodCyuvIjLsWXKbVPO098e9VtZSNJIDpbuAV/eBhzuz0qNtROmyrdRQ+ZJF3I7570lGy06ml7rQ6fxj4ai0q0jnn+z4kyUhfk8j9K57WfFF9D4Z0+1toTsnd45AGY8Kw2jHQZqh4hvLzxfi9u5TDIei5O3A7e3rV7WbWbRPBum3plM0ly5ATuAvG78aqK1Ser7GSjaK9puFlbPc3CoB++l+VcvgD/61dP4itX0/wAOR2JdJohJumA5AP8AhXDx3/8AoUd3OVSLAKsw2smff616XfWJ0+CG61GcLbyxKTuAJbI9DWeq3FXlaUb/AHHlgbT9TeS3iE0awfPjGAMHkiuk8IeH4tYuls5122aL0AOCPqau3epeFbeIi10Xzrs8GcZVSQfSrGj+L0isbkWVpHFcQxnBHI+tVKX8tyKk5uD5VZlrxH8P7eOB10sxrbuAph3YPHfPrXGalpkvh6N4DY3CofmSZDuAPq3qKdNq2oef5jXlwJvvABuCf8K2l1S/8S6ZcWmxUv4U3n5seYncURm1pLVEqNWmlzO5wmnJNFHIZ5HO5gyt1wOpOf6V1Pizw3pNrolrfRTrKzuqoqPnzARknArM2wiONhKhfnMY7etVZWRpmUllRB8gHQE9eO1Dm+a60N3FytZjbd2e6t/JlklkEqbYzyPvDtXW/GXRnkNtq8cjJlPJkUHA57H/AD2rjrWWa31q3uUkBjilUjnBxn/9depajqOn63YG1v8AzDHtJbZjB9D+FS3ytNHNiG1OMktEeAR3AjziQyhTyp4xXo/hXQrC20z+29UdIgyb1RiAW9ua4+8i06CZn0tDKMkGVxlePQUl35mrtHFdTzEkDAzwoHYDtWsrM0anKPusZqzz3dzLcLEFG44Udl9KdDHDJCguEIbaRGduN3tmopYVUkJM26MbTjuf8a6G+1myvPC8Om28LPfR7eSmCpH3j7j/ABqbmkm0kkZGm6xc3lsYflBCn5iOp9a0NPkuINBDvO7eVMVVc8BW6j8+aKK3XwsuDuk2dDoujKkM1zNK0pmbdg9vYe2Kq3Nv5UiCDagQ/Ko6AUUVjds1juzagtzeKpSRkAOdp5HTmsqaKdtWijilVYh1XHbnP9KKKulre5Gx0MNo93qFraLJiSVtsbNyFPYn1qz40sI/DOjaYLiR7q6wwmlAx5hLccUUVMHdqJlOTVSKMT4ealbjWdRgS2MbJGSSp4YE4P8AOtvxRYhmBgbY4BGfbt0ooq5q1TTyEn75iWBSxDrKDK6H5j7egrZ1jw/YWemS6nZK8b3wDvzzuH/66KKmTafqOTfNE5vTtKFhHJMHDvLgZI/pVdZvtskkEw/dyKyYB7ZxiiindyvJ7m63saNx4r1/RLiysYL4myQKgi6AJkDAx0ru3tLbV3WfUYjI+Qcq20nI78UUVFRKMYyW7/zMasVFXirHN6nHZLql2LD7WjSlUaOWTfGu3+6O1Zupzppun3M8aZmjjJzngntRRTg+aaT8io6QLF9Pdahd6fFcOogjhG5Uz8xK9an8PCWz1S4s3kEtrcrtKMudh9RRRVVVayXYcV7rNCPRtLk1aCERSLdN8gmHOP1rS1jwRe2FzHFHdWrI+CX2EMQT9KKKx5m5WOV1JKSSZj65ZzaFewWgmBaSPeSoyAM47960fCPh62n1Jdcn/eTRR7YEbpGTyWHviiik5NbGlVt0bl74n3P2PRLBFBfzT5rE8fhXL+BzeS6xa3n2sx20LvLJbovEo24Ck+gooqofBcypq9D7x+t65O11dMOWG45Pb6flWRofjHVbq0aJbiSNPOwwU/e9qKKuMVytnWoRaSaC/upLyQvOd46AE/d57VWWNZrm3h2/KzBME5xyP8aKKg1atHQ9hTS106zhs4iFh2b2KjBY9OT3rznxNqd1rN6qXEziC2/dwxA8KBx+fvRRUQ2ucGF96TlLc5zVrSZ40eCRY/LbB5PIPNdJoEtrYJG+oQmdnXKlOxxwTmiiresUdVT4THvL+4vL8LMylHYhAR901S0q7km1FoikYdWIyO4Bxg/lRRWkYpxbZT0Ssbus2Nxpd/AZWiO9d4CZI2/41mNcGacyCJAnBAyc4ooqGtCYaq7Jrry4I0mVMpIM7T2qS92SphNypFEBgnPvxRRUPZMB+iRWN5YX95qdqLtLRQY437uDwTVHUNUvdYcX+oy+cjcCI8CMZ6L6UUVb2M6aTnKT3Mi6u/s9lefZwRJDgjIGOaTRrwrDFLLGmbpHR9nHTPNFFaU4p07vv+g57mddapPbat9ncJNGNuN3B5ArVvZJILoNB8gA7EgiiinVgo2sugk2xJxG9osxXBG3cMfnio47N3jE0U2ZpRnDrwAKKKwiOTaM7UpVitHaNcTbTz24rRsdfuLzw95sscazGEplBgDB9PwoorVRXKvUym7zs+xylreMbdoohtWMng9Dmuk0f+zpLewg1GGSRb07S8YAaNvUZPSiiqnFK4qkmo6GTfRfY7y5gJ3pDIRnoT6VnWs8v2yPyyBIT8renbB9qKKIRTg2zRN6H//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a normal portal triad, central vein, and normal parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23014=[""].join("\n");
var outline_f22_30_23014=null;
var title_f22_30_23015="Gestational trophoblastic disease: Management of hydatidiform mole";
var content_f22_30_23015=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gestational trophoblastic disease: Management of hydatidiform mole",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23015/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23015/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23015/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23015/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23015/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23015/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/30/23015/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydatidiform mole is one of several related disorders of fertilization, which together make up the gestational trophoblastic diseases (GTD). GTD comprises hydatidiform mole (complete and partial), placental site trophoblastic tumor, choriocarcinoma, and gestational trophoblastic neoplasia (GTN).",
"   </p>",
"   <p>",
"    Management of hydatidiform mole, otherwise known as molar pregnancy, will be reviewed here. The clinical evaluation, diagnosis, and pathology of GTD, and the management of women with gestational trophoblastic neoplasia (GTN), are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13816?source=see_link\">",
"     \"Gestational trophoblastic disease: Pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=see_link\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management of complete and partial mole is based upon the experience of clinicians at GTD referral centers and results from observational studies; there are no data from randomized trials.",
"   </p>",
"   <p>",
"    Initial management of suspected complete or partial mole is evacuation of the uterine contents by suction curettage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Evacuation is indicated for pathologic confirmation of the diagnosis, relief of symptoms, and to prevent complications related to molar pregnancy. This procedure is a definitive therapy for most patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suction curettage is the preferred approach because it is less likely to result in uterine perforation or intrauterine adhesions than sharp curettage, and evacuates the uterus more completely than medical methods [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Patients who have no desire for future fertility may opt for hysterectomy, which eliminates the risk of local invasion, but does not prevent metastasis. The adnexae may be retained; if prominent theca lutein cysts are present, these may be drained at the time of surgery. Theca lutein cysts may also be managed expectantly, and will slowly resolve as human chorionic gonadotropin (hCG) levels fall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preoperative testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A baseline hCG level should be obtained for comparison with postoperative results. A complete blood count, and renal, liver, and thyroid function tests can be used to assess for evidence of significant anemia, hyperthyroidism, electrolyte imbalance, or severe preeclampsia. A blood type and antibody screen should also be obtained, both to prepare for heavy bleeding necessitating transfusion and to confirm the patient's Rh(D) status. A routine chest radiograph is not necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with hydatidiform mole are at risk for hemorrhage during the evacuation procedure so blood should be available and adequate venous access assured. We generally perform these procedures under general anesthesia because of the risk of hemorrhage and other complications.",
"   </p>",
"   <p>",
"    Under adequate anesthesia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    is administered and the cervix is dilated to allow passage of the suction cannula. During dilation of the cervix, brisk uterine bleeding is often encountered, which generally slows significantly once suction evacuation has commenced. Heavy bleeding is nearly always self-limited, and inappropriate transfusion should be avoided.",
"   </p>",
"   <p>",
"    A suction catheter of 12 mm is usually sufficient to evacuate a complete molar pregnancy since there is no fetus. A larger catheter may be needed to evacuate a partial mole with a coexistent fetus greater than 12 weeks of gestation. The suction curette is not advanced to the fundus; instead, it is placed just inside the internal os (",
"    <a class=\"graphic graphic_figure graphicRef57978 \" href=\"UTD.htm?34/14/35046\">",
"     figure 1",
"    </a>",
"    ). Vacuum pressures of 50 to 60 cm Hg are then applied and the hydropic placental tissue is drawn into the curette. As additional tissue is evacuated, the uterus will contract and the suction curette may then be advanced to the fundus. Suction curettage can be performed under ultrasound guidance if needed to facilitate the procedure and confirm complete evacuation of uterine contents. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    is administered, and for uteri over 14-weeks size, we suggest fundal massage to stimulate myometrial contraction.",
"   </p>",
"   <p>",
"    Clinicians should be prepared to support the patient as needed, if medical complications occur, such as thyroid storm or respiratory distress from embolization of trophoblastic tissue to the lungs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high output cardiac failure. Since serious complications are more common in women with high hCG levels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    uterine size greater than 14 to 16 weeks gestational size, these patients should be managed by clinicians experienced in the treatment of GTD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there is no fetus in a complete mole, anti-Rh(D) immune globulin is administered to Rh(D) negative women with both complete and partial moles, as trophoblastic tissue expresses the Rh(D) antigen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     POST-MOLAR FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following molar evacuation, patients must be monitored for development of postmolar GTN, defined as those patients who develop persistently elevated hCG levels, require chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    excisional surgery, or have evidence of trophoblastic metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/6\">",
"     6",
"    </a>",
"    ]. Eighteen to 28 percent of patients with complete mole develop persistent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast, following partial molar pregnancy, the risk of GTN is no more than 2 to 4 percent.",
"   </p>",
"   <p>",
"    Patients are monitored with weekly hCG levels until three consecutive normal values are obtained. Only specific hCG assays are appropriate for monitoring trophoblastic disease. If the clinician's usual laboratory does not perform such an assay, a reference laboratory should be used.",
"   </p>",
"   <p>",
"    Approximately 50 percent of patients achieve normal hCG levels six to 14 weeks after molar evacuation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/8\">",
"     8",
"    </a>",
"    ]. For comparison, the decline in hCG after term delivery, abortion, and evacuation of GTD is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef52185 \" href=\"UTD.htm?33/30/34286\">",
"     figure 2",
"    </a>",
"    ). A plateau or rise in hCG is indicative of the development of persistent trophoblastic disease, and necessitates chemotherapeutic treatment.",
"   </p>",
"   <p>",
"    Historically, patients with complete and partial molar pregnancy were followed with monthly hCG levels for a total of six months after achieving three consecutive normal values. Many patients find the six-month period of hCG follow-up difficult to complete. Many women, particularly those over age 35, are anxious to begin attempting another pregnancy. Furthermore, gonadotropin follow-up is anxiety-provoking for many women. For these reasons and others, non-compliance with recommended follow-up is common. In a review of 400 patients at the New England Trophoblast Disease Center (NETDC), 33 percent of patients did not complete six months of follow-up. Interestingly, distance from the treatment center was the only factor in this study that was predictive of failure to complete recommended follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the potential to decrease patient anxiety, shorten the duration of postponement of fertility, increase compliance, as well as decrease the financial and time cost of gonadotropin follow-up, investigators have begun to question whether the post-molar follow-up period could safely be shortened. In order for shorter periods of hCG follow-up to be widely accepted, however, studies that demonstrate the safety of this approach must be performed on large numbers of patients.",
"   </p>",
"   <p>",
"    Studies including several hundred patients have consistently shown that persistent disease does not occur among those with spontaneous regression of hCG levels to undetectable levels (assay sensitivity 5",
"    <span class=\"nowrap\">",
"     mIU/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/10-16\">",
"     10-16",
"    </a>",
"    ], with the exception of a single case report [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/16\">",
"     16",
"    </a>",
"    ]. These series strongly suggest that a significantly shorter period of follow-up is reasonable for patients with either complete or partial molar pregnancy. Theoretically, gonadotropin follow-up in molar pregnancy could be shortened for 97 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/10\">",
"     10",
"    </a>",
"    ]. Women whose hCG levels remain significantly elevated are, however, at high risk of developing persistent disease. This was illustrated in another study by the same authors that observed that 64 percent of women with hCG &gt;2000",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    four weeks after evacuation developed persistent disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Risk factors for persistent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that have consistently been shown to be predictors of development of GTN after a complete mole are: (1) hCG level over 100,000; (2) presence of large (&gt;6 cm in diameter) theca lutein cysts; and (3) significant uterine enlargement, which are all signs of marked trophoblastic proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/17\">",
"     17",
"    </a>",
"    ]. Additional factors have been suggested, but are not universally accepted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/18\">",
"     18",
"    </a>",
"    ]. Complete moles with factors associated with increased risk of persistent disease are considered high-risk complete moles. For partial moles, no clinical factors have been identified that are associated with increased risk of GTN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to emphasize the use of reliable contraception during the entire follow-up period. This eliminates the potential confusion that arises in the interpretation of a rising hCG levels in a patient who has not been using a reliable contraceptive method. A randomized controlled trial by the Gynecologic Oncology Group (GOG) examined the role of oral contraceptives (OCs) and barrier contraception in the development of postmolar tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/19\">",
"     19",
"    </a>",
"    ]. Twice as many patients in the barrier group became pregnant in the immediate follow-up period after molar evacuation. The authors concluded that oral contraceptives were the preferred method of contraception in this setting.",
"   </p>",
"   <p>",
"    As indicated in their medical eligibility criteria tables, the World Health Organization feels the risks of intrauterine contraception outweigh the benefits during the period of hCG monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prophylactic chemotherapy for high risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic chemotherapy after molar evacuation is widely practiced in developing countries in which poor medical and social resources limit effective follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/17\">",
"     17",
"    </a>",
"    ]. However, this practice, which may cause later chemoresistance, is controversial and lacks universal acceptance.",
"   </p>",
"   <p>",
"    The successful use of chemoprophylaxis at the time of surgical evacuation of a complete molar pregnancy depends, in part, on the ability to stratify patients into high versus low risk of developing postmolar GTN. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Risk factors for persistent disease'",
"    </a>",
"    above.) Several investigators report that prophylactic chemotherapy given at the time of molar evacuation reduces the risk of postmolar GTN. As an example, a placebo-controlled, randomized prospective trial demonstrated that prophylactic chemotherapy reduced the incidence of postmolar tumor from 47 to 14 percent in patients with high-risk complete molar pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/21\">",
"     21",
"    </a>",
"    ]. In patients with low-risk complete mole, however, there was no change in postmolar tumor incidence (5.6 and 7.7 percent). A similar prospective randomized trial reported postmolar GTN incidence decreased from 50 to 13.8 percent when patients were given prophylactic Actinomycin D for high-risk complete mole [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, even when women are selected for chemoprophylaxis based upon their estimated risk of persistent GTN, it is not clear that there are significant advantages to treating many high-risk patients to prevent postmolar GTN in a few, rather than treating persistent disease when it is diagnosed. In most institutions, the chemotherapeutic regimens (typically single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    ) and outcomes are similar regardless of the approach taken. Others have suggested that a more intense chemoprophylaxis regimen (ie, multiagent chemotherapy) be given to some \"ultra-high risk\" women, but this approach is not universally accepted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/18\">",
"     18",
"    </a>",
"    ]. The specific chemotherapy regimens are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=see_link&amp;anchor=H9#H9\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\", section on 'Chemotherapy regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For all of these reasons, we consider prophylactic chemotherapy only in patients with a complete mole for whom compliance with hCG follow-up may be difficult and who have any of the following high-risk features [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/17\">",
"     17",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H7\">",
"     'Risk factors for persistent disease'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      hCG level over 100,000",
"     </li>",
"     <li>",
"      Presence of large theca lutein cysts &gt;6 cm in diameter",
"     </li>",
"     <li>",
"      Significant uterine enlargement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Posttreatment reproductive outcomes did not differ between women with high risk disease who did versus did not receive a single prophylactic dose of actinomycin D in a prospective cohort study (n = 1090) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnosis of persistent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any of the following findings during the period of gonadotropin follow-up is suggestive of malignant GTN and warrants treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A plateau in the serum hCG concentration for at least four values over three weeks; eg, on days 1,7,14, and 21",
"     </li>",
"     <li>",
"      A serum hCG concentration that rises (by 10 percent or greater) for three values or more over at least two consecutive weeks; eg, on days 1,7, and 14",
"     </li>",
"     <li>",
"      Persistence of detectable serum hCG for more than six months after molar evacuation",
"     </li>",
"     <li>",
"      Histologic confirmation of choriocarcinoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some data suggest that it is reasonable to defer chemotherapy until 12 months after molar evacuation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=see_link&amp;anchor=H53#H53\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\", section on 'Recurrent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a patient with an undetectable hCG who has had a curettage, a uterine lesion seen on imaging is not diagnostic of persistent disease. In such cases, if the patient has no abnormal uterine bleeding or pelvic pain, we follow expectantly with intermittent scans and hCG levels to confirm no elevation. In addition, the radiologist should be consulted to discuss the potential etiology of the lesion. If the lesion does not change over six months to a year, the hCG is undetectable, and the patient remains asymptomatic, we recommend no further intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF PERSISTENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staging and treatment of malignant GTD is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=see_link\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COEXISTENT VIABLE FETUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A twin pregnancy may be complicated by GTD, and may present as either a mole (partial or complete) and one viable fetus or two moles. The diagnosis is suggested by ultrasound examination and confirmed by cytogenetic studies and histopathological examination after evacuation of the entire contents of the uterus.",
"   </p>",
"   <p>",
"    After appropriate counseling of the risks involved, some patients who have a normal fetus coexisting with molar tissue elect to continue the pregnancy without intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Persistent disease is more frequently observed in these cases; in one series, 12 of 22 patients (55 percent) with a complete mole and a coexisting viable fetus developed persistent gestational trophoblastic neoplasia requiring chemotherapy, five of whom developed metastatic disease necessitating multiple cycles of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/27\">",
"     27",
"    </a>",
"    ]. Other large series report persistent disease in 19 to 57 percent of cases of complete mole with a coexisting viable fetus managed conservatively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/28-33\">",
"     28-33",
"    </a>",
"    ]; use of fertility drugs does not increase risk of persistent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/34\">",
"     34",
"    </a>",
"    ]. Of note, the risk of persistence was lower in pregnancies that resulted in delivery of a surviving infant than in those that did not. By comparison, 18 to 28 percent of patients with singleton complete mole develop persistent disease.",
"   </p>",
"   <p>",
"    Pregnancy termination or preterm delivery due to vaginal hemorrhage are common complications in continuing pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/31,35\">",
"     31,35",
"    </a>",
"    ]. Hyperthyroidism and preeclampsia also occur with greater frequency in these pregnancies. A literature review of 174 pregnancies comprising a complete hydatidiform mole and coexisting fetus reported the following outcomes (not all series reported all outcomes): vaginal bleeding",
"    <span class=\"nowrap\">",
"     (74/97),",
"    </span>",
"    preeclampsia",
"    <span class=\"nowrap\">",
"     (25/92),",
"    </span>",
"    hyperthyroidism",
"    <span class=\"nowrap\">",
"     (4/71),",
"    </span>",
"    pregnancy termination",
"    <span class=\"nowrap\">",
"     (82/174),",
"    </span>",
"    preterm birth",
"    <span class=\"nowrap\">",
"     (41/66),",
"    </span>",
"    spontaneous fetal loss",
"    <span class=\"nowrap\">",
"     (41/66),",
"    </span>",
"    term live birth",
"    <span class=\"nowrap\">",
"     (40/92)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence-based guidelines to help with management of the ongoing pregnancy have not been established. Reasonable management would include, however, a chest x-ray to exclude pulmonary metastases (which would suggest the presence of a choriocarcinoma), a fetal karyotype (to exclude triploidy which would suggest partial mole), along with close maternal surveillance for development of preeclampsia and hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/1\">",
"     1",
"    </a>",
"    ]. Conservative management would not be recommended in the presence of choriocarcinoma or fetal aneuploidy. Postpartum, the placenta should be sent for evaluation by a pathologist experienced in the evaluation of GTD, and routine post-GTD surveillance should be initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=see_link\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SUBSEQUENT PREGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of repeat molar pregnancy in a conception following one molar pregnancy (complete, partial, or persistent GTN) is approximately 1 percent, which is increased compared to the 1:1000 risk of molar gestation in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/36\">",
"     36",
"    </a>",
"    ]. Therefore, ultrasound should be obtained in the late first trimester of subsequent pregnancies to confirm normal fetal development. Additionally, an hCG level should be obtained six weeks after completion of subsequent pregnancies to rule out occult choriocarcinoma. Routine pathologic evaluation of the placenta, while recommended in the past, is not necessary. However, products of conception should be evaluated by a pathologist following any spontaneous or therapeutic abortion.",
"   </p>",
"   <p>",
"    It has been reported that patients who conceive prior to completion of gonadotropin follow-up generally have favorable pregnancy outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23015/abstract/37\">",
"     37",
"    </a>",
"    ]. Certainly the studies described above, which demonstrate essentially no risk of persistent disease once a single undetectable hCG level is achieved, are reassuring (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Monitoring'",
"    </a>",
"    above). Recommendations for hCG follow-up may ultimately change, thus decreasing concern about new pregnancies in patients who have achieved non-detectable hCG values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HUMAN CHORIONIC GONADOTROPIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed discussion of hCG structure, production, and function and issues in hCG testing can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39960?source=see_link\">",
"     \"Human chorionic gonadotropin testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evacuation of a molar pregnancy is indicated for pathologic confirmation of the diagnosis, relief of symptoms, and to prevent complications related to molar pregnancy. Suction curettage is the preferred method of uterine evacuation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Hysterectomy is a reasonable alternative in women who do not desire preservation of fertility. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serious complications (eg, respiratory distress from trophoblastic embolization) are more common in women with high human chorionic gonadotropin (hCG) levels",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      uterine size greater than 14 to 16 weeks gestational size. These patients should be managed by clinicians experienced in the treatment of molar pregnancy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with at least one of the following three risk factors (theca lutein cysts &ge;6 cm, excessively enlarged uterus for dates, initial hCG &gt;100,000",
"      <span class=\"nowrap\">",
"       mIU/mL)",
"      </span>",
"      appear more likely to develop postmolar gestational trophoblastic neoplasia (uterine invasion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metastatic disease) than are those with no risk factors. We suggest prophylactic chemotherapy in high-risk patients for whom compliance with follow-up may be problematic (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prophylactic chemotherapy for high risk disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum hCG levels should be monitored after treatment of complete or partial molar pregnancy to assess for persistent disease. Patients are monitored with weekly hCG levels until three consecutive normal values are obtained. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Post-molar follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persistent disease is diagnosed if the serum hCG concentration plateaus (decline of less than 10 percent for at least four values over three weeks), rises (increase of 10 percent or greater of three or more values over two consecutive weeks), or persists for more than six months after molar evacuation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis of persistent disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A molar pregnancy may coexist with a viable fetus. These pregnancies, if allowed to proceed, often experience pregnancy complications (eg, hemorrhage, preeclampsia, preterm delivery) and they are at elevated risk of persistent gestational trophoblastic neoplasia. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Coexistent viable fetus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Human chorionic gonadotropin assays should be performed by a sandwich-type radioimmunoassay with both monoclonal antibodies and spectrometric detection systems. The same laboratory should be used for comparing serial results in an individual patient. False negative results can occur if the hCG concentration is extremely high (eg, over one million",
"      <span class=\"nowrap\">",
"       mIU/mL)",
"      </span>",
"      or hCG variants are present but not detected. False positive results can be due to a variety of factors, including pituitary secretion of hCG. When hCG levels are persistently positive at low levels, the clinician must differentiate between true positive hCG due to gestational trophoblastic disease, false positive hCG, and positive hCG due to quiescent gestational trophoblastic disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Human chorionic gonadotropin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H714247941\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to recognize Dr. Elizabeth Garner, who contributed to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/1\">",
"      Committee on Practice Bulletins-Gynecology, American College of Obstetricians and Gynecologists. ACOG Practice Bulletin #53. Diagnosis and treatment of gestational trophoblastic disease. Obstet Gynecol 2004; 103:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/2\">",
"      Gerulath AH, Ehlen TG, Bessette P, et al. Gestational trophoblastic disease. J Obstet Gynaecol Can 2002; 24:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/3\">",
"      Tidy JA, Gillespie AM, Bright N, et al. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol 2000; 78:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/4\">",
"      Stone M, Bagshawe KD. An analysis of the influences of maternal age, gestational age, contraceptive method, and the mode of primary treatment of patients with hydatidiform moles on the incidence of subsequent chemotherapy. Br J Obstet Gynaecol 1979; 86:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/5\">",
"      Soper JT. Surgical therapy for gestational trophoblastic disease. J Reprod Med 1994; 39:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/6\">",
"      Kohorn EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int J Gynecol Cancer 2001; 11:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/7\">",
"      Berkowitz RS, Goldstein DP. Chorionic tumors. N Engl J Med 1996; 335:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/8\">",
"      van Trommel NE, Massuger LF, Schijf CP, et al. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol 2006; 24:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/9\">",
"      Feltmate CM, Batorfi J, Fulop V, et al. Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation. Obstet Gynecol 2003; 101:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/10\">",
"      Wolfberg AJ, Feltmate C, Goldstein DP, et al. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy. Obstet Gynecol 2004; 104:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/11\">",
"      Kerkmeijer L, Wielsma S, Wiesma S, et al. Guidelines following hydatidiform mole: a reappraisal. Aust N Z J Obstet Gynaecol 2006; 46:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/12\">",
"      Wolfberg AJ, Growdon WB, Feltmate CM, et al. Low risk of relapse after achieving undetectable HCG levels in women with partial molar pregnancy. Obstet Gynecol 2006; 108:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/13\">",
"      Lavie I, Rao GG, Castrillon DH, et al. Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles. Am J Obstet Gynecol 2005; 192:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/14\">",
"      Batorfi J, Vegh G, Szepesi J, et al. How long should patients be followed after molar pregnancy? Analysis of serum hCG follow-up data. Eur J Obstet Gynecol Reprod Biol 2004; 112:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/15\">",
"      Wielsma S, Wiesma S, Kerkmeijer L, et al. Persistent trophoblast disease following partial molar pregnancy. Aust N Z J Obstet Gynaecol 2006; 46:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/16\">",
"      Kerkmeijer LG, Wielsma S, Massuger LF, et al. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands. Gynecol Oncol 2007; 106:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/17\">",
"      Berkowitz RS, Goldstein DP, DuBeshter B, Bernstein MR. Management of complete molar pregnancy. J Reprod Med 1987; 32:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/18\">",
"      Kim SJ, Na YJ, Jung SG, et al. Management of high-risk hydatidiform mole and persistent gestational trophoblastic neoplasia: the Korean experience. J Reprod Med 2007; 52:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/19\">",
"      Curry SL, Schlaerth JB, Kohorn EI, et al. Hormonal contraception and trophoblastic sequelae after hydatidiform mole (a Gynecologic Oncology Group Study). Am J Obstet Gynecol 1989; 160:805.",
"     </a>",
"    </li>",
"    <li>",
"     file://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf (Accessed on March 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/21\">",
"      Kim DS, Moon H, Kim KT, et al. Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstet Gynecol 1986; 67:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/22\">",
"      Limpongsanurak S. Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med 2001; 46:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/23\">",
"      Uberti EM, Fajardo Mdo C, Ferreira SV, et al. Reproductive outcome after discharge of patients with high-risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecol Oncol 2009; 115:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/24\">",
"      Agarwal R, Teoh S, Short D, et al. Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet 2012; 379:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/25\">",
"      Forum: Twin gestation comprising mole in concert with normal fetus: Test, treat, abort or let go to term. Trophoblastic Dis Update 1999; 3:3.",
"     </a>",
"    </li>",
"    <li>",
"     Royal College of Obstetricians and Gynecologists. The Management of Gestational Trophoblastic Disease, College of Obstetricians and Gynecologists, London 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/27\">",
"      Steller MA, Genest DR, Bernstein MR, et al. Clinical features of multiple conception with partial or complete molar pregnancy and coexisting fetuses. J Reprod Med 1994; 39:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/28\">",
"      Bristow RE, Shumway JB, Khouzami AN, Witter FR. Complete hydatidiform mole and surviving coexistent twin. Obstet Gynecol Surv 1996; 51:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/29\">",
"      Fishman DA, Padilla LA, Keh P, et al. Management of twin pregnancies consisting of a complete hydatidiform mole and normal fetus. Obstet Gynecol 1998; 91:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/30\">",
"      Sebire NJ, Foskett M, Paradinas FJ, et al. Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet 2002; 359:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/31\">",
"      Vaisbuch E, Ben-Arie A, Dgani R, et al. Twin pregnancy consisting of a complete hydatidiform mole and co-existent fetus: report of two cases and review of literature. Gynecol Oncol 2005; 98:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/32\">",
"      Matsui H, Sekiya S, Hando T, et al. Hydatidiform mole coexistent with a twin live fetus: a national collaborative study in Japan. Hum Reprod 2000; 15:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/33\">",
"      Hancock BW, Martin K, Evans CA, et al. Twin mole and viable fetus: The case for misdiagnosis. J Reprod Med 2006; 51:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/34\">",
"      Petignat P, Vassilakos P, Campana A. Are fertility drugs a risk factor for persistent trophoblastic tumour? Hum Reprod 2002; 17:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/35\">",
"      Wee L, Jauniaux E. Prenatal diagnosis and management of twin pregnancies complicated by a co-existing molar pregnancy. Prenat Diagn 2005; 25:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/36\">",
"      Garrett LA, Garner EI, Feltmate CM, et al. Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. J Reprod Med 2008; 53:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23015/abstract/37\">",
"      Garner EI, Lipson E, Bernstein MR, et al. Subsequent pregnancy experience in patients with molar pregnancy and gestational trophoblastic tumor. J Reprod Med 2002; 47:380.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3194 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-125.69.132.100-32DA4B247A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23015=[""].join("\n");
var outline_f22_30_23015=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preoperative testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      POST-MOLAR FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Risk factors for persistent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prophylactic chemotherapy for high risk disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnosis of persistent disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT OF PERSISTENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COEXISTENT VIABLE FETUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT OF SUBSEQUENT PREGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HUMAN CHORIONIC GONADOTROPIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H714247941\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3194\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3194|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/14/35046\" title=\"figure 1\">",
"      Suction curettage molar pregnan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/30/34286\" title=\"figure 2\">",
"      Beta hCG following evacuation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=related_link\">",
"      Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13816?source=related_link\">",
"      Gestational trophoblastic disease: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=related_link\">",
"      Gestational trophoblastic neoplasia: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39960?source=related_link\">",
"      Human chorionic gonadotropin testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_30_23016="Oropharyngeal trauma in children";
var content_f22_30_23016=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oropharyngeal trauma in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23016/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23016/contributors\">",
"     David W Roberson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23016/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23016/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23016/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23016/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/30/23016/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children often fall with objects in their mouths and may suffer trauma to the oropharynx. These injuries pose a significant diagnostic challenge because the vast majority will heal spontaneously without complications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/1-4\">",
"     1-4",
"    </a>",
"    ], but a small minority will develop deep neck infections or carotid artery injuries that cause major morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]. The approach to oropharyngeal blunt trauma relies on an assessment of the oropharyngeal wound, a rational use of diagnostic tools, primarily noninvasive radiologic techniques, and surgical intervention in selected patients.",
"   </p>",
"   <p>",
"    This review covers the evaluation and management of wounds to the hard and soft palate, tonsils, and posterior pharyngeal walls. Dental and tongue injuries are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=see_link\">",
"     \"Evaluation and management of dental injuries in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24309?source=see_link\">",
"     \"Evaluation and repair of tongue lacerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oropharyngeal injuries account for an estimated 1 percent of all pediatric trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/11\">",
"     11",
"    </a>",
"    ]. A common mechanism involves a toddler or preschool child falling with an object in the mouth or having an item pushed into their mouth by a playmate or caregiver. Commonly reported objects include writing instruments (eg, pen, pencil), toothbrushes, Popsicle sticks, lollipops, eating utensils, and drinking straws [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. Infrequently, the trauma may result from a blind finger sweep by a caregiver during a choking episode [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY AND PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oropharynx consists of the following structures:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Soft palate, uvula above",
"     </li>",
"     <li>",
"      Tongue below",
"     </li>",
"     <li>",
"      Dentition and cheeks anterolaterally",
"     </li>",
"     <li>",
"      Tonsils and tonsillar pillars posterolaterally",
"     </li>",
"     <li>",
"      Posterior pharyngeal wall",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The carotid sheath, which contains the internal carotid artery, internal jugular vein, and vagus nerve, lies immediately posterolateral to the tonsils and tonsillar pillars (",
"    <a class=\"graphic graphic_figure graphicRef76329 \" href=\"UTD.htm?34/55/35699\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The retropharyngeal space resides between the vertebral bodies of the cervical spine and the posterior pharynx. The parapharyngeal space describes the region of the neck lateral to the oropharynx and includes the carotid sheath. These potential spaces extend into the mediastinum and, when violated, allow air and bacteria to gain access.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Internal carotid artery injury (ICA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lateral oropharyngeal injury that is posterior to the molars may compress the ICA against the lateral process of a cervical vertebra, creating an intimal tear (",
"    <a class=\"graphic graphic_figure graphicRef76329 \" href=\"UTD.htm?34/55/35699\">",
"     figure 1",
"    </a>",
"    ). Thrombus formation at the site of arterial injury can extend up into the anterior and middle cerebral arteries over several hours to several days. During this time period, the patient remains asymptomatic (ie, lucid interval). With progression of the clot, the patient develops symptoms of stroke (eg, contralateral hemiparesis, ipsilateral facial drop, and aphasia). In some cases, hemorrhagic stroke and death have occurred.",
"   </p>",
"   <p>",
"    Alternatively, injury to the ICA may cause a dissecting aneurysm or pseudoaneurysm with similar neurologic sequelae.",
"   </p>",
"   <p>",
"    Rarely, ICA injury may cause immediate massive bleeding which requires emergency intubation and neck exploration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Deep neck space infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seeding of bacteria from the oropharynx into the",
"    <span class=\"nowrap\">",
"     retropharyngeal/parapharyngeal",
"    </span>",
"    spaces or introduction of organisms from a retained foreign body may cause retropharyngeal infection and abscess. If unrecognized, the infection may extend into the mediastinum. In addition, infection and thrombosis of the internal jugular vein (ie, Lemierres syndrome or jugular vein suppurative thrombophlebitis) may cause severe neck pain and fever. Any of these infections (eg, retropharyngeal abscess, mediastinitis, jugular vein suppurative thrombophlebitis) may cause severe illness with sepsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link&amp;anchor=H990947896#H990947896\">",
"     \"Deep neck space infections\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link&amp;anchor=H990948208#H990948208\">",
"     \"Deep neck space infections\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluation should focus on the mechanism of injury, wound characteristics, and the child's neurologic status. Once these factors are known, then radiograph imaging and management proceed based on the patient's estimated risk of deep structure injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanism of injury can be graded as mild, moderate, or severe. For example, a 10 kg child who falls slowly from a kneeling position with a rounded object in the mouth is at low risk of serious injury. A 40 kg child who falls while running full speed with a sharpened pencil in the mouth is at higher risk. Oropharyngeal trauma with major sequelae is suggested by the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal neurologic changes (ICA injury)",
"     </li>",
"     <li>",
"      Fever, neck pain, torticollis, or drooling in a patient presenting more than 24 hours post oropharyngeal trauma (retropharyngeal or other deep neck infection) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"       \"Deep neck space infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chest pain and fever (mediastinitis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oropharyngeal injuries resulting from major trauma (eg, air bag deployment when a child has an object in his or her mouth, gunshot wound) warrant management as zone III penetrating neck injuries with an aggressive approach to airway protection and injury identification (eg, angiography, endoscopy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical exploration). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2026?source=see_link&amp;anchor=H11#H11\">",
"     \"Penetrating neck injuries\", section on 'Emergency management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Victims of major trauma require an initial primary survey for life-threatening injuries before the emergency provider focuses on oropharyngeal injury. Rarely, hemorrhage from a major oral laceration compromises the airway and necessitates emergent endotracheal intubation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link\">",
"     \"The difficult pediatric airway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the stable patient, the clinician should focus on wound assessment, associated oropharyngeal injury (eg, dentition, jaw), and neurologic examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Wound characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thorough examination of the posterior pharynx in a young child often requires the gentle use of a tongue blade and bite block in conjunction with analgesia as needed. A suction device should be immediately available during the examination. Rarely, sedation or general anesthesia is required to adequately examine the oropharynx in an uncooperative child. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Careful wound assessment includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depth &ndash; Small superficial lacerations or scratches (&lt;2 cm long) with clear wound margins and a visible base are of less concern than puncture wounds with a sharp object (eg, pencil). However, depth of a lesion is often difficult to determine. Injury to deeper structures may be present even with apparently minor wounds [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Length &ndash; Lacerations over two centimeters in length or associated with a hanging flap usually need repair, but the location, appearance of the laceration, and whether it seems to \"fall back together\" is more important than the specific length in deciding whether to close the wound. The decision is important because almost all laceration repairs in this region require general anesthesia.",
"     </li>",
"     <li>",
"      Location &ndash; Lateral wounds, especially of the tonsillar pillars, have a greater risk of ICA injury than midline wounds [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/14\">",
"       14",
"      </a>",
"      ]. Injuries to the soft palate are more associated with potential complications than wounds to the hard palate.",
"     </li>",
"     <li>",
"      Foreign body &ndash; A protruding foreign body or concern for a retained foreign body requires additional imaging to demarcate extent of injury and localize involved anatomic structures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Associated physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any evidence of focal neurologic deficits on complete neurologic examination should prompt emergent imaging and surgical consultation. Nonspecific findings of lethargy or gait disturbance also warrant aggressive evaluation (",
"    <a class=\"graphic graphic_table graphicRef73310 \" href=\"UTD.htm?18/55/19323\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Neck auscultation over the common carotid artery may demonstrate a bruit on the side associated with the oropharyngeal laceration.",
"   </p>",
"   <p>",
"    The teeth should be examined for fracture, subluxation, and avulsion. Tongue lacerations may also be present. Malocclusion and pain with motion indicate jaw injury. Other clinical manifestations of these injuries are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=see_link\">",
"     \"Evaluation and management of dental injuries in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24309?source=see_link\">",
"     \"Evaluation and repair of tongue lacerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6615?source=see_link\">",
"     \"Jaw fractures in children\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Trismus and drooling in association with fever suggests a retropharyngeal abscess. Subcutaneous emphysema with crepitance may accompany retropharyngeal trauma with air dissecting into the mediastinum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"     \"Deep neck space infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral injuries to the lips or unexplained by the history raise suspicion for physical abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, caregivers have scratched the posterior pharyngeal wall to produce hematemesis as a form of factitious disorder by proxy (Munchausen syndrome by proxy) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately after injury, blood testing (CBC, chemistries) is only indicated if there is significant hemorrhage. In these rare situations, the child should receive a hematocrit, platelet count, type and cross, and coagulation studies (prothrombin time, partial thromboplastin time, international normalized ratio).",
"   </p>",
"   <p>",
"    Patients coming to attention with fever and concern regarding a deep neck infection should undergo a complete blood count with differential and blood culture. Measurement of inflammatory markers (eg, erythrocyte sedimentation rate or C reactive protein) is helpful in suggesting the presence of a serious infection and in monitoring response to treatment in patients with deep neck infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link&amp;anchor=H8#H8\">",
"     \"Retropharyngeal infections in children\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of imaging is to select those children at increased risk of serious sequelae and to detect foreign bodies. Significant controversy surrounds the approach to radiographic imaging in children with oropharyngeal trauma (",
"    <a class=\"graphic graphic_algorithm graphicRef60522 \" href=\"UTD.htm?0/52/847\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Approach to diagnosis and management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Plain radiographs of the neck and chest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs may detect subcutaneous air, pneumomediastinum, retropharyngeal widening from abscess or hematoma, and radiopaque foreign bodies. Patient cooperation is not necessary to obtain an adequate study. However, plain radiographs lack sensitivity relative to computed tomography angiography (CTA) or contrast enhanced magnetic resonance angiography (MRA) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/2\">",
"     2",
"    </a>",
"    ]. For this reason, plain radiographs are not generally recommended, except specifically to exclude a radiopaque retained foreign body.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Carotid ultrasound with oculoplethysmography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some specialists have used serial monitoring of carotid flow with ultrasound as a noninvasive method of observing patients while avoiding ionizing radiation. However, this approach warrants patient hospitalization and requires patient cooperation or sedation. In addition, ultrasound findings may not correlate well with blood vessel injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Computed tomography angiography (CTA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies suggest that CTA has good sensitivity for air and subcutaneous foreign bodies and is superior to plain radiographs in patients with oropharyngeal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/2,12,17\">",
"     2,12,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data does not exist for children with arterial injury after oropharyngeal trauma, systematic reviews have found that CTA has a variable sensitivity and specificity for detecting posttraumatic carotid artery injury in adults with blunt neck trauma. CTA is inferior to contrast enhanced MRA in noninvasive detection of carotid artery defects in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"     \"Evaluation of carotid artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite questions about its ability to detect ICA injury, CTA is more widely available than contrast enhanced magnetic resonance angiography (MRA) and does not require general anesthesia. CTA is also noninvasive, although the typical child will require sedation. For these reasons, many otolaryngologists (ear, nose, and throat surgeons) utilize CTA as a primary modality in their diagnostic approach in children with oropharyngeal trauma instead of contrast enhanced MRA. Carotid arterial angiography (CAA) is reserved for patients with neurologic deficit or significant ongoing hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/2,12,17\">",
"     2,12,17",
"    </a>",
"    ] or a mechanism of injury so severe that it warrants management as zone III penetrating neck injury. If CTA suggests trauma immediately adjacent to the major vascular structures (eg, when the wound track can be seen to project immediately adjacent to the carotid), CAA should usually be obtained. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Carotid artery angiography (CAA)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, the potential for CTA to miss a significant ICA injury remains a concern as does the radiation exposure. Thus, the role of CTA versus contrast enhanced MRA in children with oropharyngeal trauma warrants further study [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Magnetic resonance angiography (MRA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little data exist concerning the use of MRA in children with oropharyngeal trauma. Its use is limited by availability and patient factors, including the need for general anesthesia when used in young children and the inability to image patients with metallic implants.",
"   </p>",
"   <p>",
"    In adults, contrast enhanced MRA provides good visualization of carotid artery defects with high sensitivity and specificity relative to digital subtraction intraarterial angiography. Contrast enhanced MRA may be preferable to CTA in the older child who can remain still without the need for general anesthesia. Technological advances that shorten MRA test duration to the point that general anesthesia is unnecessary might favor its use for oropharyngeal trauma in children in the future. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link&amp;anchor=H18#H18\">",
"     \"Evaluation of carotid artery stenosis\", section on 'MR angiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Carotid artery angiography (CAA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digital subtraction CAA remains the gold standard for radiologic imaging of children with ICA injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the risk of complications from this procedure is significant. In adults, CAA has a 4 percent risk of embolic stroke and a 1 percent risk of death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation of carotid artery stenosis\", section on 'Conventional cerebral angiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CAA is typically reserved for children with neurologic deficit after oropharyngeal trauma, ongoing hemorrhage, a truly major mechanism of injury, or evidence of ICA injury on other imaging (eg, CTA, contrast enhanced MRA). Given the low frequency of these findings, CAA is rarely performed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. Although there are no direct data on this point, the risk of CAA in young children or toddlers is probably correlated with the experience of the center in performing angiography in children. If in doubt as to the risk of the study, the ED physician should discuss directly with the radiologist who will be performing the study.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study over a six year time period from a children's hospital reported that 52 of 107 children with oropharyngeal trauma had a CTA while none had a CAA [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/12\">",
"       12",
"      </a>",
"      ]. No neurologic sequelae were reported.",
"     </li>",
"     <li>",
"      An observational study of 23 children seen over six years at a children's hospital reported that 21 had one or more imaging studies; CTA was performed in 18 children, plain neck radiographs in 9, and CAA in 3 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/2\">",
"       2",
"      </a>",
"      ]. CAA followed an abnormal CTA (air near the carotid sheath) in one case and showed vessel spasm without thrombus. CAA was normal in the remaining two children; one was performed despite a normal CTA because of a carotid bruit on examination and the other study was the only imaging performed. No neurologic sequelae were seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although every emergency clinician encounters oropharyngeal trauma, major complications are rare enough that prospective studies have not been feasible. Recommendations are therefore based on observational studies and expert opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Initial stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Victims of major trauma require an initial primary survey for life-threatening injuries before the emergency provider focuses on oropharyngeal injury. Rarely, hemorrhage from a major oral laceration compromises the airway and necessitates emergent endotracheal intubation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link\">",
"     \"The difficult pediatric airway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with significant facial injury sustained during major trauma warrant cervical spine immobilization until appropriate assessment and diagnostic imaging of the neck are performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Protruding oropharyngeal foreign bodies should be left in place until they can be fully assessed, imaged, and removed under controlled conditions in the operating room.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Approach to diagnosis and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The algorithm provides an approach to evaluation and management of oropharyngeal trauma in children (",
"    <a class=\"graphic graphic_algorithm graphicRef60522 \" href=\"UTD.htm?0/52/847\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     High risk injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have suffered high-force penetrating trauma (motor vehicle accident, gunshot wound to the neck, stabbing victim) or who manifest neurologic deficit, profuse bleeding, or carotid bruit on exam after isolated oropharyngeal trauma have a high risk for vascular injury and should undergo CAA. These patients should be treated as zone III penetrating neck injuries and require an aggressive approach to airway protection, and injury identification (eg, angiography, endoscopy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical exploration). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2026?source=see_link&amp;anchor=H11#H11\">",
"     \"Penetrating neck injuries\", section on 'Emergency management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, these patients warrant immediate consultation of an otolaryngologist (ear, nose, and throat surgeon) with pediatric expertise in concert with neurosurgical or vascular surgeons. If capability to manage these patients does not exist at the admitting hospital, then the patient should be stabilized and transferred expeditiously to an appropriate institution. Further treatment is guided by CAA results and may include anticoagulation, surgical exploration of the neck, or carotid thrombus endarterectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2026?source=see_link&amp;anchor=H11#H11\">",
"     \"Penetrating neck injuries\", section on 'Emergency management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Moderate risk injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have a retained or protruding foreign body, a deep wound, or a wound of indeterminate depth with a concerning mechanism should undergo CTA or contrast enhanced MRA, particularly if the wound is lateral in the oropharynx (overlying the carotid sheath). Concerning findings on CTA include ICA abnormality, subcutaneous air near the carotid sheath, or significant tissue disruption adjacent to the carotid sheath. MRA shows similar findings but may also have the ability to show ICA injury with greater sensitivity and specificity. Patients with an abnormal CTA or MRA should receive a digital subtraction CAA. We recommend that these children undergo hospital admission.",
"   </p>",
"   <p>",
"    In addition, these patients warrant immediate consultation of an otolaryngologist (ear, nose, and throat surgeon) with pediatric expertise. If capability to manage these patients does not exist at the admitting hospital, then the patient should be transferred expeditiously to an appropriate institution. Further treatment is guided by CAA results and may include anticoagulation, surgical exploration of the neck, or carotid endarterectomy.",
"   </p>",
"   <p>",
"    If CTA or MRA suggests limited penetration, not adjacent to the carotid (eg, mid-line), we suggest that the child be discharged home to a reliable caregiver who can closely monitor for symptoms of ICA occlusion or deep neck infection and who can return promptly for reevaluation should symptoms develop (",
"    <a class=\"graphic graphic_table graphicRef73310 \" href=\"UTD.htm?18/55/19323\">",
"     table 1",
"    </a>",
"    ). In situations where social concerns do not allow discharge, or the managing physician is concerned about the risk of possible neurologic sequelae, the patient may be admitted for 24 to 48 hours for neurologic checks, recognizing that neurologic sequelae may occur 48 hours or longer after injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Low risk injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with minor trauma associated with superficial laceration (eg, a toddler tips over from a sitting position with a pencil in his or her mouth), especially midline wounds, do not require imaging or subspecialty consultation. We suggest that these children can be discharged home to reliable caregivers who can closely monitor for symptoms of internal carotid artery occlusion or deep neck infection and who can return promptly for reevaluation should symptoms develop (",
"    <a class=\"graphic graphic_table graphicRef73310 \" href=\"UTD.htm?18/55/19323\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Wound management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Laceration repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Puncture wounds and lacerations &lt;2 cm long usually heal well and do not need surgical closure. Children with hanging palatal flaps, tonsillar avulsion, retained or protruding foreign body, or gross contamination warrant repair by an otolaryngologist in the operating room. The frequency of operative care is approximately 6 to 11 percent of children with oropharyngeal trauma based on three observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/3,4,12\">",
"     3,4,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Tetanus prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oropharyngeal wounds are considered tetanus prone and require tetanus prophylaxis, as needed (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Empiric antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary evidence suggests that the infection rate is low following oropharyngeal trauma. As an example, in an observational study of 116 children with isolated penetrating palate trauma of whom 67 were prescribed antibiotics, one patient developed an infection within seven days of the injury (infection rate 1 percent [95% CI 0-5 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/18\">",
"     18",
"    </a>",
"    ]. However, no trials have evaluated the benefit of prophylactic antibiotics in children with penetrating oropharyngeal trauma, and deep neck infection (eg, retropharyngeal or parapharyngeal abscess) remains a concerning complication for deep wounds. Thus, we suggest that patients with oropharyngeal lacerations with mucosal penetration receive antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/12,17\">",
"     12,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who require admission should receive intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 6 hours, maximum dose: 4.8 grams per 24 hours) or intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    with sulbactam (50 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 6 hours: maximum dose 8 grams ampicillin per 24 hours) to cover infection caused by oral flora (anaerobic species, coagulase-negative Staphylococcus, Streptococcal species, and S. aureus) (",
"    <a class=\"graphic graphic_algorithm graphicRef60522 \" href=\"UTD.htm?0/52/847\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    three times daily, maximum dose 1.8 grams per 24 hours) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    with clavulanate (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily, maximum dose 875 mg amoxicillin) are reasonable alternatives for children who are discharged home.",
"   </p>",
"   <p>",
"    Duration of therapy is not standardized, although a minimum of five to seven days would coincide with wound healing in most instances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Child protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases where child abuse is suspected, involvement of an experienced child protection team is crucial and in many parts of the world (including the US, UK, and Australia) reporting to a governmental agency is mandatory. The safety of other children in the home must be ensured by local Child Protective Services. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"     \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to discharge, the emergency clinician or otolaryngologist (ear, nose, and throat surgeon) should counsel the caregiver to closely monitor their child for 48 to 72 hours after injury. Caregivers should be instructed about the specific symptoms of neurologic sequelae or deep neck infection and advised to seek medical attention immediately if they appear (",
"    <a class=\"graphic graphic_table graphicRef73310 \" href=\"UTD.htm?18/55/19323\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Otolaryngologists usually reevaluate children who sustain oropharyngeal trauma with mucosal penetration one to two weeks after injury. The purpose of this visit is to ensure proper healing and to assess for any unrecognized neurologic or infectious complications. Most children with superficial wounds do not require subspecialty follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Deep neck infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with new onset of infectious symptoms several days after a penetrating oropharyngeal injury need an emergent neck CT with IV contrast. Those patients with a proven neck abscess should receive intravenous antibiotics, otolaryngology (ear, nose, and throat surgery) consultation, and hospital admission. In addition, surgical intervention may be required. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Empiric antibiotic therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link&amp;anchor=H12#H12\">",
"     \"Retropharyngeal infections in children\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Cerebral vascular thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who develop focal neurologic finding or mental status change after an oropharyngeal injury should undergo emergent carotid angiography and consultation with a vascular surgeon or neurosurgeon. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'High risk injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children fully recover after experiencing oropharyngeal trauma. Based on observational studies, from 1 to 5 percent of patients develop an infectious complication (wound infection, retropharyngeal abscess, mediastinitis, or suppurative jugular venous thrombosis) and &lt;1 percent of patients sustain an internal carotid artery injury or neurologic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23016/abstract/11,12,18\">",
"     11,12,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/52/34626?source=see_link\">",
"       \"Patient information: Mouth and dental injuries in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/6/30819?source=see_link\">",
"       \"Patient information: Mouth and dental injuries in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetrating oropharyngeal wounds in children typically result from low force mechanisms and usually heal spontaneously with no sequelae. Rarely, internal carotid artery (ICA) injury or deep space neck infection may complicate oropharyngeal trauma. Key physical findings help categorize oropharyngeal trauma as minor, moderate, or severe (",
"    <a class=\"graphic graphic_table graphicRef80771 \" href=\"UTD.htm?33/54/34668\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Anatomy and Pathophysiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Approach to evaluation and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluation should focus on the mechanism of injury, location of injury (midline versus lateral), wound characteristics, and the child's neurologic status. Once these factors are known, then radiograph imaging and management proceed based on the patient's estimated risk of deep structure injury. The algorithm provides an approach to evaluation and management of oropharyngeal trauma in children (",
"    <a class=\"graphic graphic_algorithm graphicRef60522 \" href=\"UTD.htm?0/52/847\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Victims of major trauma require an initial primary survey for life-threatening injuries before the emergency provider focuses on oropharyngeal injury. Those children with major facial trauma should be placed in cervical spine immobilization until cervical spine injury is excluded. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Initial stabilization'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"       \"Trauma management: Approach to the unstable child\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"       \"Pediatric cervical spine immobilization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have suffered high-force penetrating oropharyngeal trauma should be managed as zone III penetrating neck injuries and require an aggressive approach to airway protection and injury identification (eg, angiography, endoscopy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgical exploration). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'High risk injury'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2026?source=see_link&amp;anchor=H11#H11\">",
"       \"Penetrating neck injuries\", section on 'Emergency management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Protruding oropharyngeal foreign bodies should be left in place until they can be fully assessed, imaged, and removed under controlled conditions in the operating room.",
"     </li>",
"     <li>",
"      Children with a moderate mechanism of injury and a wound with concerning features (deep, lateral, or associated with a foreign body) should undergo CTA or contrast enhanced MRA. Those patients whose imaging confirms a deep oropharyngeal wound adjacent to the ICA should undergo digital subtraction carotid artery angiography (CAA), an immediate otolaryngology (ear, nose, and throat) consult, and hospital admission. Further management is based on the results of the CAA. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Moderate risk injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Radiographic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If CTA or MRA suggests limited penetration not immediately adjacent to the carotid in a child with moderate risk of injury, then this patient may be discharged home, assuming the availability of reliable caregivers who can closely monitor for symptoms of ICA occlusion or deep neck infection and who can return promptly for reevaluation should symptoms develop (",
"      <a class=\"graphic graphic_table graphicRef73310 \" href=\"UTD.htm?18/55/19323\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Moderate risk injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a minor mechanism of injury associated with superficial laceration, especially midline wounds, may be discharged home without imaging or subspecialty consultation. The caregiver should be counselled regarding the symptoms of ICA occlusion or deep neck infection and instructed to return promptly for reevaluation should symptoms develop (",
"      <a class=\"graphic graphic_table graphicRef73310 \" href=\"UTD.htm?18/55/19323\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Low risk injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Wound care",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Puncture wounds and lacerations &lt;2 cm long usually heal well and do not need surgical closure. Children with hanging palatal flaps, tonsillar avulsion, retained or protruding foreign body, or gross contamination require repair by an otolaryngologist in the operating room. All oropharyngeal wounds are considered tetanus prone and require tetanus prophylaxis, as needed (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Wound management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with oropharyngeal lacerations with mucosal penetration receive antibiotics that provide adequate coverage for oral pathogens (eg, Staphylococcus species, Streptococcal species, and anaerobes) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Empiric antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Follow-up instructions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to discharge, the caregiver should be instructed to closely monitor their child for 48 to 72 hours after injury. Caregivers should be advised to seek medical attention immediately if symptoms of neurologic sequelae or deep neck infection appear (",
"      <a class=\"graphic graphic_table graphicRef73310 \" href=\"UTD.htm?18/55/19323\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/1\">",
"      Radkowski D, McGill TJ, Healy GB, Jones DT. Penetrating trauma of the oropharynx in children. Laryngoscope 1993; 103:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/2\">",
"      Brietzke SE, Jones DT. Pediatric oropharyngeal trauma: what is the role of CT scan? Int J Pediatr Otorhinolaryngol 2005; 69:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/3\">",
"      Schoem SR, Choi SS, Zalzal GH, Grundfast KM. Management of oropharyngeal trauma in children. Arch Otolaryngol Head Neck Surg 1997; 123:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/4\">",
"      Ratcliff DJ, Okada PJ, Murray AD. Evaluation of pediatric lateral oropharyngeal trauma. Otolaryngol Head Neck Surg 2003; 128:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/5\">",
"      Suskind DL, Tavill MA, Keller JL, Austin MB. Management of the carotid artery following penetrating injuries of the soft palate. Int J Pediatr Otorhinolaryngol 1997; 39:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/6\">",
"      Windfuhr JP. Aneurysm of the internal carotid artery following soft tissue penetration injury. Int J Pediatr Otorhinolaryngol 2001; 61:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/7\">",
"      Joseph MM, Lewis S. Stroke after penetrating trauma of the oropharynx. Pediatr Emerg Care 2002; 18:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/8\">",
"      Palmer AL, Strain JD, Henry DB, et al. Postanginal sepsis after oropharyngeal trauma. Pediatr Infect Dis J 1995; 14:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/9\">",
"      Kaplan DM, Fliss DM, Peiser Y, et al. Internal jugular vein thrombosis in a child due to a 'pencil point injury' of the palate. Int J Pediatr Otorhinolaryngol 1998; 44:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/10\">",
"      Pierrot S, Bernardeschi D, Morrisseau-Durand MP, et al. Dissection of the internal carotid artery following trauma of the soft palate in children. Ann Otol Rhinol Laryngol 2006; 115:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/11\">",
"      Chauhan N, Guillemaud J, El-Hakim H. Two patterns of impalement injury to the oral cavity: Report of four cases and review of literature. Int J Pediatr Otorhinolaryngol 2006; 70:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/12\">",
"      Soose RJ, Simons JP, Mandell DL. Evaluation and management of pediatric oropharyngeal trauma. Arch Otolaryngol Head Neck Surg 2006; 132:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/13\">",
"      Hengerer AS, DeGroot TR, Rivers RJ Jr, Pettee DS. Internal carotid artery thrombosis following soft palate injuries: a case report and review of 16 cases. Laryngoscope 1984; 94:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/14\">",
"      Deutsch MD, Kriss VM, Willging JP. Distance between the tonsillar fossa and internal carotid artery in children. Arch Otolaryngol Head Neck Surg 1995; 121:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/15\">",
"      Naidoo S. A profile of the oro-facial injuries in child physical abuse at a children's hospital. Child Abuse Negl 2000; 24:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/16\">",
"      Bolz WE, Brouwer HG, Schoenmakers CH. Measurement of HbF concentration for diagnosing a case of Munchausen by proxy syndrome. J Pediatr 2006; 148:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/17\">",
"      Randall DA, Kang DR. Current management of penetrating injuries of the soft palate. Otolaryngol Head Neck Surg 2006; 135:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/18\">",
"      Hennelly K, Kimia A, Lee L, et al. Incidence of morbidity from penetrating palate trauma. Pediatrics 2010; 126:e1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23016/abstract/19\">",
"      Hellmann JR, Shott SR, Gootee MJ. Impalement injuries of the palate in children: review of 131 cases. Int J Pediatr Otorhinolaryngol 1993; 26:157.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6518 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23016=[""].join("\n");
var outline_f22_30_23016=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY AND PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Internal carotid artery injury (ICA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Deep neck space infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Wound characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Associated physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Plain radiographs of the neck and chest",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Carotid ultrasound with oculoplethysmography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Computed tomography angiography (CTA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Magnetic resonance angiography (MRA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Carotid artery angiography (CAA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Initial stabilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Approach to diagnosis and management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - High risk injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Moderate risk injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Low risk injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Wound management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Laceration repair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Empiric antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Child protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Deep neck infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Cerebral vascular thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Approach to evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Wound care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Follow-up instructions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6518\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6518|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/52/847\" title=\"algorithm 1\">",
"      Pediatric oropharyngeal trauma algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6518|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/55/35699\" title=\"figure 1\">",
"      Oropharynx anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6518|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/55/19323\" title=\"table 1\">",
"      OP trauma symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 2\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/54/34668\" title=\"table 3\">",
"      Pediatric oropharyngeal trauma assessment and imaging",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=related_link\">",
"      Deep neck space infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=related_link\">",
"      Evaluation and management of dental injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24309?source=related_link\">",
"      Evaluation and repair of tongue lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=related_link\">",
"      Evaluation of carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6615?source=related_link\">",
"      Jaw fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/6/30819?source=related_link\">",
"      Patient information: Mouth and dental injuries in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/52/34626?source=related_link\">",
"      Patient information: Mouth and dental injuries in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2026?source=related_link\">",
"      Penetrating neck injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=related_link\">",
"      Retropharyngeal infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_30_23017="Diagnosis and management of priapism in sickle cell disease";
var content_f22_30_23017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and management of priapism in sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23017/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23017/contributors\">",
"     Joshua J Field, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23017/contributors\">",
"     Vijaya M Vemulakonda, MD, JD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23017/contributors\">",
"     Michael R DeBaun, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23017/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23017/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23017/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23017/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23017/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/30/23017/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Priapism is a sustained penile erection in the absence of sexual activity or desire. The definition of \"sustained\" in this setting is unclear, but priapism is generally defined as an unwanted erection lasting more than two to four hours.",
"   </p>",
"   <p>",
"    Prompt recognition and appropriate treatment of a priapism episode in males with sickle cell disease (SCD) is critical, as the end result of prolonged",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    repeated episodes of priapism can be ischemia and fibrosis in the corpus cavernosa of the penis, potentially leading to impaired sexual function and impotence.",
"   </p>",
"   <p>",
"    Few evidence-based guidelines exist for the management of these episodes. Thus, in the absence of randomized clinical trials and large, detailed prospective studies, clinicians must rely largely on case reports, small case series, and clinical experience. A practical approach to the diagnosis and management of priapism in patients with SCD will be presented here [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/1\">",
"     1",
"    </a>",
"    ]. A general overview of the subject of priapism is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7127?source=see_link\">",
"     \"Priapism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall management of the patient with SCD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Physiology of erection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penile erection occurs when there is increased blood volume in the paired lateral corpora cavernosa and single corpus spongiosum, and is normally maintained by the partial obstruction of venous drainage (",
"    <a class=\"graphic graphic_figure graphicRef66964 \" href=\"UTD.htm?11/3/11319\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link&amp;anchor=H2095227#H2095227\">",
"     \"Overview of male sexual dysfunction\", section on 'Physiology of male sexual function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathophysiology of priapism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Priapism occurs when there is either unregulated arterial inflow to the penis or persistent obstruction of venous outflow [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As a result, priapism can be broadly classified as high flow (non-ischemic) or low flow (ischemic) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     High flow (arterial) priapism",
"    </span>",
"    &nbsp;&mdash;&nbsp;High flow (arterial, nonischemic) priapism is typically due to trauma, causing injury to the cavernosal artery. This is a rare cause of priapism in men with SCD. Typically the penis is neither fully rigid nor painful. This condition does not require emergent treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Low flow (ischemic) priapism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low flow (ischemic, venoocclusive) events represent the vast majority of priapism episodes among individuals with SCD. The basis for low flow priapism in SCD is stasis, hypoxia, and acidosis of venous blood during a normal erection, resulting in sickling of erythrocytes within the venous sinusoids of the corpus cavernosa.",
"   </p>",
"   <p>",
"    This constellation of events causes venous outflow obstruction of the corporeal bodies and engorgement of the corpora cavernosa, with sparing of spongiosum and glans. The corpora cavernosa are rigid and tender to palpation, and pain is typically present. Low flow priapism is considered a medical emergency. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Nitric oxide pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although venous obstruction is the predominant cause of priapism in males with SCD, the pathogenesis of priapism may be related to decreased nitric oxide (NO) bioavailability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/5\">",
"     5",
"    </a>",
"    ], which is a more general phenomenon in SCD that contributes to SCD-related morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cell-free plasma hemoglobin released from hemolyzed red cells scavenges available NO, resulting in increased vascular tone, platelet activation, and upregulation of vascular adhesion molecules [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced levels of NO have been implicated in the pathogenesis of pulmonary hypertension, priapism, and leg ulcers in patients with SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/6,8\">",
"       6,8",
"      </a>",
"      ]. In addition, there is a fivefold increased risk of developing pulmonary hypertension in adults with SCD and a history of priapism [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/7\">",
"       7",
"      </a>",
"      ]. Individuals with the clinical triad of pulmonary hypertension, priapism, and leg ulcers generally have increased hemolysis, fewer pain and acute chest syndrome (ACS) episodes, and a lower rate of avascular necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increased risk of priapism in the setting of a low NO state is counterintuitive, since penile erection requires the presence of high levels of NO. NO mediates smooth muscle relaxation through increasing levels of cyclic GMP (cGMP), resulting in smooth muscle relaxation, vasodilation of penile arteries and an erect penis. Phosphodiesterase type 5 (PDE-5) degrades cGMP, providing regulation of smooth muscle tone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link&amp;anchor=H2095400#H2095400\">",
"     \"Overview of male sexual dysfunction\", section on 'Role of blood flow and nitric oxide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among individuals with SCD, there is a chronic reduction in NO bioavailability, a significant downregulation of PDE-5, and uncontrolled cGMP activity.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    therapy targets the NO axis, inhibiting PDE-5, increasing levels of cGMP, leading to prolonged smooth muscle relaxation, causing increased venous outflow and erection in patients with erectile dysfunction (ED).",
"   </p>",
"   <p>",
"    Among individuals with SCD,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    has been evaluated as a therapy to prevent priapism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/10\">",
"     10",
"    </a>",
"    ]. The rationale for the use of PDE-5 inhibitors for priapism in males with SCD is that PDE-5 inhibitors may also increase expression of PDE-5 with more chronic use. Cyclic GMP (cGMP), present in high levels due to chronic PDE-5 inhibition, acts on the PDE-5 promoter region, resulting in the upregulation of PDE-5 expression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/11\">",
"     11",
"    </a>",
"    ]. As a result, PDE-5 expression is \"reset\", controlling the elevated cGMP signaling seen in priapism and restoring balance in this pathway. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'PDE-5 inhibitors'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of male sexual dysfunction\", section on 'Pharmacotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although limited data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    may be an effective therapy for the prevention of priapism in males with SCD, we do not recommend the use of sildenafil outside of a clinical trial, given data demonstrating that sildenafil therapy for pulmonary hypertension in patients with SCD was associated with an increased rate of pain episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=see_link&amp;anchor=H24#H24\">",
"     \"Pulmonary complications of sickle cell disease\", section on 'Clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11962021\">",
"    <span class=\"h3\">",
"     Adenosine pathway (adenosine 2b receptor)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from a murine model of SCD suggest that elevated levels of adenosine in the penis contribute to the pathogenesis of priapism. Compared with wild type mice, transgenic SCD mice have more priapic events and higher levels of adenosine. Lowering adenosine levels with the addition of adenosine deaminase prevents and reverses priapic events [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Adenosine signaling in this SCD murine model of priapism is mediated through the adenosine 2B receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The role of the adenosine pathway in priapism has not been evaluated in people with SCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Genetic influences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several candidate gene association studies have been performed in an attempt to link priapism with specific genetic modifiers, with inconclusive results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical variability in sickle cell anemia\", section on 'Priapism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for developing priapism in patients with SCD include prolonged sexual activity, fever or dehydration, exposure to alcohol, marijuana, or cocaine, or use of psychotropic agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    , or testosterone. A prior history of trauma to the area may suggest the presence of \"high flow priapism\", with damage to the cavernosal artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among boys and men with sickle cell disease (SCD), estimates of the prevalence of priapism have ranged from 6 to as high as 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/1,15-18\">",
"     1,15-18",
"    </a>",
"    ]. Episodes of priapism may occur at any age, but typically become a more significant clinical problem after puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/19\">",
"     19",
"    </a>",
"    ]. The mean age of onset is 12 to 15 years, with 75 to 90 percent of individuals reporting their first episode prior to 20 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/15,16,18\">",
"     15,16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vast majority of patients with SCD and priapism are homozygous for hemoglobin S. However, priapism has been described in patients with hemoglobin SC disease, sickle cell beta thalassemia, as well as in those with sickle cell trait [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/15,20,21\">",
"     15,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some patients present with priapism and a negative history for hemoglobinopathy but are found on hemoglobin electrophoresis to have SCD. This was shown in a review of 39 African American men with low-flow priapism, in whom 6 of the 39 men denied a history of SCD or other hemoglobinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/22\">",
"     22",
"    </a>",
"    ]. Hemoglobin electrophoresis revealed the presence of hemoglobin S and elevated hemoglobin F levels in four of these men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Priapism events may occur in the setting of a systemic pain episode in SCD, although a significant percentage of events occur during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Risk factors for developing priapism include prolonged sexual activity, fever or dehydration, exposure to alcohol, marijuana, or cocaine, or use of psychotropic agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    , or testosterone. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A prior history of trauma to the area may suggest the presence of \"high flow priapism\", with damage to the cavernosal artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with SCD and priapism typically present with an erect, painful penis and a soft glans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to lack of information, many men with SCD are not aware that priapism is a complication of this disease and may not be aware of the consequences of a prolonged priapism episode [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/22\">",
"     22",
"    </a>",
"    ]. In a review of 39 patients with priapism who presented for medical care, the mean duration of symptoms was 22 hours (range 6 to 70 hours), with four presenting to the hospital more than 36 hours after the onset of symptoms.",
"   </p>",
"   <p>",
"    Episodes of priapism may be well-defined acute episodes, repetitive episodes with varying lengths of time between events (termed \"stuttering\" priapism, defined as episodes lasting more than a few minutes but less than three hours), or a combination of acute and stuttering events [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ]. Stuttering episodes typically occur in clusters, approximately two to three times per week for several weeks prior to the abating of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of the different types of priapism is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ]. In a review of 46 men with SCD and a history of priapism, 52 percent had an acute episode and 72 percent had a history of stuttering priapism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/15\">",
"     15",
"    </a>",
"    ]. In another report of 20 men with SCD and a history of priapism, 4 had only one attack, while the remaining 16 patients had 1 to 52 episodes per year [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/17\">",
"     17",
"    </a>",
"    ]. The average duration of a typical episode and of the longest self-limited episode were 1.6 and 7.0 hours, respectively.",
"   </p>",
"   <p>",
"    Acute and stuttering episodes are not mutually exclusive. Twenty-eight percent of individuals who have an acute event have stuttering episodes later, and 61 percent with stuttering episodes go on to have an acute event [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/18\">",
"     18",
"    </a>",
"    ]. The etiology of stuttering priapism is not clear, but may be associated with scarring of intracavernous venules [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most episodes of priapism resolve without medical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/16\">",
"     16",
"    </a>",
"    ]. However, prolonged episodes may lead to progressive changes in the histology of the corpus cavernosa [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/27\">",
"     27",
"    </a>",
"    ]. During the first 12 hours, subtle and reversible histologic changes are visible; however, after 24 to 48 hours of priapism, irreversible changes can occur, including necrosis of cavernosal smooth muscle and endothelial cells, and fibroblast proliferation, ultimately leading to fibrosis of corpus cavernosa and erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Erectile dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute or stuttering episodes of priapism in men with SCD are frequently associated with ED, here defined as the inability to acquire or sustain an erection of sufficient rigidity for sexual intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link&amp;anchor=H2095590#H2095590\">",
"     \"Overview of male sexual dysfunction\", section on 'Erectile dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following acute episodes or stuttering priapism, 29 to 36 percent reported ED [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. Similarly, a history of stuttering priapism resulted in ED in 25 percent of men with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/15\">",
"     15",
"    </a>",
"    ]. Boys with prepubertal priapism events retained better function following the event, as only 14 percent noted ED [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of a priapism episode strongly influences subsequent ED [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In a study of 39 men with SCD, all individuals who presented to the hospital &gt;36 hours after the onset of symptoms had abnormal erectile function, whereas all men who had presented for medical care within 12 hours retained normal erectile function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;High and low flow priapism can be differentiated via color duplex Doppler ultrasonography or blood gas measurement from aspirated cavernosal blood. However, aspiration should only be performed when clinically indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     High flow priapism",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood flow measurements by color duplex Doppler ultrasonography typically show normal to high blood flow velocities in the cavernosal arteries. A cavernosal artery fistula or pseudoaneurysm may be present.",
"     </li>",
"     <li>",
"      Blood aspirated from the corpus cavernosum in patients with high flow priapism is normally oxygenated and bright red in color. High flow priapism is typically associated with a pO2 &gt;90 mmHg, pCO2 &lt;40 mmHg, and a pH of approximately 7.40.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Low flow priapism",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood flow measurements by color duplex Doppler ultrasonography typically show little or no blood flow in the cavernosal arteries.",
"     </li>",
"     <li>",
"      Blood aspirated from the corpus cavernosum in patients with low flow priapism is hypoxic and dark in color. Cavernous blood gas values consistent with low flow include a pO2 &lt;30 mmHg, pCO2 &gt;60 mmHg, and a pH &lt;7.25.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized clinical trials identifying the optimal treatment for priapism are lacking. Although numerous therapies have been tested in small studies, there is no accepted, standard therapy for the prevention or treatment of priapism episodes in SCD.",
"   </p>",
"   <p>",
"    For episodes of priapism lasting more than two hours, patients should be advised to drink extra fluids, use oral analgesics for pain control, attempt to urinate as soon as priapism begins, and present themselves to an emergency department or specialized sickle cell center for intravenous hydration and parenteral analgesia.",
"   </p>",
"   <p>",
"    All of the treatments reviewed below are in reference to low flow (ischemic) priapism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Acute priapism",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Aspiration and irrigation of the corpus cavernosum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration of blood from the corpus cavernosum and subsequent irrigation with saline or adrenergic agonists has become the standard of care for individuals with an episode of priapism lasting more than two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/1\">",
"     1",
"    </a>",
"    ]. Rapid detumescence within 4 to 12 hours of initiating this procedure, allowing oxygenated blood to re-enter the cavernosa, is the desired endpoint of this treatment, decreasing the risk of hypoxia, fibrosis, and subsequent erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, the duration of a priapism episode strongly influences subsequent ED. In a study of 39 men with SCD, all men with priapism who had presented for medical care within 12 hours retained normal erectile function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The procedure is typically conducted by a urologist or a clinician familiar with the anatomy who has been properly instructed on how to perform the procedure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among children and others who have not had the procedure before, aspiration and irrigation can be performed under conscious sedation along with local anesthesia.",
"     </li>",
"     <li>",
"      Home self-intracavernosal injections can be taught to patients with SCD and recurrent episodes of prolonged priapism [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/20,32-34\">",
"       20,32-34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Alpha- and beta- adrenergic agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instillation of alpha- and beta- adrenergic agonists (usually mixed",
"    <span class=\"nowrap\">",
"     alpha-/beta-)",
"    </span>",
"    into the corpus cavernosum has been examined in males with SCD. Pure alpha-agonists are vasoconstrictors and induce contraction of the smooth muscle of penile helicine arteries of corpus cavernosa, causing blood to flow out of the corpus cavernosa, relieving the priapism. Alternatively, pure beta-agonists are vasodilators and relax smooth muscle, increasing arterial blood flow back into the corpus cavernosum, worsening the condition.",
"   </p>",
"   <p>",
"    The majority of evidence is for effectiveness of the mixed alpha- and beta-adrenergic agents epinephrine and etilefrine and the alpha-1 selective adrenergic agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    . The most complete study using this approach was initially introduced in 39 priapism episodes in 15 boys and adolescents with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/35\">",
"     35",
"    </a>",
"    ]. In this case series, participants with priapism that occurred less than 24 hours before presentation to the Emergency Department received penile aspiration followed by a 10 mL instillation of a 1:1,000,000 solution of epinephrine. Aspiration was then continued until detumescence was achieved. This approach resulted in 95 percent success rate of detumescence.",
"   </p>",
"   <p>",
"    In a less rigorous case series, six children with SCD and acute priapism were given intracavernous injections of 5 mg of etilefrine, a sympathomimetic drug with mixed",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    properties available in Europe, Africa, and Asia, but not in the United States. Oral administration of this agent (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice per day for 30 days) was also given, and penile aspiration was performed if the episode lasted longer than six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/33\">",
"     33",
"    </a>",
"    ]. Five of six children (83 percent) responded to instillation and aspiration.",
"   </p>",
"   <p>",
"    However, the American Urological Association prefers the use of intracavernous injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    , because this agent minimizes the risk of cardiovascular side effects that are more common following the use other sympathomimetic medications such as epinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/3,36,37\">",
"     3,36,37",
"    </a>",
"    ]. Their recommendation is for instillation of 1 mL of a phenylephrine solution diluted with normal saline to a concentration of 100 to 500",
"    <span class=\"nowrap\">",
"     microg/mL,",
"    </span>",
"    every 3 to 5 minutes, for approximately one hour, before deciding that the treatment will not be successful.",
"   </p>",
"   <p>",
"    In cases of prolonged priapism (ie, episodes lasting &gt;72 hours), irrigation is much less successful, perhaps due to an acidic pH in the corporal blood. Higher doses of adrenergic agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    , may be necessary to overcome the acidic environment within corporeal tissues that accompanies low flow priapism in order to achieve detumescence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management is reserved for males with SCD who do not achieve detumescence with first-line therapy. In general, the principle behind surgery for priapism (the Winter procedure) involves shunting blood away from the corpus cavernosum to the corpus spongiosum, thus relieving vascular occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Creation of a shunt from the corpus cavernosum to the corpus spongiosum via the glans penis is the most common procedure (glans-cavernosum shunt). Case series have demonstrated immediate detumescence following glans-cavernosum shunt surgery, with minimal surgical morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/40\">",
"     40",
"    </a>",
"    ]. However, reoperation is often required and erectile dysfunction is a frequent complication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7127?source=see_link&amp;anchor=H15#H15\">",
"     \"Priapism\", section on 'Surgical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In studies of adults including some patients with SCD, the overall rate of impotence is approximately 50 percent after proximal or distal shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/42\">",
"     42",
"    </a>",
"    ]. This number is lower in patients with",
"    <span class=\"nowrap\">",
"     refractory/recurrent",
"    </span>",
"    priapism after initial distal shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/41\">",
"     41",
"    </a>",
"    ]. However, an adult and a pediatric study suggest that there may be higher conservation of potency with early surgical treatment (&lt;30 percent impotence) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. A limitation of these studies is that they rely on self-reported impotence rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Transfusion therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential beneficial effect of transfusion therapy for priapism is controversial and exchange transfusion, when used as treatment for priapism in SCD, has been associated with acute neurological events such as headaches, seizures, and obtundation requiring ventilatory support (eg, the ASPEN syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The proposed etiology for the occurrence of neurological events following exchange transfusion for acute priapism is the rapid elevation in hemoglobin (&gt;12",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    and release of procoagulant and vasoactive factors from the corpus cavernosa.",
"   </p>",
"   <p>",
"    In the cases describing the ASPEN syndrome, partial exchange transfusions were performed with hemoglobin values following transfusion &gt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In contrast, a case series of 41 erythrocytapheresis exchange transfusions performed for the management of priapism found no neurological complications when the target hemoglobin was &lt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and hemoglobin S percentage &lt;50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case report and case series noted benefit of exchange transfusion alone for the treatment of acute priapism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/48,49\">",
"     48,49",
"    </a>",
"    ], although the reported outcome was detumescence delayed to one to two days after exchange transfusion. If exchange transfusions are performed for acute priapism, the post transfusion hemoglobin should be &lt;10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15988015\">",
"    <span class=\"h3\">",
"     Chronic blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monthly, chronic blood transfusions to prevent priapic events have been performed based on expert opinion, although data to support this practice are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Stuttering priapism",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Alpha and beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small studies have examined the use of oral alpha- and beta-agonists to treat stuttering priapism or to prevent relapses of acute priapism episodes. Beneficial responses in a small number of patients with SCD have been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    and etilefrine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/20,33,35\">",
"     20,33,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    therapy has been used, largely anecdotally, to reduce vasoocclusive events in SCD as well as to prevent priapism events. A starting dose of 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, titrating up to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    as tolerated, for men with SCD and repeated episodes of priapism, has been suggested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"     \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case report of a 25-year-old man with SCD and a history of stuttering and acute priapism episodes reported that there were no subsequent episodes of priapism for seven months while the patient was being treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A small case series of four patients with SCD found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      at oral doses of approximately 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day prevented episodes of stuttering priapism [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Hormonal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little data exist for the use of hormonal therapies in males with SCD, presumably to suppress sleep-related erections in an attempt to prevent recurrent episodes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diethylstilbestrol was examined in 11 patients in the only double-blind placebo-controlled study for priapism therapies in SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/23\">",
"       23",
"      </a>",
"      ]. Using a cross-over study design, there was no difference in frequency of priapism events when participants were receiving diethylstilbestrol compared with no therapy.",
"     </li>",
"     <li>",
"      The gonadotropin-releasing hormone agonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      was successfully used in an 18-year-old man with SCD, however, no further studies have validated the findings of this report [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since these hormonal therapies are targeted to decrease testosterone production, they are associated with many unwanted side effects, including gynecomastia and loss of erectile function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     PDE-5 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the role of dysregulated NO in the pathophysiology of priapism in SCD, therapy with the PDE-5 inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    was reported to alleviate stuttering priapism episodes in three of four patients with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/53\">",
"     53",
"    </a>",
"    ]. Four men with SCD were treated with sildenafil (25 to 50 mg) or tadalafil (10 mg every other day) with 17 to 24 months of follow-up. Three men reported no recurrences of their priapism while on PDE-5 inhibitor therapy, while one individual noted no improvement in symptoms. All study participants tolerated sildenafil or tadalafil well.",
"   </p>",
"   <p>",
"    Notably, all three study participants who reported a response to therapy discontinued the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    during the study, thinking their priapism was controlled, and each had recurrent symptoms when this treatment was stopped.",
"   </p>",
"   <p>",
"    One case report noted an acute priapism episode in a man with sickle cell trait. After taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    50 mg for erectile dysfunction, he developed a sustained erection that lasted for six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to exacerbation of pain episodes when this agent was used to treat pulmonary hypertension in patients with SCD, we do not recommend PDE-5 inhibitor therapy outside of a clinical trial setting. A more complete discussion of this subject can be found elsewhere. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Nitric oxide pathway'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=see_link&amp;anchor=H18#H18\">",
"     \"Pulmonary complications of sickle cell disease\", section on 'Pulmonary hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8658814\">",
"    <span class=\"h3\">",
"     Anti-androgens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h4\">",
"     Finasteride",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 5-alpha reductase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    was given as a single agent to 35 patients with SCD and recurrent priapism (ie, at least two episodes per week of &gt;40 minutes duration). The drug was given at a dose of 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for the first 40 days, 3",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    from day 41 to day 80, and then 1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    from day 81 to 120. Results included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean number of priapism episodes per month were 23, 12, 4, and 2 at the beginning of the study, and at 40, 80, and 120 days, respectively.",
"     </li>",
"     <li>",
"      The number of patients who were entirely free from priapism episodes were zero, 5, 19, and 16 at the beginning of the study, and at 40, 80, and 120 days, respectively.",
"     </li>",
"     <li>",
"      No patient presented with acute priapism requiring drug discontinuation or surgical or hematological procedures. The only side effect was painless gynecomastia in six patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional long-term experience with this agent will be required before it can be recommended for this indication, especially since the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    in patients treated for benign prostatic hyperplasia has been associated with decreased libido and ejaculatory or erectile dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link&amp;anchor=H10#H10\">",
"     \"Medical treatment of benign prostatic hyperplasia\", section on '5-alpha-reductase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8658837\">",
"    <span class=\"h4\">",
"     Bicalutamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small case series examining the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/2/30758?source=see_link\">",
"     bicalutamide",
"    </a>",
"    for treatment of refractory priapism included two patients with SCD and suggested that it is well-tolerated and potentially efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/56\">",
"     56",
"    </a>",
"    ]. However, in a case of stuttering priapism, bicalutamide was not effective [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/57\">",
"     57",
"    </a>",
"    ]. There are no prospective studies evaluating the use of bicalutamide for the treatment of refractory priapism in SCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     TECHNIQUE FOR ASPIRATION/IRRIGATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our technique for aspiration and irrigation for low flow priapism is, in the following order:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using a 25 or 27 gauge needle, administer a penile ring block to aid in local pain control.",
"     </li>",
"     <li>",
"      Place two 19 or 21 gauge needles through the glans, one into each corporal body. One needle is for irrigation and the other is for aspiration.",
"     </li>",
"     <li>",
"      Aspirate any clot that may be present, if possible. This may be sufficient in about 30 percent of cases. The initial blood sample should be sent for blood gas determination if there is a concern as to the etiology of the priapism (ie, ischemic versus nonischemic). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once low flow priapism is confirmed, sympathomimetic drugs may be injected. Typically,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      is used, diluted to 1000",
"      <span class=\"nowrap\">",
"       microg/mL",
"      </span>",
"      and injected in an amount of 0.5 to 1 mL every five minutes for a total of three injections. This procedure, when coupled with aspiration, is sufficient in the majority of cases.",
"     </li>",
"     <li>",
"      If priapism has not yet resolved, the remaining",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      is diluted in saline to a final concentration of 10",
"      <span class=\"nowrap\">",
"       microg/mL",
"      </span>",
"      and the corporal bodies are irrigated with the diluted",
"      <span class=\"nowrap\">",
"       phenylephrine/saline",
"      </span>",
"      mixture.",
"     </li>",
"     <li>",
"      If priapism has not responded to the above procedures, a formal surgical shunt procedure should be considered (eg, Winter's shunt or Al-Ghorab shunt). If there is a response to the shunting procedure, serial examination should be performed every 8 to 12 hours, with repeated aspiration and irrigation performed if there is a recurrence of the priapism along with pain. If recurrence is more frequent, reoperation with a Winter's shunt should be considered. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Surgical management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than the avoidance of inciting risk factors and the use of agents for the treatment of stuttering priapism, there are no specific recommendations that can be made for avoidance of future episodes of priapism. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Risk factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H37\">",
"     'Treatment of stuttering priapism'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A full bladder may trigger an episode of priapism. Accordingly, males with SCD need to urinate regularly in an attempt to reduce the incidence of this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23017/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/40/34433?source=see_link\">",
"       \"Patient information: Priapism (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high frequency of priapism in boys and men with sickle cell disease (SCD), education of all males with SCD is an important component of successful therapy. Accordingly, episodes of priapism lasting longer than two to four hours should compel initiation of a pre-defined action plan for treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establish a diagnosis of SCD &mdash; Among individuals who present with priapism without an established diagnosis of SCD, hemoglobin electrophoresis should be performed, as the individual may not be aware that he has one of the sickle cell disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link\">",
"       \"Diagnosis of sickle cell syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Key points to obtain in a history include prior episodes of priapism, duration of current episode, medication history or drug use (eg, cocaine), and maneuvers (eg, exercise, application of heat, sitz baths) that the patient may have used to treat prior episodes. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnose the cause of the priapism &mdash; Almost all priapism episodes in patients with SCD are due to \"low flow priapism\", which can be diagnosed either by blood flow measurements or evaluation of blood aspirated from the corpus cavernosum. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Low flow priapism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Treatment of acute priapism",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend the use of aspiration of blood from the corpus cavernosum followed by saline irrigation and instillation of adrenergic agonists as initial treatment for individuals with SCD and an episode of low flow priapism lasting more than two hours (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Acute priapism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Technique for aspiration/irrigation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Due to the risk of permanent damage, surgery should be considered when priapism lasts beyond 12 hours and after aspiration and instillation have failed. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Surgical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based on limited evidence of efficacy, coupled with known complications of the procedure, we urge caution for the use of red blood cell exchange transfusion for the acute treatment of priapism. If an exchange transfusion is performed, the post-transfusion hemoglobin should not exceed 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Treatment of stuttering priapism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standard treatment for stuttering priapism. Based upon limited experience, we suggest that one or more of the following be employed (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Stuttering priapism'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       Hydroxyurea",
"      </a>",
"      &mdash; We suggest a starting dose of 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, titrating up to 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      as tolerated.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"       Pseudoephedrine",
"      </a>",
"      &mdash; A reasonable approach is to start with an oral dose of 30 to 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of pseudoephedrine at bedtime and an additional 30 mg dose when priapism occurs.",
"     </li>",
"     <li>",
"      Chronic blood transfusion &mdash; Monthly, chronic blood transfusions to decrease percent hemoglobin S.",
"     </li>",
"     <li>",
"      Penile self-injection &mdash; Penile self-injection with an alpha agonist, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      . This therapy must be initiated under the guidance of a urologist experienced with the procedure and with significant patient education.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/1\">",
"      Rogers ZR. Priapism in sickle cell disease. Hematol Oncol Clin North Am 2005; 19:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/2\">",
"      Aboseif SR, Lue TF. Hemodynamics of penile erection. Urol Clin North Am 1988; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     American Urological Association website: www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=priapism (Accessed on August 05, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/4\">",
"      Montague DK, Jarow J, Broderick GA, et al. American Urological Association guideline on the management of priapism. J Urol 2003; 170:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/5\">",
"      Champion HC, Bivalacqua TJ, Takimoto E, et al. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A 2005; 102:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/6\">",
"      Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/7\">",
"      Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007; 21:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/8\">",
"      Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006; 107:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/9\">",
"      Ballas SK. Sickle cell anemia with few painful crises is characterized by decreased red cell deformability and increased number of dense cells. Am J Hematol 1991; 36:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/10\">",
"      Claudino MA, Franco-Penteado CF, Corat MA, et al. Increased cavernosal relaxations in sickle cell mice priapism are associated with alterations in the NO-cGMP signaling pathway. J Sex Med 2009; 6:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/11\">",
"      Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology 2006; 67:1043.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health website: file://www.nih.gov/news/health/jul2009/nhlbi-28.htm (Accessed on October 14, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/13\">",
"      Mi T, Abbasi S, Zhang H, et al. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 2008; 118:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/14\">",
"      Wen J, Jiang X, Dai Y, et al. Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism. J Sex Med 2010; 7:3011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/15\">",
"      Adeyoju AB, Olujohungbe AB, Morris J, et al. Priapism in sickle-cell disease; incidence, risk factors and complications - an international multicentre study. BJU Int 2002; 90:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/16\">",
"      Mantadakis E, Cavender JD, Rogers ZR, et al. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 1999; 21:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/17\">",
"      Fowler JE Jr, Koshy M, Strub M, Chinn SK. Priapism associated with the sickle cell hemoglobinopathies: prevalence, natural history and sequelae. J Urol 1991; 145:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/18\">",
"      Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med 1980; 140:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/19\">",
"      Molitierno JA Jr, Carson CC 3rd. Urologic manifestations of hematologic disease sickle cell, leukemia, and thromboembolic disease. Urol Clin North Am 2003; 30:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/20\">",
"      Okpala I, Westerdale N, Jegede T, Cheung B. Etilefrine for the prevention of priapism in adult sickle cell disease. Br J Haematol 2002; 118:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/21\">",
"      Birnbaum BF, Pinzone JJ. Sickle cell trait and priapism: a case report and review of the literature. Cases J 2008; 1:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/22\">",
"      Bennett N, Mulhall J. Sickle cell disease status and outcomes of African-American men presenting with priapism. J Sex Med 2008; 5:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/23\">",
"      Serjeant GR, de Ceulaer K, Maude GH. Stilboestrol and stuttering priapism in homozygous sickle-cell disease. Lancet 1985; 2:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/24\">",
"      Tarry WF, Duckett JW Jr, Snyder HM 3rd. Urological complications of sickle cell disease in a pediatric population. J Urol 1987; 138:592.",
"     </a>",
"    </li>",
"    <li>",
"     Embury SH, Hebble RP, Mohandas N, Steinberg MH. Sickle Cell Disease: Basic Principles and Clinical Practice, Raven Press, New York 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/26\">",
"      Hekal IA, Meuleman EJ. Idiopathic low-flow priapism in prepuberty: a case report and a review of literature. Adv Urol 2008; :549861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/27\">",
"      Spycher MA, Hauri D. The ultrastructure of the erectile tissue in priapism. J Urol 1986; 135:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/28\">",
"      Gbado&eacute; AD, Koffi KS, Akakpo-Maxwell O, et al. [Management of priapism in sickle-cell diseases with alpha-adrenergic agonists]. Sante 2002; 12:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/29\">",
"      Burnett AL, Allen RP, Tempany CM, et al. Evaluation of erectile function in men with sickle cell disease. Urology 1995; 45:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/30\">",
"      Chakrabarty A, Upadhyay J, Dhabuwala CB, et al. Priapism associated with sickle cell hemoglobinopathy in children: long-term effects on potency. J Urol 1996; 155:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/31\">",
"      Powars DR, Johnson CS. Priapism. Hematol Oncol Clin North Am 1996; 10:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/32\">",
"      Virag R, Bachir D, Lee K, Galacteros F. Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine. Urology 1996; 47:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/33\">",
"      Gbado&eacute; AD, Atakouma Y, Kusiaku K, Assimadi JK. Management of sickle cell priapism with etilefrine. Arch Dis Child 2001; 85:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/34\">",
"      Teloken C, Ribeiro EP, Chammas M Jr, et al. Intracavernosal etilefrine self-injection therapy for recurrent priapism: one decade of follow-up. Urology 2005; 65:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/35\">",
"      Mantadakis E, Ewalt DH, Cavender JD, et al. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism. Blood 2000; 95:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/36\">",
"      Dittrich A, Albrecht K, Bar-Moshe O, Vandendris M. Treatment of pharmacological priapism with phenylephrine. J Urol 1991; 146:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/37\">",
"      Lee M, Cannon B, Sharifi R. Chart for preparation of dilutions of alpha-adrenergic agonists for intracavernous use in treatment of priapism. J Urol 1995; 153:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/38\">",
"      Munarriz R, Wen CC, McAuley I, et al. Management of ischemic priapism with high-dose intracavernosal phenylephrine: from bench to bedside. J Sex Med 2006; 3:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/39\">",
"      Bruno D, Wigfall DR, Zimmerman SA, et al. Genitourinary complications of sickle cell disease. J Urol 2001; 166:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/40\">",
"      Noe HN, Wilimas J, Jerkins GR. Surgical management of priapism in children with sickle cell anemia. J Urol 1981; 126:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/41\">",
"      Nixon RG, O'Connor JL, Milam DF. Efficacy of shunt surgery for refractory low flow priapism: a report on the incidence of failed detumescence and erectile dysfunction. J Urol 2003; 170:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/42\">",
"      Tabibi A, Abdi H, Mahmoudnejad N. Erectile function and dysfunction following low flow priapism: a comparison of distal and proximal shunts. Urol J 2010; 7:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/43\">",
"      Adetayo FO. Outcome of management of acute prolonged priapism in patients with homozygous sickle cell disease. West Afr J Med 2009; 28:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/44\">",
"      Raveenthiran V. A modification of Winter's shunt in the treatment of pediatric low-flow priapism. J Pediatr Surg 2008; 43:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/45\">",
"      Rackoff WR, Ohene-Frempong K, Month S, et al. Neurologic events after partial exchange transfusion for priapism in sickle cell disease. J Pediatr 1992; 120:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/46\">",
"      Siegel JF, Rich MA, Brock WA. Association of sickle cell disease, priapism, exchange transfusion and neurological events: ASPEN syndrome. J Urol 1993; 150:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/47\">",
"      Ballas SK, Lyon D, Hall N, et al. Safety of blood exchange transfusion for priapism complications sickle cell disease. J Clin Apher 2006; 21:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/48\">",
"      Rifkind S, Waisman J, Thompson R, Goldfinger D. RBC exchange pheresis for priapism in sickle cell disease. JAMA 1979; 242:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/49\">",
"      Walker EM Jr, Mitchum EN, Rous SN, et al. Automated erythrocytopheresis for relief of priapism in sickle cell hemoglobinopathies. J Urol 1983; 130:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/50\">",
"      Al Jam'a AH, Al Dabbous IA. Hydroxyurea in the treatment of sickle cell associated priapism. J Urol 1998; 159:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/51\">",
"      Saad ST, Lajolo C, Gilli S, et al. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol 2004; 77:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/52\">",
"      Levine LA, Guss SP. Gonadotropin-releasing hormone analogues in the treatment of sickle cell anemia-associated priapism. J Urol 1993; 150:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/53\">",
"      Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med 2006; 3:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/54\">",
"      Kassim AA, Fabry ME, Nagel RL. Acute priapism associated with the use of sildenafil in a patient with sickle cell trait. Blood 2000; 95:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/55\">",
"      Rachid-Filho D, Cavalcanti AG, Favorito LA, et al. Treatment of recurrent priapism in sickle cell anemia with finasteride: a new approach. Urology 2009; 74:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/56\">",
"      Dahm P, Rao DS, Donatucci CF. Antiandrogens in the treatment of priapism. Urology 2002; 59:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23017/abstract/57\">",
"      Molina Escudero R, Rodriguez Fernandez E, Lledo Garcia E, et al. Stuttering priapism: case report and bibliographic review. Arch Esp Urol 2010; 63:559.",
"     </a>",
"    </li>",
"    <li>",
"     Priapism. In: The Management of Sickle Cell Disease, 4th ed, National Institutes of Health publication 02-2117, 2002. p.129.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7143 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23017=[""].join("\n");
var outline_f22_30_23017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Physiology of erection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathophysiology of priapism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - High flow (arterial) priapism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Low flow (ischemic) priapism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Nitric oxide pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11962021\">",
"      - Adenosine pathway (adenosine 2b receptor)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Genetic influences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Erectile dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      High flow priapism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Low flow priapism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Acute priapism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Aspiration and irrigation of the corpus cavernosum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Alpha- and beta- adrenergic agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Surgical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15988015\">",
"      - Chronic blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Stuttering priapism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Alpha and beta agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Hormonal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - PDE-5 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8658814\">",
"      - Anti-androgens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Finasteride",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8658837\">",
"      Bicalutamide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      TECHNIQUE FOR ASPIRATION/IRRIGATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Treatment of acute priapism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Treatment of stuttering priapism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7143\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7143|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/3/11319\" title=\"figure 1\">",
"      Anatomy of the penis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=related_link\">",
"      Clinical variability in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=related_link\">",
"      Diagnosis of sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/40/34433?source=related_link\">",
"      Patient information: Priapism (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7127?source=related_link\">",
"      Priapism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_30_23018="Cocaine: Acute intoxication";
var content_f22_30_23018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cocaine: Acute intoxication",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23018/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23018/contributors\">",
"     Lewis Nelson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23018/contributors\">",
"     Oladapo Odujebe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23018/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23018/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23018/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/30/23018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/30/23018/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/30/23018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine, purported to be the most potent stimulant of natural origin, is extracted from the leaves of the coca plant (Erythroxylum coca), which is indigenous to the Andean highlands of South America. Natives in this region chew or brew coca leaves into a tea for refreshment and to relieve fatigue, similar to the customs of chewing tobacco and drinking tea or coffee in other cultures.",
"   </p>",
"   <p>",
"    Pure cocaine was first isolated in the 1880s and was first used as a local anesthetic in eye surgery. It was particularly useful in surgery of the nose and throat because of its ability to provide anesthesia and constrict blood vessels, thereby limiting bleeding. Cocaine was legal and widely used in the United States during the second half of the 19",
"    <sup>",
"     th",
"    </sup>",
"    Century and was a main ingredient of the original Coca-Cola&reg;. Despite legislative attempts dating from the early 20",
"    <sup>",
"     th",
"    </sup>",
"    century to eradicate its use, cocaine remains a common and dangerous drug of abuse.",
"   </p>",
"   <p>",
"    This topic review will discuss the basic pharmacology, clinical presentation, and management of acute cocaine intoxication. Treatment for chronic cocaine abuse, general management of acute drug overdose, and other aspects of drug abuse are discussed elsewhere. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef70334 \" href=\"UTD.htm?34/60/35789\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=see_link\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34649?source=see_link\">",
"     \"Pulmonary complications of cocaine abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than alcohol, cocaine is the most common cause of acute drug-related emergency department (ED) visits in the United States (US). It accounts for nearly twice the number of reports to the Drug Abuse Warning Network (DAWN) as marijuana or hashish the next leading cause [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/1\">",
"     1",
"    </a>",
"    ]. Death from unintentional cocaine overdose and cocaine-related violence occurs throughout the world [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine is well-absorbed following contact with the oral, nasal, gastrointestinal, rectal, and vaginal mucosa, or via the pulmonary alveoli following inhalation. Cocaine's vasoconstrictive properties prolong the rate of absorption and delay its peak effect when absorbed from mucosal surfaces. The bioavailability of cocaine is approximately 90 percent when smoked and about 80 percent after intranasal use. Bioavailability is decreased when cocaine is ingested, though this is not well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The alkaloidal form of cocaine is extracted from the coca leaf by mechanical degradation in the presence of a hydrocarbon solvent. The resultant product is converted into a hydrochloride salt and extracted into an aqueous phase, from which water is subsequently evaporated to yield a white powder (cocaine hydrochloride).",
"   </p>",
"   <p>",
"    Smokeable cocaine is formed by dissolving the hydrochloride form of cocaine in water and adding a strong base. A hydrocarbon solvent is then added, the cocaine base is extracted into the organic phase, and the solvent then evaporated. \"Free-basing\" is a term used to refer to smoking or inhaling cocaine base following extraction, and \"crack\" is an analogous compound used in solid form.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A table summarizing the time of onset, time to peak action, and duration of action for various routes of exposure is provided (",
"    <a class=\"graphic graphic_table graphicRef57492 \" href=\"UTD.htm?6/57/7067\">",
"     table 2",
"    </a>",
"    ). These parameters were determined in volunteers with a history of cocaine use, by administering cocaine via the various routes and measuring serum levels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolites &ndash; There are three major metabolites of cocaine: benzoylecgonine (BE) formed from spontaneous hydrolysis (&gt;50 percent), ecgonine methyl ester (EME) formed from metabolism by plasma pseudocholinesterase (32 to 49 percent), and norcocaine formed from metabolism by the p450 system (N-demethylation) (5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/7\">",
"       7",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      BE is a potent vasoconstrictor in vitro. BE and EME have poor blood-brain barrier penetration, so central neurologic effects are related to cocaine that enters the CNS prior to metabolism. EME is a vasodilator, sedative, and anticonvulsant, and is protective against lethal doses of cocaine [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. In vitro, BE has minimal effect on cardiac sodium and potassium channels and in animal models it is virtually inactive [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/11\">",
"       11",
"      </a>",
"      ]. The metabolite anhydroecgonine methyl ester (AEME), or methylecgonine, is formed by pyrolysis (superheating) of cocaine. It has muscarinic receptor (M2) agonist properties that may contribute to bronchospasm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A transesterification reaction between ethanol and cocaine produces a unique agent, benzoylmethylecgonine, also called cocaethylene or ethyl cocaine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/12\">",
"     12",
"    </a>",
"    ]. In healthy volunteers given cocaine and ethanol, cocaethylene accounted for up to 17 percent of the metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/13\">",
"     13",
"    </a>",
"    ]. Cocaethylene has a long duration of action (up to 13 hours depending on the route of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/14\">",
"     14",
"    </a>",
"    ]), and like cocaine, is vasoconstrictive, cardiotoxic, dysrhythmogenic, and neurotoxic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Cocaethylene is as potent as cocaine at inhibiting dopamine reuptake [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The serum concentration of cocaethylene varies by the route of administration of cocaine. Approximately 24 percent of cocaine is converted to cocaethylene when administration is intravenous, 18 percent when the drug is insufflated and 34 percent when cocaine is used orally. The physiologic effects of cocaethylene typically outlast the effects that would have been observed if cocaine alone was used by any of the common routes of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cocaine's volume of distribution is about 2.7",
"    <span class=\"nowrap\">",
"     L/kg,",
"    </span>",
"    and it is about 90 percent protein bound. It is unclear whether these values change in overdose states [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/6\">",
"     6",
"    </a>",
"    ]. The serum half-life of cocaine is 0.5 to 1.5 hours. A minor amount is excreted unchanged in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/18\">",
"     18",
"    </a>",
"    ]. BE and EME are excreted in the urine, and have serum half-lives of 5 to 8 hours and 3.5 to 6 hours, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine's effects occur primarily via three mechanisms, which are discussed below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blockade of reuptake of biogenic amines &ndash; Cocaine is an indirect sympathomimetic agent, which increases the availability of biogenic amines at adrenergic receptors by blocking their presynaptic reuptake. These effects are described in neurons containing serotonin and catecholamines (ie, dopamine, norepinephrine, and epinephrine) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Cocaine stimulates alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors through increased levels of norepinephrine, and to a lesser extent epinephrine. Cocaine has preferential alpha-receptor activity on the cardiac and peripheral vasculature and additional cardiac effects through beta-adrenergic agonism. The alpha-adrenergic agonist effects of norepinephrine cause vasoconstriction in both cardiac and peripheral vasculature.",
"      <br/>",
"      <br/>",
"      The euphoric properties of cocaine derive from the inhibition of neuronal serotonin reuptake in the CNS, while addiction has been linked to effects on dopamine reuptake. In animal studies, effects on the dopamine-containing neuronal systems traveling from the limbic region to the frontal cortex are strongly associated with cocaine addiction [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sodium (Na+) channel blockade &ndash; Cocaine slows or blocks nerve conduction and acts as a local anesthetic by altering the recovery of the neuronal Na+ channels. Local anesthetics block conduction by decreasing or preventing the large transient increase in the permeability of excitable membranes to Na+ that normally is produced by a slight depolarization of the membrane. Cocaine has similar effects on cardiac Na+ channels and is able to slow Na+ current in cardiac myocytes. With severe overdose, these cardiac Na+ channel effects manifest on an electrocardiogram as prolongation of the QRS complex, and clinically as negative inotropy.",
"     </li>",
"     <li>",
"      Excitatory amino acid stimulation &ndash; Cocaine increases the concentration of the excitatory amino acids glutamate and aspartate in the brain, particularly in the nucleus accumbens [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/22\">",
"       22",
"      </a>",
"      ]. Glutamate is the main excitatory neurotransmitter of the central nervous system (CNS) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/23\">",
"       23",
"      </a>",
"      ]. Aspartate has similar actions, although its exact role as a neurotransmitter is not as well defined; it is only active at certain subtypes of glutamate receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/24\">",
"       24",
"      </a>",
"      ]. Aspartate also serves as a precursor for glutamate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine produces a dose-dependent increase in heart rate and blood pressure accompanied by increased arousal, improved performance on tasks of vigilance and alertness, and a sense of self-confidence, euphoria, and well-being. Use is typically followed by a craving for more of the drug. Cocaine produces end-organ toxicity in virtually every organ system in the body, primarily through its hemodynamic effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5429611\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cocaine use is associated with arterial vasoconstriction and enhanced thrombus formation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. It causes tachycardia, hypertension, increased myocardial oxygen demand, and increased vascular shearing forces. Cocaine causes coronary vasoconstriction in a dose-dependent fashion and is associated with cardiac ischemia in 5 to 6 percent of patients with cocaine-related visits to the emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/28\">",
"     28",
"    </a>",
"    ]. At high blood concentrations, cocaine's negative inotropic effects may cause acute depression of left ventricular function and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/29\">",
"     29",
"    </a>",
"    ]. Cocaine can cause supraventricular and ventricular dysrhythmias through direct actions at myocardial receptors or as a complication of myocardial ischemia. Aortic dissection and rupture occur rarely after cocaine use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"    <br/>",
"    <br/>",
"    Chronic cocaine use can cause accelerated atherogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/31,32\">",
"     31,32",
"    </a>",
"    ] and left ventricular hypertrophy, which increase the risk of myocardial ischemia or infarction, and can lead to dilated cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=see_link\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5429618\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine can cause a variety of central nervous system (CNS) complications including psychomotor agitation, seizures, coma, headache, intracranial hemorrhage, and focal neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/15\">",
"     15",
"    </a>",
"    ]. Cocaine-induced psychomotor agitation can cause hyperthermia when peripheral vasoconstriction prevents the body from dissipating the heat being generated from persistent agitation. Mortality can be as high as 33 percent when hyperthermia develops in the setting of cocaine intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/33\">",
"     33",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Psychomotor agitation occurs via several mechanisms. Cocaine causes an increase in the CNS excitatory amino acids glutamate and aspartate, and release of the excitatory neurotransmitters norepinephrine, serotonin, and dopamine. The hyperthermia seen in cocaine-intoxicated patients is directly related to the extent of their psychomotor agitation and the ambient temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"    <br/>",
"    <br/>",
"    Seizures occur in approximately 3 to 4 percent of cocaine-related emergency department visits following acute or chronic use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/29,34\">",
"     29,34",
"    </a>",
"    ]. Seizures may occur after large doses in patients without an underlying seizure focus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/29\">",
"     29",
"    </a>",
"    ]. Headaches occur often and are likely due to neurotransmitter dysregulation or hemodynamic alterations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/15\">",
"     15",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Cocaine is associated with both focal neurologic deficits and coma. Possible etiologies include vasoconstriction (ie, transient ischemic attack or ischemic stroke) and intracerebral hemorrhage. Numerous reports describe patients with subarachnoid, intraventricular, and intraparenchymal bleeding associated with cocaine use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. Other neurologic complications, such as paralysis from vasospasm-induced anterior spinal cord syndrome, occur rarely [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5429625\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crack cocaine requires high temperatures to be vaporized and smoked. Angioedema and pharyngeal burns can occur when crack is smoked. Injury to the upper and lower airway occurs primarily from inhalation of heated fumes and is not a direct toxic effect of the drug.",
"    <br/>",
"    <br/>",
"    Intranasal and inhalational cocaine use is associated with pneumothorax, pneumomediastinum, and pneumopericardium [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. These complications result from the Valsalva maneuver applied by the user to avoid exhaling the drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34649?source=see_link\">",
"     \"Pulmonary complications of cocaine abuse\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Cocaine is associated with exacerbations of reversible airway disease and bronchospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Crack lung can also cause shortness of breath. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Crack lung'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"    Cocaine use is associated with vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/25\">",
"     25",
"    </a>",
"    ], vasospasm, and enhanced thrombus formation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/26\">",
"     26",
"    </a>",
"    ]. This predisposes patients who use cocaine to pulmonary infarction. Patients with this complication usually present with shortness of breath and pleuritic chest pain, as well as the other findings that may be confused with pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. It is not known whether the risk of pulmonary embolism is increased among cocaine abusers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5429632\">",
"    <span class=\"h2\">",
"     Gastrointestinal and renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine users have a disproportionate incidence of perforated ulcers. Possible mechanisms include increased sympathetic tone causing increased gastric acid production or local ischemia in the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Cocaine is also implicated in cases of ischemic colitis, intestinal infarction, and metabolic acidosis. Patients presenting with signs and symptoms of bowel obstruction may be engaged in body packing (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Body packers and stuffers'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/15\">",
"     15",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Although less common, splenic and renal infarction can occur from cocaine use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In cocaine users, minor abnormalities of liver enzymes are common and rarely associated with symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/52\">",
"     52",
"    </a>",
"    ]. More severe hepatic failure can be seen following hyperthermia due to psychomotor agitation. (See CNS manifestations above in this section).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5429639\">",
"    <span class=\"h2\">",
"     Other organ systems",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Musculoskeletal &ndash; Patients with cocaine toxicity can present with a spectrum of musculoskeletal concerns. Signs can range from mild creatinine phosphokinase and myoglobin elevation to electrolyte alterations (hyperkalemia, hypocalcemia) seen with rhabdomyolysis. Patients can demonstrate a range of complications from localized or diffuse muscle pain to frank compartment syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/15,53\">",
"       15,53",
"      </a>",
"      ]. Patients with severe rhabdomyolysis may have a lactic acidosis, life-threatening hyperkalemia, and renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"      </a>",
"      .) For treatment (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link&amp;anchor=H25399006#H25399006\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Treatment'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Ophthalmologic &ndash; Sympathetic stimulation causes mydriasis through activation of the dilator fibers of the iris. The pupil usually maintains its ability to constrict to light. Cocaine, like other mydriatic agents, can cause acute angle-closure glaucoma, and vasospasm of the retinal vessels can produce unilateral or bilateral vision loss [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. Patients who smoke crack cocaine may develop mydriasis (unilateral or bilateral), suffer corneal epithelial destruction, or singe their eyebrows and lashes (madarosis) due to heat or direct topical effects [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/15,56\">",
"       15,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pregnancy (pre and postnatal exposure) &ndash; Chronic cocaine use during pregnancy is associated with problems in fetal development [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/57\">",
"       57",
"      </a>",
"      ]. Acute cocaine exposure in pregnancy is associated with abruptio placentae [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/58\">",
"       58",
"      </a>",
"      ]. The effects of in-utero cocaine exposure are discussed more extensively elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link&amp;anchor=H18#H18\">",
"       \"Overview of illicit drug use in pregnant women\", section on 'Cocaine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=see_link&amp;anchor=H16#H16\">",
"       \"Infants of mothers with substance abuse\", section on 'Cocaine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Passive cocaine exposure &ndash; Children and elderly patients can present with signs and symptoms of cocaine intoxication",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complications of cocaine exposure by proximity to users of inhalational cocaine. Cocaine exposure can also occur via ingestion of cocaine or crack, typically when cocaine is left within a child's reach. The incidence of unintentional cocaine exposure may be as high as 5 percent among all children presenting to urban emergency departments [",
"      <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pediatric considerations'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Hematologic and other effects of adulterants ��� Levamisole, an immunomodulator, has been found in cocaine and can cause agranulocytosis, leukoencephalopathy, and cutaneous vasculitis, possible leading to cutaneous necrosis. Clenbuterol, another adulterant, can cause tachycardia, hyperglycemia, palpitations, and hypokalemia. (See",
"      <a class=\"local\" href=\"#H5429510\">",
"       'Adulterants and their effects'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5429510\">",
"    <span class=\"h1\">",
"     ADULTERANTS AND THEIR EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5429517\">",
"    <span class=\"h2\">",
"     Levamisole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levamisole is a common adulterant of cocaine that can cause agranulocytosis, leukoencephalopathy, or cutaneous vasculitis, possibly leading to cutaneous necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/60-66\">",
"     60-66",
"    </a>",
"    ]. A review of published cases of levamisole-related toxicity noted that 52 percent of these patients presented with oropharyngeal complaints, while 27 percent presented with soft tissue infections or purpura [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/67\">",
"     67",
"    </a>",
"    ]. Exposure to cocaine adulterated with levamisole should be suspected in patients with these entities or complaints. Levamisole was used as an adjuvant treatment for colon cancer and an immunomodulator for various conditions and is now used primarily in veterinary practice as an anthelminthic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/68\">",
"     68",
"    </a>",
"    ]. A small case series describes an association between levamisole and hyponatremia, but this phenomenon has yet to be formally studied [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States Drug Enforcement Agency first noted levamisole mixed with cocaine in 2003 and beginning in 2008 investigators in New Mexico reported that some patients who had been exposed to cocaine were developing agranulocytosis (confirmed by bone marrow histopathology). In 2008, levamisole was found in about 44 percent of seized cocaine, and by 2009, this amount rose to 69 to 73 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/68\">",
"     68",
"    </a>",
"    ]. In 2010, investigators in Colorado found that 78 percent of patients with a urine drug screen positive for cocaine also tested positive for levamisole [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5429582\">",
"    <span class=\"h2\">",
"     Clenbuterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clenbuterol, a beta adrenergic agonist, has been found as an adulterant in cocaine and heroin. It can cause hyperglycemia and hypokalemia.",
"   </p>",
"   <p>",
"    In early 2005, cases were reported in the northeastern and southern United States describing a number of patients with atypical presentations following heroin or cocaine use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/70\">",
"     70",
"    </a>",
"    ]. The most common findings were tachycardia (89 percent), hyperglycemia (78 percent), palpitations (78 percent), and hypokalemia (78 percent). In one case series, 67 percent of the patients had all four findings. Other common findings included nausea, hypotension, chest pain, venous hyperoxia, lactic acidosis, agitation, and anxiety. Investigators attributed these symptoms to the heroin and cocaine supply being adulterated with clenbuterol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychomotor agitation is a common, important feature of many overdose and disease states, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Amphetamine abuse",
"     </li>",
"     <li>",
"      Phencyclidine abuse",
"     </li>",
"     <li>",
"      Hypoglycemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=see_link\">",
"       \"Hypoglycemia in adults: Clinical manifestations, definition, and causes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypoxia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link\">",
"       \"Oxygenation and mechanisms of hypoxemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Alcohol and sedative-hypnotic withdrawal syndromes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"       \"Management of moderate and severe alcohol withdrawal syndromes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Serotonin syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"       \"Serotonin syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neuroleptic malignant syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"       \"Neuroleptic malignant syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Heat-related illness (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"       \"Severe hyperthermia (heat stroke) in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thyroid storm (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33655?source=see_link\">",
"       \"Thyroid storm\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Subarachnoid hemorrhage (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"       \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Infections of the central nervous system (ie, meningitis and encephalitis) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Seizures (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"       \"Overview of the management of epilepsy in adults\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Several psychiatric diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of these diagnoses are determined from the patient's medical history. A review of the patient's medications and a detailed account of their substance abuse preferences through family, friends, and first-responders, may provide valuable clues. Diagnostic testing may include CT scan of the head and lumbar puncture as appropriate. We discourage indiscriminate drug testing as a means to differentiate diagnostic possibilities because of the high rate of false positive results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other diagnostic possibilities include cardiopulmonary disease, such as acute coronary syndrome, pulmonary embolus, aortic dissection, and pneumothorax. These diagnoses are generally identified through standard tests such as an electrocardiogram, chest radiograph, echocardiography, chest CT, or cardiac biomarkers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link\">",
"     \"Overview of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=see_link\">",
"     \"Primary spontaneous pneumothorax in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most situations, general supportive care with sedation, cooling, and intravenous fluids is appropriate while diagnostic testing is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LABORATORY AND RADIOGRAPHIC EVALUATION",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General testing &ndash; Routine laboratory evaluation in the potentially poisoned patient should include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Electrocardiogram, to rule out conduction system poisoning by drugs that effect the QRS or QTc intervals",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific testing &ndash; Benzoylecgonine (BE), the major urinary metabolite of cocaine, is the analyte usually tested for in blood, urine, saliva, hair, and meconium. Cocaine is rapidly metabolized and detectable in blood and urine only briefly (ie, several hours) after use. BE can be detected in the urine for several days following intermittent use and up to 10 days or more after heavy use.",
"      <br/>",
"      <br/>",
"      Although the assay for BE is highly accurate, false positives and false negatives may occur, albeit rarely. A drug assay \"positive for cocaine\" does not necessarily connote acute cocaine use, due to BE's prolonged presence. BE is not a psychostimulant and can cause a clinical false positive result (ie, patient's symptoms are mistakenly attributed to acute cocaine intoxication). Analytical false positives are rare, as few xenobiotics are inappropriately detected by the BE immunoassay. Should test results and clinical findings be inconsistent, clinicians should discuss the matter with their laboratory director to determine what xenobiotics may have caused false results. Gas chromatography-mass spectrometry is the gold standard for testing for cocaine and its metabolites. This usually requires that the specimen be sent to a specialized laboratory.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiographs can play a role in the detection of body stuffing and packing. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Body packers and stuffers'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional laboratory and radiographic testing can be helpful depending on the clinical setting. As examples, a troponin, creatine kinase, electrocardiogram, and chest radiograph are obtained in a patient with chest pain, creatine kinase and urine myoglobin are obtained in a patient at risk for rhabdomyolysis, and a CT of the head, followed by cerebrospinal fluid analysis if the CT is nondiagnostic, is obtained in a patient with symptoms concerning for intracranial hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;General management of the overdose patient is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .) Specific management strategies for cocaine overdose are discussed below. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef70334 \" href=\"UTD.htm?34/60/35789\">",
"     table 1",
"    </a>",
"    ). The management of myocardial infarction diagnosed in the setting of cocaine intoxication is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=see_link\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Airway and breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen should be administered as needed. If rapid sequence tracheal intubation is necessary, we suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    &nbsp;",
"    <strong>",
"     not",
"    </strong>",
"    be used. Plasma cholinesterase (PChE) metabolizes both succinylcholine and cocaine, and coadministration of succinylcholine can prolong the effects of cocaine and the paralysis from succinylcholine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/15\">",
"     15",
"    </a>",
"    ]. In the setting of rhabdomyolysis and hyperthermia, succinylcholine may worsen hyperkalemia and cause life-threatening arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest using a nondepolarizing neuromuscular blocker, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    , if paralysis is indicated. Acceptable induction agents in cocaine-intoxicated patients include: benzodiazepines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cardiovascular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since most cardiovascular stimulation from cocaine is centrally mediated via the sympathetic nervous system, sedation with a benzodiazepine, using an appropriate dose and route of administration, is generally sufficient to alleviate cardiovascular symptoms. Benzodiazepine dosing for psychomotor agitation is described below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Psychomotor agitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients with severe, refractory, or symptomatic cocaine-induced hypertension,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    can be used to counteract the alpha-adrenergic effects of cocaine (caused by norepinephrine release). Phentolamine is given as an intravenous bolus. The usual dose is 5 to 10 mg every 5 to 15 minutes as necessary. Chest pain associated with acute cocaine intoxication is discussed below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Chest pain'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Beta-adrenergic antagonists (ie, beta blockers) should",
"    <strong>",
"     NOT",
"    </strong>",
"    be used in the treatment of cocaine-related cardiovascular complications because they may create unopposed alpha-adrenergic stimulation and are associated with coronary vasoconstriction and end-organ ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/25,71\">",
"     25,71",
"    </a>",
"    ]. This proscription includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    , which has predominantly beta-blocking effects. In the rare circumstance when beta blockers must be used, their administration should be preceded by that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    to prevent unopposed alpha-adrenergic stimulation.",
"   </p>",
"   <p>",
"    Hypertensive emergencies can be seen in the setting of acute cocaine intoxication and are usually defined as an elevated blood pressure associated with end-organ damage. There are no treatment goals specifically defined for cocaine-related hypertensive emergencies, but the initial aim of treatment in general hypertensive crises is to rapidly lower the diastolic pressure to about 100 to 105 mmHg; this goal should be achieved within two to six hours, with the maximum initial fall in mean arterial blood pressure not exceeding 25 percent of the presenting value. Cocaine-related hypertension should be treated judiciously given its usually self-limited nature (hypertension generally resolves when cocaine is metabolized) and the importance of avoiding hypotension. Treatment with benzodiazepines, and possibly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    , as described above, is sufficient in most cases. Hypertensive emergencies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link&amp;anchor=H6#H6\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\", section on 'Goal of therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=see_link\">",
"     \"Treatment of specific hypertensive emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a patient no longer appears acutely agitated and other signs of sympathetic excess (eg, tachycardia, diaphoresis) have resolved but significant hypertension persists, acute cocaine exposure is unlikely to be the cause. In such cases, hypertension should be managed based upon the patient&rsquo;s medical comorbidities and clinical status.",
"   </p>",
"   <p>",
"    Cocaine toxicity usually causes hypertension, but massive toxicity may result in hypotension due to sodium-channel blockade, cardiac dysrhythmias, or cardiac ischemia. Patients with hypotension are treated with intravenous isotonic saline. If hypotension persists after two to three liters of rapidly infused isotonic saline, direct-acting vasopressors such as norepinephrine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    can be given and titrated to effect. An electrocardiogram (ECG) should be obtained, and if there are signs of QRS widening (suggesting sodium channel blockade), hypertonic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    should be administered at a dose of 1 to 2",
"    <span class=\"nowrap\">",
"     mEq/kg",
"    </span>",
"    by bolus via a large bore IV. A repeat ECG should be obtained to evaluate whether QRS narrowing has occurred in response to treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=see_link&amp;anchor=H15#H15\">",
"     \"Tricyclic antidepressant poisoning\", section on 'Sodium bicarbonate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of patients suspected to be body packers or stuffers is discussed briefly below and in detail elsewhere. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Body packers and stuffers'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"     \"Internal concealment of drugs of abuse (body packing)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Psychomotor agitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agitated patients are sedated as needed with benzodiazepines, after ensuring they are not hypoglycemic or hypoxic. We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    be given in an initial dose of 10 mg IV, then 5 to 10 mg IV every three to five minutes until agitation is controlled. Monitor patients for respiratory depression and hypotension. Intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    can be used if IV access is unavailable, but its peak effect is typically delayed (10 to 20 minutes).",
"   </p>",
"   <p>",
"    Hyperthermic patients should be cooled rapidly, optimally in 30 minutes or less, to a goal core body temperature of &lt;102&deg;F. Immersion in ice or ice water is the most rapid cooling method for severely hyperthermic patients; cooling via evaporative spray may be sufficient in moderately hyperthermic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Gastrointestinal decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the popular methods of cocaine use are nonenteral (ie, inhalational, intravenous, and intranasal), the majority of patients who present with cocaine intoxication will not require gastrointestinal decontamination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/34\">",
"     34",
"    </a>",
"    ]. Decontamination should be performed, if required, by removing any cocaine powder from nares, mouth, or oropharynx. Gentle nasal irrigation with 0.9 percent (isotonic) saline could be used if the patient presents with a visible white powder presumed to be cocaine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/18\">",
"     18",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    reduces the lethality of oral cocaine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/75\">",
"     75",
"    </a>",
"    ]. The dose of activated charcoal is 1 gram per kg body weight (up to 50 grams), and should be administered by mouth every four hours for several doses. Body packing and stuffing is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"     \"Internal concealment of drugs of abuse (body packing)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SPECIFIC SYNDROMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine-associated chest pain (CACP) accounts for approximately 40 percent of all cocaine-related visits to the emergency department (ED) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/34\">",
"     34",
"    </a>",
"    ]. Acutely, cocaine causes vasoconstriction and enhances thrombus formation, increasing the risk of myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Approximately 6 percent of patients presenting with CACP manifest elevations in biomarkers consistent with myocardial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/28,76\">",
"     28,76",
"    </a>",
"    ]. The management of myocardial infarction diagnosed in the setting of cocaine intoxication is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=see_link\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although acute coronary syndrome remains an important concern, ED clinicians should avoid prematurely discounting alternative diagnoses in patients with CACP but no clear evidence of myocardial infarction. Pneumothorax and crack lung can also present as chest pain following cocaine abuse. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Crack lung'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    According to one retrospective cohort study, patients with CACP most commonly complain of: substernal chest pain (76 percent), shortness of breath (62 percent),",
"    <span class=\"nowrap\">",
"     tightness/pressure/squeezing",
"    </span>",
"    (55 percent), and diaphoresis (48 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation of patients with suspected CACP pain includes an ECG, chest radiograph, and biomarkers to exclude myocardial infarction. Two prospective observational studies suggest the ECG has limited accuracy in the setting of CACP, and ECG evidence of ischemia or infarction may not correlate with myocardial infarction, as diagnosed by an elevation in cardiac biomarkers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/28,77\">",
"     28,77",
"    </a>",
"    ]. According to these studies, the sensitivity and specificity of the ECG are approximately 36 and 90 percent respectively. However, the number of patients diagnosed with myocardial infarction in each study was small so the accuracy of the ECG in CACP remains unclear.",
"   </p>",
"   <p>",
"    Early management of patients with CACP includes the administration of oxygen and reduction of sympathetic outflow using benzodiazepines given intravenously (IV). We suggest benzodiazepines be given to patients who are anxious, agitated, hypertensive, or tachycardic; we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    be given in addition to patients with hypertension. We give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    (5 mg IV every three to five minutes) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    (1 mg IV every 5 to 10 minutes) until sedation is achieved. We give nitroglycerin 0.4 mg sublingual every five minutes as needed for a maximum of three doses. If additional nitroglycerin is needed, an infusion can be started with the dose titrated to effect.",
"   </p>",
"   <p>",
"    No study has clearly demonstrated whether benzodiazepines or nitrates are more efficacious in the management of CACP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. In one prospective controlled trial, 12 patients with CACP randomly assigned to receive sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    (NTG) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    had significantly more rapid and more complete relief of pain than the 15 patients assigned to treatment with NTG alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacologic treatment of patients with CACP differs in several important ways from the standard treatment of myocardial ischemia from atherosclerotic coronary artery disease. Beta blockers are contraindicated in patients who have recently used cocaine (&lt;24 hours), and in patients with CACP. Beta blockers may lead to unopposed alpha adrenergic stimulation which can cause coronary arterial vasoconstriction, ischemia, and infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. This proscription includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    , which has predominantly beta-blocking effects.",
"   </p>",
"   <p>",
"    Studies that advocate administration of beta-blockers to patients with CACP have predominantly been retrospective and unable to characterize when patients used cocaine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/82-85\">",
"     82-85",
"    </a>",
"    ]. Since the urine drug screen (testing for the cocaine metabolite benzoylecgonine (BE)) can be positive many days after cocaine was last used, it is likely that there is a period after which the use of beta-blockers is safe despite a positive immunoassay. However, in a patient presenting acutely with chest pain after cocaine use, the use of beta-blockers remains contraindicated. This approach is consistent with guidelines for the management of CACP promulgated by the American Heart Association [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    is contraindicated in patients suspected of having an aortic dissection, but can be given at standard doses to patients with CACP when myocardial ischemia is the suspected cause.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     Phentolamine",
"    </a>",
"    , an alpha-adrenergic antagonist, can be used to reduce cocaine-induced coronary artery vasoconstriction when managing CACP or hypertension that is unresponsive to benzodiazepines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/25,71,87,88\">",
"     25,71,87,88",
"    </a>",
"    ]. Phentolamine is given as an IV bolus of 1 to 2.5 mg every 5 to 15 minutes as necessary. In one prospective observational study, adult patients with no history of cocaine use were given a low dose (2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    of intranasal cocaine while undergoing cardiac catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/25\">",
"     25",
"    </a>",
"    ]. Cocaine caused an increase in heart rate, blood pressure, and coronary vascular resistance, and narrowing of the coronary artery diameter by 13 percent. Coronary artery diameter returned to baseline with the administration of phentolamine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Crack lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crack lung is a syndrome of hemorrhagic alveolitis from inhalational cocaine use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/89\">",
"     89",
"    </a>",
"    ]. Cough and shortness of breath are common presenting symptoms. Additional signs and symptoms may include: acute lung injury, hypoxia, chest pain, hemoptysis, fever, focal infiltrates, and bronchospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/42\">",
"     42",
"    </a>",
"    ]. A chest radiograph and a history of cocaine use provide the basis for diagnosis. Patients may have an eosinophilia, which suggests an immune-mediated component [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management includes maintenance of oxygenation, ventilation, and symptomatic care. Patients with airway compromise may require endotracheal intubation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    should not be used. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Airway and breathing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Body packers and stuffers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body packers have been called swallowers, internal carriers, couriers, or mules [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/91\">",
"     91",
"    </a>",
"    ]. The term body packer is used to refer to persons who swallow large quantities of prepackaged drugs with the intention of smuggling these drugs across international borders. Body stuffers are persons who swallow relatively small quantities of drugs in poorly constructed packets (usually in haste) to avoid repercussions from law enforcement agents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Body stuffers with symptoms of cocaine overdose (eg, tachycardia, hypertension, hyperthermia, agitation, seizures, or cardiac dysrhythmias) are treated in standard fashion. Management begins with stabilization of the airway, breathing, and circulation, and continues with gastrointestinal decontamination with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    , whole bowel irrigation, or both. Presentation and management of body packers and stuffers is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"     \"Internal concealment of drugs of abuse (body packing)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastrointestinal decontamination is generally performed in patients suspected of body packing, body stuffers with a concerning ingestion, or symptomatic body stuffers, unless they are being prepared for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/91\">",
"     91",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    reduces the lethality of oral cocaine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/75\">",
"     75",
"    </a>",
"    ]. The dose of activated charcoal is 1 gram per kg body weight (up to 50 grams), and should be administered by mouth every four hours for several doses. Whole bowel irrigation (WBI) with polyethylene glycol-electrolyte lavage solution is recommended in body packers for gentle evacuation of the gastrointestinal tract. WBI is given (usually via a nasogastric tube) at a rate of 2 liters per hour in adults until the gastrointestinal tract is clear. Use of oil-based laxatives is not recommended because they reduce the tensile strength of packets [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of the patients who sustain adverse outcomes has symptoms at presentation or within the first few hours [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. The most common issues include: cocaine-induced toxic effects, intestinal obstruction, and medical assessment following arrest. Symptomatic cocaine body packers usually require surgical intervention for immediate removal of the packets. Patients are also treated with benzodiazepines for agitation and seizures,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    for ventricular dysrhythmias, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    or sodium",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    for severe hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children can present with signs and symptoms of cocaine intoxication or complications of cocaine exposure from being around adults who use cocaine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/59,94-96\">",
"     59,94-96",
"    </a>",
"    ]. Unintentional cocaine exposure in children may occur from passive inhalation of free-base cocaine vapors or ingestion. The incidence of unintentional cocaine exposure among all children treated in the emergency department may be as high as 6 percent, particularly in urban settings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/59,94,96\">",
"     59,94,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational data suggests that passive exposure to cocaine may manifest as more frequent respiratory symptoms in infants, with and without fever [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/94\">",
"     94",
"    </a>",
"    ], and more frequent generalized and focal seizures in children below eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/95\">",
"     95",
"    </a>",
"    ]. Clinical findings in older children are similar to adults.",
"   </p>",
"   <p>",
"    Fetal exposure to cocaine is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=see_link&amp;anchor=H16#H16\">",
"     \"Infants of mothers with substance abuse\", section on 'Cocaine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of illicit drug use in pregnant women\", section on 'Cocaine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Specific management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no special decontamination procedures in children who are exposed to cocaine. Management of children exposed to crack cocaine fumes or cocaine residue is symptomatic. In rare circumstances, children have been used to smuggle drugs from foreign countries by making them swallow packets of cocaine. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Body packers and stuffers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cocaine-exposed children may need to be admitted to the hospital. Social work",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    child protective services must be notified. The involvement of local law enforcement authorities follows local practices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those patients requiring decontamination, dosing is provided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Pediatric doses",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       Activated Charcoal",
"      </a>",
"      (AC) &ndash; 0.5 to 1",
"      <span class=\"nowrap\">",
"       gm/kg",
"      </span>",
"      of body weight with cathartic, for the initial dose.",
"     </li>",
"     <li>",
"      Multidose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       Activated Charcoal",
"      </a>",
"      (MDAC) &ndash; 0.25 to 0.5",
"      <span class=\"nowrap\">",
"       gm/kg",
"      </span>",
"      q 2 to 4 hours for 12 hours, without a cathartic.",
"     </li>",
"     <li>",
"      Whole Bowel Irrigation (WBI) &ndash; 0.25",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour. Administer orally or via nasogastric tube. Administer for 4 to 6 hours or until rectal effluent is clear. Children may tolerate polyethylene glycol (NuLYTLELY&trade;) better than other irrigation fluids because it contains 50 percent less total salt and may cause fewer electrolyte abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe complications of cocaine abuse are managed as described above and admitted to the hospital at the appropriate level of care. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Initial management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In general, patients who present with acute symptoms from cocaine toxicity that resolve are observed for six to eight hours. Patients who have returned to their baseline level of function can generally be discharged after this period with appropriate referrals.",
"   </p>",
"   <p>",
"    Patients who present with cocaine-associated chest pain (CACP) are observed for eight to twelve hours while two sets of cardiac biomarkers and repeat electrocardiograms (ECG) are obtained. This assumes the patient is pain-free, or rapidly made pain-free, and has a normal initial ECG. Cardiac biomarkers are typically performed 8 to 12 hours apart. Although this is not the standard approach to the management of patients with suspected acute coronary syndromes (ACS) unrelated to cocaine, the incidence of myocardial infarction in patients with CACP is extremely low (approximately 6 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/28,97-99\">",
"     28,97-99",
"    </a>",
"    ]. For patients with CACP at low risk for ACS, observation in a chest pain unit is reasonable.",
"   </p>",
"   <p>",
"    The results of an observational study of 59 patients with CACP at low risk for ACS suggest that such patients can be discharged safely after nonischemic ECGs, normal cardiac biomarkers, and a negative coronary computerized tomography angiography (CTA) study [",
"    <a class=\"abstract\" href=\"UTD.htm?22/30/23018/abstract/100\">",
"     100",
"    </a>",
"    ]. However, further research is needed before such an approach can be recommended.",
"   </p>",
"   <p>",
"    Patients in whom cocaine use is not the sole risk factor for ACS or who have a moderate or high TIMI risk score should be evaluated like any patient presenting to the emergency department with a possible ACS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who present with psychomotor agitation, hyperthermia, or other neurological complications of cocaine toxicity may require admission for monitoring and management of sequelae. If after six to eight hours of observation their symptoms are completely resolved, they are awake, alert, and ambulate without difficulty, and their reexamination reveals no concerning findings, they may discharged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89983587\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cocaine produces end-organ toxicity in virtually every organ system in the body, primarily through its hemodynamic effects. Among its more important effects are hypertension, arterial vasoconstriction (eg, coronary arteries), thrombus formation, psychomotor agitation (neurologic effects can range from agitation to seizures to intracranial hemorrhage), severe hyperthermia, dyspnea (from pneumothorax, pulmonary infarction or other pulmonary injury), and ischemic bowel. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Numerous drugs and disease states can mimic the cardiovascular effects",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      psychomotor agitation of acute cocaine overdose. A discussion of these is provided. A thorough history, including medications and preferred drugs of abuse, is often the key to diagnosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Benzoylecgonine (BE), the major urinary metabolite of cocaine, is the analyte usually tested for. Cocaine is rapidly metabolized and detectable in blood and urine only briefly (ie, several hours) after use. BE can be detected in the urine for several days following intermittent use and up to 10 days or more after heavy use. Therefore, a drug assay \"positive for cocaine\" does not necessarily connote acute cocaine use. Additional testing is performed based on clinical circumstances. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory and radiographic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A detailed approach to management is provided above. A summary table to facilitate emergent management is provided (",
"      <a class=\"graphic graphic_table graphicRef70334 \" href=\"UTD.htm?34/60/35789\">",
"       table 1",
"      </a>",
"      ). If rapid sequence tracheal intubation (RSI) is necessary, we suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      &nbsp;",
"      <strong>",
"       not",
"      </strong>",
"      be used because it can prolong the effects of cocaine and cause other complications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A nondepolarizing neuromuscular blocker, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=see_link\">",
"       rocuronium",
"      </a>",
"      , may be used if RSI is necessary. Acceptable induction agents include: benzodiazepines,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Airway and breathing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cardiovascular stimulation from cocaine is centrally mediated via the sympathetic nervous system. We suggest initial treatment with a benzodiazepine, using an appropriate dose and route to alleviate cardiovascular symptoms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Suitable dosing is described above. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Psychomotor agitation'",
"      </a>",
"      above.) In patients with severe, refractory, or symptomatic cocaine-induced hypertension, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"       phentolamine",
"      </a>",
"      be used to counteract the alpha-adrenergic effects of cocaine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Phentolamine is given as an intravenous bolus. The usual dose is 5 to 10 mg every 5 to 15 minutes as necessary. We recommend that beta blockers, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      ,",
"      <strong>",
"       NOT",
"      </strong>",
"      be used in patients with acute cocaine toxicity because of the risk of cardiovascular complications from unopposed alpha-adrenergic stimulation (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cardiovascular complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rule out hypoglycemia and hypoxia as the cause of psychomotor agitation. For cocaine-induced agitation, we suggest treatment with benzodiazepines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      5 to 10 mg IV every 3 to 5 minutes until agitation is controlled) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Psychomotor agitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although chest pain is a common presentation of acute cocaine intoxication, myocardial infarction is uncommon. Early management of cocaine-associated chest pain includes the administration of oxygen and reduction of sympathetic outflow using benzodiazepines. We suggest benzodiazepines be given to patients who are anxious, agitated, hypertensive, or tachycardic (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We give",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      5 mg every 3 to 5 or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      1 mg every 5 to 10 minutes as an intravenous dose until sedation is achieved. We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      be given in addition to patients with hypertension (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Beta blockers are",
"      <strong>",
"       contraindicated",
"      </strong>",
"      . (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Chest pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Crack lung is a syndrome of hemorrhagic alveolitis from inhalational cocaine use. Cough and shortness of breath are common presenting symptoms. Patients with airway compromise may require tracheal intubation. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Crack lung'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Passive exposure to cocaine may cause more frequent respiratory symptoms in infants, with and without fever, and more frequent generalized and focal seizures in children below eight years. Clinical findings in older children are similar to adults. There are no special decontamination procedures in children who are exposed to cocaine. Fetal exposure to cocaine is discussed separately. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pediatric considerations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=see_link&amp;anchor=H16#H16\">",
"       \"Infants of mothers with substance abuse\", section on 'Cocaine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disposition strategies are discussed above. Body packers and stuffers are discussed briefly above and in detail elsewhere. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Disposition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"       \"Internal concealment of drugs of abuse (body packing)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Drug Abuse Warning Network (DAWN) dawninfo.samhsa.gov (Accessed on December 19, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/2\">",
"      Degenhardt L, Roxburgh A, Barker B. Underlying causes of cocaine, amphetamine and opioid related deaths in Australia. J Clin Forensic Med 2005; 12:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/3\">",
"      Coffin PO, Galea S, Ahern J, et al. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction 2003; 98:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/4\">",
"      Preti A, Miotto P, De Coppi M. Deaths by unintentional illicit drug overdose in Italy, 1984-2000. Drug Alcohol Depend 2002; 66:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/5\">",
"      Marzuk PM, Tardiff K, Leon AC, et al. Fatal injuries after cocaine use as a leading cause of death among young adults in New York City. N Engl J Med 1995; 332:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/6\">",
"      Jeffcoat AR, Perez-Reyes M, Hill JM, et al. Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking. Drug Metab Dispos 1989; 17:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/7\">",
"      Inaba T, Stewart DJ, Kalow W. Metabolism of cocaine in man. Clin Pharmacol Ther 1978; 23:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/8\">",
"      Hoffman RS, Kaplan JL, Hung OL, Goldfrank LR. Ecgonine methyl ester protects against cocaine lethality in mice. J Toxicol Clin Toxicol 2004; 42:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/9\">",
"      Schuelke GS, Konkol RJ, Terry LC, Madden JA. Effect of cocaine metabolites on behavior: possible neuroendocrine mechanisms. Brain Res Bull 1996; 39:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/10\">",
"      Schreiber MD, Madden JA, Covert RF, Torgerson LJ. Effects of cocaine, benzoylecgonine, and cocaine metabolites in cannulated pressurized fetal sheep cerebral arteries. J Appl Physiol 1994; 77:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/11\">",
"      Raimo EB, Schuckit MA. Alcohol dependence and mood disorders. Addict Behav 1998; 23:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/12\">",
"      Bourland JA, Martin DK, Mayersohn M. In vitro transesterification of cocaethylene (ethylcocaine) in the presence of ethanol. esterase-mediated ethyl ester exchange esterase-mediated ethyl ester exchange. Drug Metab Dispos 1998; 26:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/13\">",
"      Harris DS, Everhart ET, Mendelson J, Jones RT. The pharmacology of cocaethylene in humans following cocaine and ethanol administration. Drug Alcohol Depend 2003; 72:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/14\">",
"      Herbst ED, Harris DS, Everhart ET, et al. Cocaethylene formation following ethanol and cocaine administration by different routes. Exp Clin Psychopharmacol 2011; 19:95.",
"     </a>",
"    </li>",
"    <li>",
"     Goldfrank, LR, Flomenbaum, NE, Hoffman, JR, et al. Goldfrank's Toxicologic Emergencies, 8th Ed, McGraw-Hill Medical Publishing Division, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/16\">",
"      Wilson LD, French S. Cocaethylene's effects on coronary artery blood flow and cardiac function in a canine model. J Toxicol Clin Toxicol 2002; 40:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/17\">",
"      Hearn WL, Flynn DD, Hime GW, et al. Cocaethylene: a unique cocaine metabolite displays high affinity for the dopamine transporter. J Neurochem 1991; 56:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/18\">",
"      Jatlow PI. Drug of abuse profile: cocaine. Clin Chem 1987; 33:66B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/19\">",
"      Tella SR, Schindler CW, Goldberg SR. Cardiovascular effects of cocaine in conscious rats: relative significance of central sympathetic stimulation and peripheral neuronal monoamine uptake and release mechanisms. J Pharmacol Exp Ther 1992; 262:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/20\">",
"      Tella SR, Schindler CW, Goldberg SR. Cocaine: cardiovascular effects in relation to inhibition of peripheral neuronal monoamine uptake and central stimulation of the sympathoadrenal system. J Pharmacol Exp Ther 1993; 267:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/21\">",
"      Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987; 237:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/22\">",
"      Smith JA, Mo Q, Guo H, et al. Cocaine increases extraneuronal levels of aspartate and glutamate in the nucleus accumbens. Brain Res 1995; 683:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/23\">",
"      Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004; 9:984.",
"     </a>",
"    </li>",
"    <li>",
"     Goldfrank, LR, Flomenbaum, NE, Hoffman, JR, et al. Goldfrank's Toxicologic Emergencies, Neurotransmitters and Neuromodulators, 8th Ed, McGraw-Hill Medical Publishing Division, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/25\">",
"      Lange RA, Cigarroa RG, Yancy CW Jr, et al. Cocaine-induced coronary-artery vasoconstriction. N Engl J Med 1989; 321:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/26\">",
"      Kugelmass AD, Oda A, Monahan K, et al. Activation of human platelets by cocaine. Circulation 1993; 88:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/27\">",
"      Rezkalla SH, Mazza JJ, Kloner RA, et al. Effects of cocaine on human platelets in healthy subjects. Am J Cardiol 1993; 72:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/28\">",
"      Hollander JE, Hoffman RS, Gennis P, et al. Prospective multicenter evaluation of cocaine-associated chest pain. Cocaine Associated Chest Pain (COCHPA) Study Group. Acad Emerg Med 1994; 1:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/29\">",
"      Koppel BS, Samkoff L, Daras M. Relation of cocaine use to seizures and epilepsy. Epilepsia 1996; 37:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/30\">",
"      Fisher A, Holroyd BR. Cocaine-associated dissection of the thoracic aorta. J Emerg Med 1992; 10:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/31\">",
"      Kolodgie FD, Wilson PS, Cornhill JF, et al. Increased prevalence of aortic fatty streaks in cholesterol-fed rabbits administered intravenous cocaine: the role of vascular endothelium. Toxicol Pathol 1993; 21:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/32\">",
"      Dressler FA, Malekzadeh S, Roberts WC. Quantitative analysis of amounts of coronary arterial narrowing in cocaine addicts. Am J Cardiol 1990; 65:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/33\">",
"      Marzuk PM, Tardiff K, Leon AC, et al. Ambient temperature and mortality from unintentional cocaine overdose. JAMA 1998; 279:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/34\">",
"      Brody SL, Slovis CM, Wrenn KD. Cocaine-related medical problems: consecutive series of 233 patients. Am J Med 1990; 88:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/35\">",
"      Daras M, Tuchman AJ, Marks S. Central nervous system infarction related to cocaine abuse. Stroke 1991; 22:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/36\">",
"      Levine SR, Brust JC, Futrell N, et al. Cerebrovascular complications of the use of the \"crack\" form of alkaloidal cocaine. N Engl J Med 1990; 323:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/37\">",
"      Ramadan NM, Levine SR, Welch KM. Pontine hemorrhage following \"crack\" cocaine use. Neurology 1991; 41:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/38\">",
"      Schwartz KA, Cohen JA. Subarachnoid hemorrhage precipitated by cocaine snorting. Arch Neurol 1984; 41:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/39\">",
"      Maeder M, Ullmer E. Pneumomediastinum and bilateral pneumothorax as a complication of cocaine smoking. Respiration 2003; 70:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/40\">",
"      Savader SJ, Omori M, Martinez CR. Pneumothorax, pneumomediastinum, and pneumopericardium: complications of cocaine smoking. J Fla Med Assoc 1988; 75:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/41\">",
"      Uva JL. Spontaneous pneumothoraces, pneumomediastinum, and pneumoperitoneum: consequences of smoking crack cocaine. Pediatr Emerg Care 1997; 13:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/42\">",
"      Ettinger NA, Albin RJ. A review of the respiratory effects of smoking cocaine. Am J Med 1989; 87:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/43\">",
"      Osborn HH, Tang M, Bradley K, Duncan BR. New-onset bronchospasm or recrudescence of asthma associated with cocaine abuse. Acad Emerg Med 1997; 4:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/44\">",
"      Rome LA, Lippmann ML, Dalsey WC, et al. Prevalence of cocaine use and its impact on asthma exacerbation in an urban population. Chest 2000; 117:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/45\">",
"      Delaney K, Hoffman RS. Pulmonary infarction associated with crack cocaine use in a previously healthy 23-year-old woman. Am J Med 1991; 91:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/46\">",
"      Smith GT, McClaughry PL, Purkey J, Thompson W. Crack cocaine mimicking pulmonary embolism on pulmonary ventilation/perfusion lung scan. A case report. Clin Nucl Med 1995; 20:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/47\">",
"      Lee HS, LaMaute HR, Pizzi WF, et al. Acute gastroduodenal perforations associated with use of crack. Ann Surg 1990; 211:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/48\">",
"      Pecha RE, Prindiville T, Pecha BS, et al. Association of cocaine and methamphetamine use with giant gastroduodenal ulcers. Am J Gastroenterol 1996; 91:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/49\">",
"      Sharma R, Organ CH Jr, Hirvela ER, Henderson VJ. Clinical observation of the temporal association between crack cocaine and duodenal ulcer perforation. Am J Surg 1997; 174:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/50\">",
"      Novielli KD, Chambers CV. Splenic infarction after cocaine use. Ann Intern Med 1991; 114:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/51\">",
"      Edmondson DA, Towne JB, Foley DW, et al. Cocaine-induced renal artery dissection and thrombosis leading to renal infarction. WMJ 2004; 103:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/52\">",
"      Kothur R, Marsh F, Posner G. Liver function tests in nonparenteral cocaine users. Arch Intern Med 1991; 151:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/53\">",
"      Flaque-Coma J. Cocaine and rhabdomyolysis: report of a case and review of the literature. Bol Asoc Med P R 1990; 82:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/54\">",
"      Hoffman RS, Reimer BI. \"Crack\" cocaine-induced bilateral amblyopia. Am J Emerg Med 1993; 11:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/55\">",
"      Libman RB, Masters SR, de Paola A, Mohr JP. Transient monocular blindness associated with cocaine abuse. Neurology 1993; 43:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/56\">",
"      Ravin JG, Ravin LC. Blindness due to illicit use of topical cocaine. Ann Ophthalmol 1979; 11:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/57\">",
"      Addis A, Moretti ME, Ahmed Syed F, et al. Fetal effects of cocaine: an updated meta-analysis. Reprod Toxicol 2001; 15:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/58\">",
"      Flowers D, Clark JF, Westney LS. Cocaine intoxication associated with abruptio placentae. J Natl Med Assoc 1991; 83:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/59\">",
"      Rosenberg NM, Meert KL, Knazik SR, et al. Occult cocaine exposure in children. Am J Dis Child 1991; 145:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/60\">",
"      Buchanan JA, Heard K, Burbach C, et al. Prevalence of levamisole in urine toxicology screens positive for cocaine in an inner-city hospital. JAMA 2011; 305:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/61\">",
"      Schneider S, Meys F. Analysis of illicit cocaine and heroin samples seized in Luxembourg from 2005-2010. Forensic Sci Int 2011; 212:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/62\">",
"      Gross RL, Brucker J, Bahce-Altuntas A, et al. A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine. Clin Rheumatol 2011; 30:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/63\">",
"      Muirhead TT, Eide MJ. Images in clinical medicine. Toxic effects of levamisole in a cocaine user. N Engl J Med 2011; 364:e52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/64\">",
"      Lung D, Lynch K, Agrawal S, et al. Images in emergency medicine. Adult female with rash on lower extremities. Vasculopathic purpura and neutropenia caused by levamisole-contaminated cocaine. Ann Emerg Med 2011; 57:307, 311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/65\">",
"      Chang A, Osterloh J, Thomas J. Levamisole: a dangerous new cocaine adulterant. Clin Pharmacol Ther 2010; 88:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/66\">",
"      Vagi SJ, Sheikh S, Brackney M, et al. Passive multistate surveillance for neutropenia after use of cocaine or heroin possibly contaminated with levamisole. Ann Emerg Med 2013; 61:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/67\">",
"      Chai PR, Bastan W, Machan J, et al. Levamisole exposure and hematologic indices in cocaine users. Acad Emerg Med 2011; 18:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/68\">",
"      Centers for Disease Control and Prevention (CDC). Agranulocytosis associated with cocaine use - four States, March 2008-November 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/69\">",
"      Friend K, Milone MC, Perrone J. Hyponatremia associated with levamisole-adulterated cocaine use in emergency department patients. Ann Emerg Med 2012; 60:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/70\">",
"      Centers for Disease Control and Prevention (CDC). Atypical reactions associated with heroin use--five states, January-April 2005. MMWR Morb Mortal Wkly Rep 2005; 54:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/71\">",
"      Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001; 345:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/72\">",
"      Armstrong LE, Crago AE, Adams R, et al. Whole-body cooling of hyperthermic runners: comparison of two field therapies. Am J Emerg Med 1996; 14:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/73\">",
"      Costrini A. Emergency treatment of exertional heatstroke and comparison of whole body cooling techniques. Med Sci Sports Exerc 1990; 22:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/74\">",
"      Gaffin SL, Gardner JW, Flinn SD. Cooling methods for heatstroke victims. Ann Intern Med 2000; 132:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/75\">",
"      Tomaszewski C, McKinney P, Phillips S, et al. Prevention of toxicity from oral cocaine by activated charcoal in mice. Ann Emerg Med 1993; 22:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/76\">",
"      Weber JE, Chudnofsky CR, Boczar M, et al. Cocaine-associated chest pain: how common is myocardial infarction? Acad Emerg Med 2000; 7:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/77\">",
"      Hollander JE, Lozano M, Fairweather P, et al. \"Abnormal\" electrocardiograms in patients with cocaine-associated chest pain are due to \"normal\" variants. J Emerg Med 1994; 12:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/78\">",
"      Honderick T, Williams D, Seaberg D, Wears R. A prospective, randomized, controlled trial of benzodiazepines and nitroglycerine or nitroglycerine alone in the treatment of cocaine-associated acute coronary syndromes. Am J Emerg Med 2003; 21:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/79\">",
"      Baumann BM, Perrone J, Hornig SE, et al. Randomized, double-blind, placebo-controlled trial of diazepam, nitroglycerin, or both for treatment of patients with potential cocaine-associated acute coronary syndromes. Acad Emerg Med 2000; 7:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/80\">",
"      Lange RA, Cigarroa RG, Flores ED, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 1990; 112:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/81\">",
"      Boehrer JD, Moliterno DJ, Willard JE, et al. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med 1993; 94:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/82\">",
"      Hoffman RS. Cocaine and beta-blockers: should the controversy continue? Ann Emerg Med 2008; 51:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/83\">",
"      Dattilo PB, Hailpern SM, Fearon K, et al. Beta-blockers are associated with reduced risk of myocardial infarction after cocaine use. Ann Emerg Med 2008; 51:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/84\">",
"      Fung SC, Chan YC, Lau FL. Beta-blockers are associated with reduced risk of myocardial infarction after cocaine use. Ann Emerg Med 2008; 52:88; author reply 89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/85\">",
"      Freeman K, Feldman JA. Cocaine, myocardial infarction, and beta-blockers: time to rethink the equation? Ann Emerg Med 2008; 51:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/86\">",
"      McCord J, Jneid H, Hollander JE, et al. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation 2008; 117:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/87\">",
"      Hollander JE. The management of cocaine-associated myocardial ischemia. N Engl J Med 1995; 333:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/88\">",
"      Albertson TE, Dawson A, de Latorre F, et al. TOX-ACLS: toxicologic-oriented advanced cardiac life support. Ann Emerg Med 2001; 37:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/89\">",
"      Forrester JM, Steele AW, Waldron JA, Parsons PE. Crack lung: an acute pulmonary syndrome with a spectrum of clinical and histopathologic findings. Am Rev Respir Dis 1990; 142:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/90\">",
"      Kissner DG, Lawrence WD, Selis JE, Flint A. Crack lung: pulmonary disease caused by cocaine abuse. Am Rev Respir Dis 1987; 136:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/91\">",
"      Traub SJ, Hoffman RS, Nelson LS. Body packing--the internal concealment of illicit drugs. N Engl J Med 2003; 349:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/92\">",
"      June R, Aks SE, Keys N, Wahl M. Medical outcome of cocaine bodystuffers. J Emerg Med 2000; 18:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/93\">",
"      Pollack CV Jr, Biggers DW, Carlton FB Jr, et al. Two crack cocaine body stuffers. Ann Emerg Med 1992; 21:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/94\">",
"      Lustbader AS, Mayes LC, McGee BA, et al. Incidence of passive exposure to crack/cocaine and clinical findings in infants seen in an outpatient service. Pediatrics 1998; 102:e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/95\">",
"      Mott SH, Packer RJ, Soldin SJ. Neurologic manifestations of cocaine exposure in childhood. Pediatrics 1994; 93:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/96\">",
"      Bateman DA, Heagarty MC. Passive freebase cocaine ('crack') inhalation by infants and toddlers. Am J Dis Child 1989; 143:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/97\">",
"      Hollander JE, Hoffman RS, Gennis P, et al. Cocaine-associated chest pain: one-year follow-up. Acad Emerg Med 1995; 2:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/98\">",
"      Weber JE, Shofer FS, Larkin GL, et al. Validation of a brief observation period for patients with cocaine-associated chest pain. N Engl J Med 2003; 348:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/99\">",
"      Cunningham R, Walton MA, Weber JE, et al. One-year medical outcomes and emergency department recidivism after emergency department observation for cocaine-associated chest pain. Ann Emerg Med 2009; 53:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/30/23018/abstract/100\">",
"      Walsh K, Chang AM, Perrone J, et al. Coronary computerized tomography angiography for rapid discharge of low-risk patients with cocaine-associated chest pain. J Med Toxicol 2009; 5:111.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 303 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23018=[""].join("\n");
var outline_f22_30_23018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5429611\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5429618\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5429625\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5429632\">",
"      Gastrointestinal and renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5429639\">",
"      Other organ systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5429510\">",
"      ADULTERANTS AND THEIR EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5429517\">",
"      Levamisole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5429582\">",
"      Clenbuterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LABORATORY AND RADIOGRAPHIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Airway and breathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cardiovascular complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Psychomotor agitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Gastrointestinal decontamination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SPECIFIC SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Crack lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Body packers and stuffers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Specific management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Decontamination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Pediatric doses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89983587\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/303\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/303|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/60/35789\" title=\"table 1\">",
"      Cocaine toxicity - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/57/7067\" title=\"table 2\">",
"      Cocaine kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=related_link\">",
"      Hypoglycemia in adults: Clinical manifestations, definition, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=related_link\">",
"      Infants of mothers with substance abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=related_link\">",
"      Internal concealment of drugs of abuse (body packing)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34649?source=related_link\">",
"      Pulmonary complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33655?source=related_link\">",
"      Thyroid storm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=related_link\">",
"      Treatment of specific hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_30_23019="Thyroid volume in children";
var content_f22_30_23019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Thyroid volume in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age, years",
"       </td>",
"       <td class=\"subtitle1\">",
"        Volume (mL), mean &plusmn; SD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"       <td class=\"centered\">",
"        3.1 &plusmn; 1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        3.3 &plusmn; 1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        9",
"       </td>",
"       <td class=\"centered\">",
"        3.6 &plusmn; 1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"       <td class=\"centered\">",
"        4.0 &plusmn; 1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        11",
"       </td>",
"       <td class=\"centered\">",
"        4.9 &plusmn; 1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        12",
"       </td>",
"       <td class=\"centered\">",
"        5.3 &plusmn; 1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        13",
"       </td>",
"       <td class=\"centered\">",
"        6.1 &plusmn; 1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        14",
"       </td>",
"       <td class=\"centered\">",
"        6.3 &plusmn; 1.5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Thyroid volume in Italian children without iodine deficiency, as measured by ultrasound. Thyroid volume is calculated using the formula of a rotation ellipsoid model: width x length x thickness x 0.52 for each lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Aghini-Lombardi F, Antonangeli L, Pinchera A, et al, J Clin Endocrinol Metab 1997; 82:1136.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23019=[""].join("\n");
var outline_f22_30_23019=null;
var title_f22_30_23020="Radiation therapy for esophageal cancer";
var content_f22_30_23020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Schema for definitive and palliative treatment for esophageal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Suggested scheme for definitive treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            External beam radiotherapy (EBRT)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            45 to 50 Gy in 1.8 to 2.0 Gy fractions, five times aweek with concurrent chemotherapy followed by brachytherapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Brachytherapy after EBRT and not concurrent with chemotherapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            HDR: total dose of 10 Gy, 5 Gy fractions,&nbsp;one fraction per week starting&nbsp;two to three&nbsp;weeks following completion of EBRT",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            LDR: total dose of 20 Gy single course, 0.4 to 1.0 Gy per hour starting&nbsp;two to three&nbsp;weeks after completion of EBRT",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Suggested scheme for palliative treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Recurrence after EBRT or short life expectancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Brachytherapy* (HDR: 10 to 14 Gy in one to two fractions or LDR: 20 to 40 Gy in one to two fractions at 0.4 to 1.0 Gy per hour)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            No previous EBRT",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            EBRT 30 to 40 Gy in two to three&nbsp;Gy fractions followed by brachytherapy* (HDR: 10 to 14 Gy in one to two fractions or LDR: 20 to 25 Gy in a single course at 0.4 to 1.0 Gy per hour)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            No previous EBRT and life expectancy &gt;6 months",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Guidelines similar to those for definitive therapy above",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Gy: gray; HDR: high-dose rate; LDR: low-dose rate.",
"     <br>",
"      * All brachytherapy doses specified 1 cm from midsource/mid-dwell position. Applicator diameter of 6&nbsp;to 10 mm is recommended.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Gaspar LE, Nag S, Herskovic,A, et al. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Int J Radiat Oncol Biol Phys 1997; 38:127.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23020=[""].join("\n");
var outline_f22_30_23020=null;
var title_f22_30_23021="Relationship between transmembrane pressure and filtration";
var content_f22_30_23021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graph showing the direct relationship between transmembrane pressure and filtration rate when plasmapheresis is performed with hemodialysis equipment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 290px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In contrast to the usual practice, filtration rate is graphed as the independent variable and transmembrane pressure is the dependent variable. The maximum filtration rate is achieved at a relatively low transmembrane pressure of about 40 mmHg (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Gurland HJ, Lysaght MJ, Samtleben W, Schmidt B, Nephron 1984; 36:173.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23021=[""].join("\n");
var outline_f22_30_23021=null;
var title_f22_30_23022="Actions of aldosterone";
var content_f22_30_23022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urinary effects of aldosterone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 214px; height: 316px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of aldosterone on the daily urinary excretion of K+, Na+, Cl-, and H+ (as NH4+) in a normal subject maintained on a constant dietary intake. Note that the quantitatively most prominent effect is the marked reduction in NaCl excretion. (From Liddle, GW, Arch Intern Med 1958; 102:998. By permission of the American Medical Association, copyright 1958.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23022=[""].join("\n");
var outline_f22_30_23022=null;
var title_f22_30_23023="Pramipexole vs levodopa complications";
var content_f22_30_23023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Pramipexole versus levodopa complications",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 358px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative probability of reaching the first dopaminergic complication (A) and the individual complications wearing off (B), dyskinesias (C), and freezing (D) by treatment assignment. First dopaminergic complication is defined as the first occurrence of wearing off, dyskinesias, or on-off fluctuations. Initial treatment with pramipexole is associated with a reduction in dyskinesias and wearing off compared with levodopa, but the latter results in a reduction in freezing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Data from: Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61:1044.",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_30_23023=[""].join("\n");
var outline_f22_30_23023=null;
